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GENERAL INTRODUCTION 
1. Physiology of the cerebrospinal fluid (CSF) 
The CSF has 2 anatomical locations: the ventricular one and the subarachnoid 
one. The extracellular fluid of the brain (ECF), the neurone's environment, is in direct 
anatomical continuity with the CSF and the exchange between ECF and CSF occurs 
via patent extracellular channels in the ependyma and appears to be relatively 
unrestricted. The ease of material exchange between CSF and brain suggests that the 
fluid in both compartments (ECF and CSF) are similar in composition and that CSF 
may provide an important route of material access to or exit from brain. 
The CSF formation 
The rate of CSF formation in adult man has been established between 0.35 
and 0.40 ml/minute (= 600 ml/day). The total CSF volume is about 150 ml. This 
means that CSF volume is daily replaced 4 times. In (young) children the CSF volume 
and daily CSF production are lower. In figure 1 the general relations of blood, brain, 
ECF and CSF are shown by a scheme, where the ventricular fluid is regarded as a 
single compartment containing a single choroid plexus. The blood comes into relation 
with the brain in two ways; firstly through the highly vascularized choroid plexuses and 
secondly through the capillaries of the brain parenchyma. Current evidence suggests 
that ± 70% of the CSF is produced through secretion by the choroid plexuses and ± 
30% from the capillary bed of brain and meninges. The epithelial cells of the choroid 
plexus are structurally polarized. The basolateral surface is in contact with the blood 
capillaries, the apical surface with the ventricular CSF via their villi. The rate of the 
active sodium transport from the epithelial cells of the choroid plexus into the 
ventricles, due to the presence of a Na+K+ATPase pump, located at the apical 
surface of these plexus cells, regulates the movement of negatively charged ions and 
water (osmotic balance) and determines the CSF formation (figure 2). 
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Figure 1: Diagram of fluid compartments of the blood-brain-CSF system. Continuous arrows represent 
proven directions of CSF flow. Interrupted arrows indicate where diffusion of water and solutes may 
occur between the different compartments: (a) across the blood-brain barrier, between brain capillaries 
and extracellular fluid; (b) across the epithelia of the choroid plexuses; (c) across the ependyma; (d) 
across the piaglial membranes; (e) and (f) across the cell membranes of neurons and glial cells. Thick 
outline represents the arachnoid-dural enclosure of the system. (With permission from Davson H. In: 
Physiology and Pathophysiology of the cerebrospinal fluid. Editors: Davson H, Welch K, Segal B, 
Churchill Livingstone, London 1987 ρ 10). 
Blood brain/CSF banier 
Adjacent choroid epithelial cells are sealed together by tight junctions that 
impede passage of both small molecules and proteins, creating the blood CSF barrier 
(BCB). Similar junctions exist between the endothelial cells lining the cerebral 
capillaries, creating the blood brain barrier (BBB). The tight junctions of the epithelial 
cells are a little more "leaky" than the ones present between endothelial cells of blood 
capillaries and they restrict the passage of blood proteins into CSF in function of their 
size and molecular weight. The entry of small molecules and nutrients into the brain is 
regulated by specific transport systems at both barriers. The BBB and BCB do not 
function in the same way. The BBB of the cerebral capillaries is principally in charge 
of transporting those substances which the brain consumes rapidly and in large 
quantities like: glucose, aminoacids, ketones. The transport is a facilitated diffusion 
system, which moves molecules directly and quickly into the brain without consuming 
energy. In contrast, the BCB of the plexus epithelium transfers "micro nutrient" 
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substances directly into the CSF. Most substances are essential to the brain but in 
relatively small amounts over extended periods like: vitamins B6 and C, folate and 
nucleosides. In figure 2, the flow of molecules across the BCB and the regulating 
transport processes are presented. The transport of these "micro nutrient" substances 
is mostly an active energy consuming system. 
• ACTIVE TRANSPORT 
L j Г-АСІПТАТЕО DIFFUSION 
:.- ION EXCHANGE (FACILITATED) 
• ION EXCHANGE (ACTIVE) 
Figure 2. Row of molecules across the blood-CSF barrier is regulated by several mechanisms in the 
choroid plexus. Some micronutrients, such as vitamin C, are pulled into the epithelial cells at the 
basolateral surface by an energy-consuming process known as active transport; the micronutrients are 
released into the CSF at the apical surface by another regulated process, facilitated diffusion, which 
requires no energy. Essential ions are also controllably exchanged between the CSF and blood plasma. 
Transport of an ion in one direction is linked to the transport of a different ion in the opposite 
direction, as in the exchange of sodium (Na+) ions for potassium (K+) ions. (With permission from 
Spector R. In: Scientific American, November 1989). 
The CSF absorption 
In a steady state, by definition, the rate of absorption of CSF equals its rate of 
formation. The bulk flow reabsorption of the CSF into the venous system takes place 
in the pacchionian granulations and arachnoid villi, functioning like a system of one­
way valve (figure 1). The choroid plexus has an important role in removing waste 
products from the CSF into the blood by an active transport system such as: small 
inorganic ions, drugs or metabolic derivatives of neurotransmitters (figure 2). Finally, 
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some solutes disappear by diffusion from the CSF into the adjacent brain and 
capillaries to be removed by the circulation like: glucose and lactate. This last flow 
reflects the bidirectionality of the carrier mediated transport system of the brain 
capillaries. 
The functions of the CSF 
Four major functions of the CSF have been defined: 
1. to surround, support and protect nervous system, whereby the delicate neural 
tissue is cushioned from external forces; 
2. to control the microchemical environment of nervous tissue in continuous 
unrestricted exchange with the ECF; 
3. to remove products of cerebral metabolism, serving as a "lymphatic like" 
drainage system and "sink action" of the brain; 
4. to distribute biologically active substances within the central nervous system 
(CNS) and to provide special intracerebral transport. 
2. The progress in CSF analysis 
Until IS years ago CSF analysis for clinical practice was limited to a restricted 
number of determinations such as: cytology, protein and glucose content, protein 
electrophoresis, microbiological and serological tests. From the middle of the seventies 
the interest for measuring more specific CSF components and the importance of 
CSF/blood protein relations increased. The necessity for simultaneous blood and CSF 
measurements in order to evaluate an abnormal composition of the CSF became 
clear. With the introduction of new sensitive micromethods, the used CSF volume for 
component analysis decreased significantly and therefore the possibility for extension 
of diagnostic tests increased. The interest for investigating humoral immunological 
processes in inflammatory neurological diseases such as: multiple sclerosis (MS) or 
infections with CNS involvement (human immunodeficiency virus (HIV)-infect or 
neuroborreliosis) by way of CSF analysis of immunoglobulines and specific antibodies 
was obvious. Also the interest for the investigation of the cellular immune response in 
the CSF increased by determining subpopulations of immunocompetent cells in CSF 
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and soluble products (cytokines) of these cells. The importance of the assay of brain 
specific proteins in CSF as markers of brain damage increased. The appearance of 
more metastatic malignities in the CNS during the last years determined the 
importance for tumourmarker investigations in CSF. Furthermore, especially in 
neurogeriatric patients, studies were performed on abnormalities in vitamins and 
neurotransmitter metabolites in CSF. Finally, CSF studies in neurometabolic disorders 
met also increasing interest. 
The outline of this study 
Books have appeared about (new) CSF analyses. Most books deal with general 
information about the physiology of the CSF or CSF abnormalities in different 
neurological diseases. Publications mostly deal with the description of CSF 
abnormalities in some chemical or cellular components in distinct neurological 
diseases. 
This thesis presents an overview of convential and new CSF components and 
the diagnostic value of these investigations (chapter 2). In the same chapter a 
proposal for a strategy of CSF investigation is presented. The different CSF 
components are subdivided in 9 diagnostic groups. Each group consists of a number 
of coherent CSF components which define a special aspect of the (abnormal) CNS 
metabolism. The main point of this thesis concerns studies on the relevance of CSF 
analyses with respect to 4 diagnostic groups for the neurological diagnostics. The 
results are presented in the next 3 chapters: 
chapter 3: brain energy metabolism in young neurological patients after fasting; 
chapter 4: brain specific proteins in neurological patients; 
chapter 5: humoral and cellular immunology in neurological patients with an 
inflammatory disease. 
The choice for these 4 diagnostic groups was based on the following 
considerations: 
1. These components might be relevant not only for diagnostics but also for 
prognostics and for studying medication effects. 
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2. In various neurological diseases the clinicians need objective parameters for 
assessing the disease activity. 
3. Studies about these components are closely linked with important research 
lines within our neurological department. 
CHAPTER 2 
CSF DIAGNOSTICS: CLINICAL CHEMICAL AND CLINICAL ASPECTS 
K.J.B. Lamers and R.A. Wevers 
TIJDSCHRIFT NED. VER. KLIN. CHEM. 1992;17:110-123 
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SUMMARY 
Cerebrospinal fluid (CSF) and brain extracellular fluid are in direct contact 
with each other. Therefore CSF can provide information about the metabolism of the 
brain. We have developed a strategy for CSF investigation in which various aspects of 
(abnormal) brain metabolism can be studied. Brain-specific proteins in CSF reveal 
information about the (degree of) cell damage in the central nervous system (CNS); 
isoelectric focusing (IEF) and Ig indices about intrathecal humoral immune response; 
lymphocyte markers on cellular immune response; tumour markers on metastases into 
CNS; neurotransmitter metabolites and central monoaminergic activity; vitamin 
deficiencies; metabolic products within the CNS. Abnormalities in the composition of 
CSF are commonly found in patients with neurological diseases. 
We describe the determination of the above-mentioned chemical and cellular 
components in CSF and their value for differential neurological diagnostics. 
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DIAGNOSTIC CSF ANALYSIS 
Introduction 
There is direct contact between the cerebrospinal fluid (CSF) and extracellular 
Quid of the brain. It is generally accepted that CSF reflects the metabolism of the 
brain and spinal cord. About 70% of the CSF is formed by the choroid plexus; the 
rest is formed extrachoroidally by the brain in particular via the brain capillaries, the 
ependyma of the ventricles and via the blood vessels entering the subarachnoidal 
space through their walls. About 600 ml of CSF is produced per day. Production and 
absorption are in equilibrium. Bulk absorption of CSF takes place via the arachnoid 
villi into the venous system. This absorption is unidirectional and non-selective. On the 
basis of a total volume of 150 ml, the CSF is renewed about four times per day. A 
minor part of CSF absorption takes also place via the cervical and lumbar roots into 
the lymphatic system. In addition, certain products are removed actively by the 
choroid plexus like: small inorganic ions and drugs and finally products diffuse into 
the brain and are removed via capillary endothelial cells. 
The term "blood-brain barrier' (BBB) describes the dynamic equilibrium and 
the exchange of components between the blood, brain and CSF. The term covers the 
blood-CSF barrier (BCB) and the BBB, but both barriers are not identical. Various 
systems are responsible for the transport of substances across the BBB. There are 
carrier-dependent transport systems for the hexose components, neutral amino acids, 
alkaline amino acids, acid amino acids, monocarboxylic acids, nucleosides and purines. 
Vitamins and hormones are also transported via carriers. Proteins from the blood 
diffuse through the tight junctions located between endothelial cells into brain and 
CSF. Besides the interaction between the CSF and extracellular fluid of the brain, the 
composition of the CSF components (proteins and low molecular substances) is 
defined by the concentration of the blood components via the transport functions of 
the BCB. Correct evaluation of (abnormal) CSF constituents can only be made if 
blood and CSF are sampled and analysed simultaneously. Biochemical abnormalities 
in the CSF resulting from abnormal brain metabolism can then be distinguished from 
abnormalities in the CSF constituents resulting from blood and/or BCB disturbances. 
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Over the past 10 years, many studies have been published on the value of CSF 
for the diagnosis of diseases of the central nervous system. The great potential of CSF 
diagnostics at the present time encouraged us to develop a special strategy to ensure 
an adequate request policy. For this purpose, we divided the request form and 
laboratory procedures into 9 diagnostic (sub)groups, so that the physician can select 
and indicate the aspects of interest for biochemical analysis, in order to support or 
exclude a special neurological diagnosis: 
- Group 1: cells, blood pigments, BCB. 
- Group 2: minerals. 
- Group 3: brain-specific proteins. 
- Group 4: humoral immunology. 
- Group 5: cellular immunology. 
- Group 6: brain metastases / tumour markers. 
- Group 7: neurotransmitters. 
- Group 8: vitamins. 
- Group 9: metabolic investigations. 
These diagnostic (sub)groups are discussed with regard to the type of analysis 
and the diagnostic value. 
Group 1: cells, blood pigments, BCB 
Cells 
Cell counting and cytological examination should be done as quickly as possible 
after the lumbar puncture. Cell number can be counted in a Fuchs-Rosenthal 
chamber using phase contrast microscopy. A leukocyte number of < 4/μ1 is normal. 
Cytological examination is of diagnostic value also in patients with normal cell number 
and it is valuable in the differential diagnosis. It is necessary to enrich the cells using, 
for example, a cytocentrifuge (cytospin), Sayk sedimentation chamber or membrane 
filtration. 
Survival of CSF cells 
Red and white cells are very fragile in CSF after a lumbar puncture. At room 
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temperature, cell loss, especially granulocytes, can be expected within 2 hours and 
changes occur in cell morphology. Therefore, CSF for cell investigation must be 
analysed within 2 hours after puncture, preferable already within 30 minutes. 
Diagnostic value 
It is generally accepted that lymphocytes and monocytes in CSF have a 
haematogenic origin. Pericytes, microglia cells and macrophages in the brain and CSF 
are transformed blood monocytes. In normal CSF the lymphocyte to monocyte ratio is 
about 7:3. Small quantities of lymphocytes and monocytes are also present in the 
connective tissue of the choroid plexus and the leptomeninges in a similar ratio as that 
found in CSF. Local inflammation causes a sharp increase in the number of cells and 
more rapid cell transformation. In pathological conditions, white blood cells also 
appear in the CSF from the brain compartment. The cells disappear from the CSF 
through degeneration or disperse with the blood via the arachnoid villi and possibly 
via the lymphatic system. 
The following cells can be found in (ab)normal CSF: 
a. Round (immunocompetent) lymphocytes 
• Small lymphocytes. These are seen in viral infection, including human 
immunodeficiency virus (HIV) infection and in multiple sclerosis (MS). We discuss 
this subject further under the heading cellular immunology. 
• Large stimulated lymphocytes (lymphoid cells). These cells indicate a 
pathological cellular or humoral reaction. 
• Very occasionally, plasma cells are seen in neurological disorders like: MS, 
neuroborreliosis, neurosyphilis, herpetic encephalitis. 
b. Mononuclear phagocytes 
• Monocytes are often present in normal CSF. There is an increase in the 
number of cells in the case of infection, ischemia, neoplasia, trauma and 
haemorrhage. 
• Activated monocytes are larger than normal monocytes and display vacuoles 
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without phagocytosed material. Their presence indicates a reaction to an infection or 
meningeal stimulation (e.g. myelography). 
• Macrophages are activated monocytes with phagocytosed material. They can be 
differentiated on the basis of the phagocytosed material and can include lipophages, 
erythrophages (12-18 hours after haemorrhage) and siderophages with haemosidcrin, 
i.e. a haemoglobin degradation product. The latter macrophage appears 6 to 8 days 
after haemorrhage and can still be encountered several weeks afterwards. 
Leukocytophages may also be present as a reaction to infection or trauma. 
с Granulocytes 
Normal CSF does not contain granulocytes. Very sporadically, 1 granulocyte/μΐ 
may occur. CSF pleocytosis with granulocytes is very suspicious of acute bacterial 
infection of the brain and/or meninges (the number of cells can increase to 20,000 
leukocytes/μΐ within a few hours) or an early stage viral infection. An increased 
number of granulocytes can also occur after meningeal stimulation, trauma, infarction 
and haemorrhage. 
d. Eosinophils 
Normal CSF does not contain eosinophils. A strong eosinophilic reaction is 
found particularly in association with parasitic diseases, such as cysticercosis and 
trichinosis (5% to 30%). Slight eosinophilia (2% to 4%) may also occur after viral 
infection and meningeal stimulation. Slight eosinophilia is therefore of little diagnostic 
value. 
e. Tumour cells 
Tumour cell examination in CSF requires specialized knowledge of cell 
morphology and cell pathology. This test can only be carried out by personnel who 
have wide experience with the examination of pathological cells. A study by Glass [1] 
on the correlation between the presence of malignant cells in CSF and the 
pathological substrate at autopsy of 117 brains of patients with brain tumours (mainly 
metastases) showed that 26% of the cases had malignant cells in the CSF. 
15 
Blood pigments 
To distinguish intracranial or intraspinal haemorrhage from traumatic puncture, 
it is necessary to collect CSF in 3 separate tubes. In the case of traumatic puncture, 
the CSF will become steadily clearer and the number of cells will decrease from the 
first to the third tube. This is not the case with haemorrhage, where the colour of the 
fluid and number of cells remain about the same in all 3 tubes. Lysis of erythrocytes 
occurs within 2 to 4 hours, which releases blood pigments into the CSF. After the CSF 
cells have been centrifugea, traumatic puncture revéales a clear supernatant and 
haemorrhage usually a coloured supernatant. Three major pigments may be present 
after haemorrhage: oxyhaemoglobin, bilirubin and methaemoglobin. 
Oxyhaemoglobin 
Oxyhaemoglobin is red and, after dilution, pink. Within 2 hours after the onset 
of haemorrhage in the subarachnoid space, oxyhaemoglobin will be released from 
erythrocytes to a maximum level during the first 36 hours. After 7 to 10 days the 
protein has disappeared. 
Bilirubin 
Bilirubin is yellow. It is an iron-free derivative of haemoglobin which is formed 
by macrophages and other cells in the leptomeninges by means of degradation of 
haemoglobin by the enzyme haeme-oxygenase. Bilirubin does not appear until about 
10 hours after the onset of haemorrhage with a maximum of 48 hours. It may still be 
present 2 to 4 weeks later. Bilirubin in the CSF after haemorrhage must be 
distinguished from an increased CSF bilirubin level resulting from bilirubinemia 
(icterus and haemolysis in newborns) or a (strongly) increased CSF total protein level 
(> 2000 mg/1). After the exclusion of the latter causes, the bilirubin level in CSF can 
reflect the severity of the meningeal symptoms after subarachnoid haemorrhage. 
Methaemoglobin 
Methaemoglobin is dark brown. It is a product of haemoglobin and is 
characteristic of an encapsulated subdural haematoma. 
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Blood pigment analysis 
Method: The supematants of 2 or 3 tubes are mixed for spectroscopic examination. 
An extinction of < 23 mE at 415 nm excludes the presence of blood pigments. If the 
extinction value is higher an absorption spectrum is performed between 400 and 600 
nm and the levels of haemoglobin and/or bilirubin can be calculated. 
Diagnostic value 
If CSF only contains oxyhaemoglobin, this indicates traumatic puncture or intracranial 
haemorrhage which occurred less than 2 to 4 hours before the lumbar puncture. If 
oxyhaemoglobin and bilirubin are present, a haemorrhage is the cause in 95% of the 
cases. The presence of erythrophages in the cell composition provides additional 
evidence for haemorrhage. The more bilirubin present (compared to oxyhaemoglobin) 
the 'older' the haemorrhage. Computer tomography is an accurate method for 
detecting or excluding haemorrhage, but it is well-known that haemorrhagic infarcts 
can give rise to isodensity [2]. CSF analysis, particularly a combination of 
spectroscopic examination and cytology can make an important additional contribution 
to the diagnosis of intracranial haemorrhage. 
Blood CSF barrier 
Permeability disturbance of the BCB can be determined in two ways: the 
determination of the total protein content of the CSF or the CSF/serum albumin ratio 
(Q alb). The former parameter is generally used, but it has several disadvantages: the 
protein content can also be raised by immunoglobulin production within the CNS, cell 
degeneration within the brain and an increased blood-protein level. An increased 
albumin ratio only occurs in the case of increased permeability of the BCB. 
Therefore, the albumin ratio is a better parameter than the total protein content. The 
permeability of the BCB for blood proteins depends on the molecular size and the 
hydrodynamic radius of the protein [3]. In newborns, the BCB is not yet fully 
developed and therefore albumin ratio of the CSF is high. The BCB is mature at the 
age of 3 months. Permeability decreases steadily over the next two years, after which 
it gradually increases with age. Statz [4] published reference values for the total CSF 
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protein content and albumin ratio in children and Tibbling [5] in adults (see Table 1). 
Various neuropathological circumstances can cause increased permeability of the 
BCB, such as anoxia, ischemia, intoxication, inflammatory reactions and head injuries. 
Slight permeability disturbances (Q alb to 10 χ IO"3) occur in e.g. MS, amytrophic 
lateral sclerosis (ALS) and chronic HIV encephalitis; moderate BCB disturbances (Q 
alb to 20 χ 10"3) in e.g. viral meningitis, diabetic polyneuropathy, brain infarcts and 
meningoencephalitis; severe BCB disturbances (Q alb > 20 χ IO"3) in e.g. the Guillain 
Barré syndrome, neuroborreliosis, herpes simplex encephalitis and bacterial, including 
tuberculous, meningitis. 
Table 1. Reference values In CSF: total protein and CSF serum albumin ratio 
CSF tout protein (mg/1) CSF£enim albumin ratio (ilO"3) 
0- 1 week 
1- 4 weeks 
1- 3 months 
3- 6 months 
6-12 months 
1-10 years 
11-18 years 
18-30 years 
31-40 years 
41-50 years 
51-60 years 
61-70 years 
mean 
770 
660 
450 
290 
270 
220 
250 
360 
360 
430 
4S0 
530 
range 
450-1090 
510-1010 
240-650 
230-370 
170-350 
160-310 
160-400 
± 2 S d 
240-490 
240-490 
270-600 
290-670 
262-790 
mean 
12.6 
10.2 
5.3 
3.1 
2.5 
1.9 
2.3 
3.7 
4.0 
4.6 
5.5 
5.6 
range 
5.6-23.2 
7.6-16.4 
2.3-10.6 
го-4.8 
1.4- 4.5 
1.0- 4.5 
1.0- 5.0 
± 2 S d 
1.7- 5.7 
1.8- 6.2 
го-7.2 
гі- 8.9 
гг- 9.9 
Group Ъ. minerals 
Sodium 
The sodium concentration in CSF (144-152 mmol/1) is slightly higher than in 
18 
plasma. The choriodal CSF production is determined to a large extent by the blood 
sodium transport across the BCB. CSF concentration depends strongly on the blood 
concentration and has little clinical significance. 
Potassium 
The potassium concentration in CSF (2.7 to 3.1 mmol/1) is lower than in 
plasma. The concentration is extremely constant and changes in plasma concentrations 
have little influence on the CSF concentration. Sodium/potassium ATPase which is 
involved in the active transport of potassium in the choroid plexus, plays an important 
role in CSF potassium homeostasis. An active transport system seems present in the 
brain which transports (excess) potassium e.g. after haemorrhage to the blood. 
As potassium has a depolarizing effect on cell membranes, the brain 
compartment benefits from adequate regulation to maintain a stable potassium 
concentration. 
Calcium 
The calcium concentration in CSF (1.02 to 1.18 mmol/1) is considerably lower 
than in plasma. The concentration is determined by carrier dependent transport. The 
clinical significance of the CSF calcium concentration is not yet clear. 
Phosphate 
The concentration in CSF (0.40 to 0.55 mmol/]) is about 50% of the plasma 
concentration. CSF concentration is independent of the plasma concentration. 
Increased CSF phosphate levels are only observed if the CSF protein concentration is 
very high (e.g. BCB disturbance). 
Group 3: brain-specific proteins 
In brain, there are a number of brain-specific proteins which are characteristic 
for certain cell types, e.g. S-100 and glial fibrillary acidic protein (GFA) are present in 
astrocytes, myelin basic protein (MBP), proteolipid protein (PLP) and myelin-
associated glycoprotein (MAG) in Oligodendroglia and myelin and neuron-specific 
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enolase (NSE) in neurons. If the brain is damaged, these proteins are released into 
the extra-cellular fluid and the CSF. Increased CSF levels might therefore indicate 
(ir)reversible damage of certain cell structures [6-9]. Over the past 5 years, we have 
done a great deal of research into 3 brain-specific proteins: 
• S-100, an acidic protein (M=21000). It exists as subtype S-100 a (subunits α + ß) 
and subtype S-100 b (2ß subunits). S-100 can be assayed by particle counting 
immunoassay (PACIA). 
• NSE (M=90000) is the γγ isoenzyme of enolase. Outside the CNS, NSE can be 
found in diverse cells of the neuroendocrinological system. NSE can be assayed using 
a radio immunoassay (RIA) kit from Pharmacia. 
• MBP (M=18500) is an alkaline protein and makes up about 30% of the protein in 
central and peripheral myelin. MBP can be assayed using a RIA kit from DSL [10]. 
As antigen human basic protein (whole molecule) is used and as antiserum polyclonal 
rabbit antihuman MBP. 
Diagnostic value 
S-100, NSE and MBP are markers for glia cell damage, neuron damage and 
demyelination, respectively. Increased CSF S-100 levels can be observed after acute 
CNS damage, e.g. cerebrovascular accidents, viral infections and head injuries. The 
increase is related to the severity of the affection and the extent of the lesions. 
Increased NSE levels are often seen in association with traumatic, ischemic and 
infectious processes of the CNS as result of neuron damage. In chronic degenerative 
processes, low values are sometimes observed. MBP is increased particularly in 
patients with active demyelination. During acute relapse, MS patients show (strongly) 
elevated MBP values. In the remission phase, the levels are usually normal. Several 
authors have shown that the MBP level is an important parameter for the activity oi 
the disease process [10-12]. The MBP concentration in MS is not related to the IgG 
index or intrathecal IgG production [10,11], but it is related to the IgM index and 
intrathecal IgM production [13] and to gadolinium-DTPA enhancement on MRI [14]. 
It has also been shown that in MS patients who have received a high dose oi 
intravenous methylprednisolone, the increased MBP levels are reduced or normalized 
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and the decrease of MBP is related with decrease in IgM index [13] and with the 
clinical improvement of the patient [15]. We reported that the reference values of the 
above-mentioned proteins in children and adults are age-dependent [16]. Measuring 
brain-specific proteins in CSF can give an important indication about the affected 
brain compartment, provides information about the prognosis and monitors the effect 
of treatment. Obviously, the time of the lumbar puncture in relation to the onset of 
the disease is very important. 
Group 4: humoral immunology 
Ig indices 
The absolute value of IgG concentration in CSF depends on many factors like: 
IgG concentration in serum, blood/CSF barrier function, age of the patient, volume of 
CSF extracted and finally local IgG synthesis in central nervous system. These 
influences restricted the diagnostic significance for detection of local IgG synthesis in 
CNS on the basis of increased absolute IgG concentration in CSF. This led very early 
on to the development of ratios, quotients to eliminate several of these individual 
variations in the single patient. The basic idea was the formation of CSF/serum 
concentration quotients [17]. The IgG index = IgG CSF χ albumin serum / IgG serum 
χ albumin CSF. The CSF/serum ratio of IgG eliminates the individual variation of 
serum IgG. By referring this IgG CSF/serum quotient to the albumin CSF/serum 
quotient, it is possible to eliminate the variation of the IgG quotient by the individual 
blood CSF barrier function too. There have been many approaches for the correlation 
of both these quotients to obtain a high sensitivity for the discrimination between a 
locally synthesized IgG fraction (in brain) and the blood derived IgG fraction in CSF. 
By empirical and theorical aspects it became obvious that the relation between the 
CSF/serum quotients of two molecules of different size (e.g. IgG and albumin) can be 
described by a hyperbolic function [18]. This approach can be applied uniquely to 
CSF samples of ventricular, cisternal or lumbar origin from children or adults to 
identify local IgG synthesis in the central nervous system. It should be mentioned that 
a linear approach (index) is physiologically incorrect and must lead to a severe loss of 
accuracy in the range of the blood CSF barrier dysfunction, especially for larger 
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molecules like IgA or IgM. In figure 1 the (hyperbolic) relations between Q alb and Q 
Ig's for 361 neurological patients without immunological disturbances in CNS is 
presented. For evaluation of immunoglobulin indices, graphic representation of 
immunoglobulin quotients (Q Ig's) and barrier functions (Q alb) can also be used in a 
diagramm. It should be stressed that the calculation of these indices is not possible in 
case of haemorrhage. 
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Figure 1. CSF/serum concentration quotients of the immunoglobulins G, A and M at the normal and 
pathological barrier with permeabilities up to Q (Alb) = 30 χ IO"3 (double linear plot). The upper 
lines represent a hyperbolic function that is defined in the text. Data from η = 361 patients were 
involved in each groups. (With permission of Reiber H. In: Protein transfer at the blood CSF barrier 
and the quantitation of the humoral immune response within the central nervous system. CCA 
1987;163:319-328). 
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Formulas for calculating intrathecal production of immunoglobulins 
Besides the application of the Ig indices, various formulas have been reported 
over the past years for the calculation of intrathecally produced CSF IgG. Intrathecal 
IgG is total CSF IgG minus the transsudate IgG. The first formulas [19,20] were 
based on a linear relationship between Q Alb and Q IgG. More recent formulas make 
use of a hyperbolic [18] or exponential function [21]. The application of the latter two 
formulas led to a clear reduction in the number of false positive results in case of 
BCB disturbances, while the sensitivity is maintained. Soeverijn [22] compared 
Reiber's hyperbolic formula to 5 other formulas and showed that Reiber's formula 
produced the best accordance with the golden standard, the IEF. The calculation of 
intrathecal production of IgG and, in analogy to IgG, IgA and IgM has considerable 
diagnostic and prognostic potentials and can also be used for monitoring treatment. 
Diagnostic value 
IgG index 
An increased IgG index is observed in many neuroimmunological diseases, 
including infections. In more than 80% of patients with MS, increased IgG indices are 
found. It is not yet known about the antigen specificity of abnormal IgG in MS. There 
seems no relationship in MS between the severity or the activity of the disease and 
the intrathecal production of IgG [23,24]. Increased IgG indices are also found in 
about 30% of patients with chronic meningitis or encephalitis from various causes, 
such as bacteria, virus and protozoa and in diseases like: cerebral serum lupus 
erythematosus (SLE), polyradiculitis, sarcoidosis and chronic myelopathy. 
IgA index 
An increased IgA index is seldom found in MS patients (12%). In aseptic 
meningitis abnormalities are found in 40% and in herpes encephalitis in almost 100% 
as a result of virus-specific IgA antibody production [25]. In neurotuberculosis an 
increased IgA index is often accompanied by normal IgG and IgM indices. 
Determination of the dimer IgA index is more sensitive than the total IgA index [26]. 
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IgM index 
IgM production is the first sign of a recent infection and of primary antigenic 
stimulation. IgG production occurs at a later (chronic) stage. Many publications have 
appeared on (abnormal) IgM indices in neurological diseases. In various infectious 
diseases, such as neurosyphilis, acute aseptic meningo-encephalitis, herpes 
encephalitis, НГ infection, an increased IgM index is measured in more than 50% of 
the cases [27]. Increased IgM indices are also seen in cerebral SLE [28] and in 30 to 
60% of MS patients with a short disease duration [29,30]. Sharief [31] showed that an 
increase in the IgM index is usually associated with oligoclonal IgM bands on 
electrophoresis. This indicates an oligoclonal aspect of intrathecally produced IgM. 
According to this author the determination of oligoclonal IgM is more sensitive than 
the IgM index. The same author reported that cerebral IgM production is related to 
the activity of the disease in MS and that early detection of oligoclonal IgM in 
patients with acute isolated lesions of the brain stem and spinal cord has more 
predictive value for the development of MS than oligoclonal IgG [32]. IgM index 
determination is important for the early diagnosis of inflammatory neurological 
diseases and for monitoring the effect of therapy. A persistent IgM production in CNS 
indicates continuous antigenic stimulation. We can determine 4 Ig index profiles with 
respect to IgG, IgA and IgM for the differential diagnostics: 
• IgG dominance with sporadically IgA and/or IgM increases, for example in MS and 
chronic HIV encephalitis. 
• IgM dominance, for example in active neurosyphilis and in neuroborreliosis. 
• IgG + IgA, for example in bacterial meningitis and neurotuberculosis. 
• IgG + IgA + IgM, for example in mumps meningoencephalitis and in opportunistic 
infections. 
Protein electrophoresis 
Over the past 30 years, CSF protein electrophoresis on agar or cellulose 
acetate has found an important application in the diagnosis of MS and infectious 
diseases of the CNS, particularly the detection of oligoclonal gamma bands. CSF 
oligoclonal banding indicates the presence of an intrathecal immune response. In the 
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meantime, new protein separation techniques have been developed to increase the 
sensitivity. IEF on agarose or Polyacrylamide has been strongly recommended in 
recent years. Oligoclonal bands with help of IEF are observed much more frequent in 
comparison with conventional electrophoresis methods with agar or cellulose acetate. 
The latter methods therefore needed to be replaced by IEF with immunoblotting or 
immunoñxation and the use of unconcentrated CSF and diluted serum. Staining can 
be performed by means of immuno-horseradish peroxidase labelling or with silver 
stain. It is necessary to perform parallel serum and CSF of the patient to establish 
CSF-specific oligoclonal bands. We perform IEF on agarose with Pharmalytes and 
stain after immunoblotting with immuno-horseradish peroxidase label, according to 
the method described by Thompson [33]. 
Antibody typing 
Oligoclonal gamma bands can be further characterized. The separated protein 
fractions are blotted on to a nitrocellulose membrane and labelled and detected by 
specific antibodies. In this way, for each immunoglobulin band, the isotype: IgG, IgA, 
IgM, kappa or lambda-free light chains, can be determined [30] as well as the possible 
identity of the antibody, e.g. anti-herpes, anti-borrelia or anti-HIV antibody. 
Diagnostic value 
In MS, oligoclonal IgG bands restricted to the CSF are observed in more than 
90% of the cases. In patients with chronic infection of the CNS (bacteria, virus, 
fungus) IgG oligoclonal bands are found in ± 40% of the cases like: herpes, varicella, 
toxoplasmosis, mumps, rubella, tuberculous bacilli, borrelia and aspergillus. These 
oligoclonal abnormalities are also found regularly in other inflammatory diseases, such 
as neurolupus. Oligoclonal bands may also be present in serum. If the CSF bands are 
a "mirror" pattern of the serum bands, the process is limited to the systemic 
compartment. If additional CSF bands are present, from a biochemical point of view, 
the immune process is extended to the CNS, e.g. in HIV infection, SSPE, 
neurosyphilis, neurosarcoidosis, neuro-Behcet's syndrome and neuroborreliosis. Finally, 
a paraprotein pattern can also be observed in which a monoclonal band pattern is 
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seen in both CSF and serum, due either to myeloma or so-called benign" 
paraprotein. Figure 2 shows diagrams of CSF/serum couples in various neurological 
diseases using agarose IEF. 
It is important to realize that local IgG production in CSF, established by 
means of an increased IgG index or oligoclonal bands, can be found many years after 
an adequate anti infection treatment e.g. neurosyphilis or neuroborreliosis. Oligoclonal 
IgG bands with antibody activity against the responsible agent are observed in the 
CSF in herpes encephalitis, meningoradiculitis (herpes zoster), SSPE, HIV infection, 
neurobrucellosis and tuberculous meningitis. Oligoclonal IgM bands are observed in 
MS (40%), neurosyphilis (22%), meningitis (44%) and encephalitis (22%). Oligoclonal 
IgM disappears again rapidly, in contrast with oligoclonal IgG. The presence of 
oligoclonal free kappa and lambda chains in CSF is a sensitive indication for recent 
antigenic immune response within the CNS, comparable with IgM. According to 
Sindic et al. [30] the detection of oligoclonal free kappa chains in CSF is the best test 
to support the diagnosis of MS. In addition, free light chains can also be found in the 
CSF in inflammatory diseases of the CNS. 
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Figure 2. IEF couples (CSF + serum) in 9 neurological patients. Method: agarose IEF with 
unconcentrated CSF and diluted serum, overblotting on to nitrocellulose membrane and immuno­
detection of IgG by means of double antibody coupling with horseradish peroxidase as staining 
method. С = CSF, S = serum, Ν = normal, Ρ = paraproteinemia, MS = multiple sclerosis, * = 
systemic immunopathology ("mirror" pattern), SSPE = subacute sclerotic panencephalitis. (Received 
from Thompson E. Institute of Neurology, Queen Square, London, with permission). 
Complement components C3 and C4 
The complement system activates various inflammatory reactions by means of 
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its component products and participates in immune regulation. An increase in C3 and 
C4 components indicates activation of the complement system. Increased C3 and C4 
consumption may be seen in association with immune complex formation. 
Macrophages, lymphocytes and astrocytes in the brain can produce these components. 
Intrathecal production of Ci and C4 components can be established by means of the 
determination of C3 and C4 indices, in analogy to the IgG index. An increased C4 
index indicates intrathecal production, while a decreased index indicates intrathecal 
consumption. 
Diagnostic value 
Intrathecal C3 and C4 production has been established in aseptic meningitis 
[34]. In 37 patients infected with HIV 1 virus, intrathecal C4 production could be 
measured in 80% [35]. C4 production is correlated with IgG production. It is possible 
that C4 production in combination with many antibodies can neutralize the virus [36]. 
C3 and C4 production was also demonstrated in MS patients during exacerbation [37]. 
In 12 patients with diffuse CNS SLE, we found a significantly increased C4 index 
which was correlated with an increased IgM index [28]. Determination of C3 and C4 
indices may be important for (differential) diagnosis and to measure the activity of 
auto-immune diseases and/or inflammatory diseases of the CNS. 
Group 5: cellular immunology 
Lymphocytes (subpopulations) are involved in the cellular and humoral 
immune response. Blood lymphocytes reflect the systemic immune response and CSF 
lymphocytes the immune response within the brain compartment. It is assumed that 
only 'activated lymphocytes' can pass the BCB. With help of new methods, it has 
become possible to evaluate lymphocyte subsets in CSF which contains a low or 
normal number of cells. We have developed a sensitive micro-fluorescence method 
[38]. Flow cytometry can also be used for these tests [39]. At our laboratory, the 
following CSF and blood lymphocyte subsets are assayed routinely: CD3: Τ cell, CD4: 
helper/inducer Τ cell, CD8: suppressor/cytotoxic Τ cell, HLA/DR: MHC class II 
antigen, CD2(h В cell. Lymphocyte subsets have been studied in CSF and blood in 
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various neurological diseases, including infections of the CNS [40,41]. Abnormalities 
were found in the relative proportions of lymphocyte subsets in CSF. Also in MS 
patients studies are performed in order to determine the cellular immunity 
involvement of the brain. Decreased percentages of CD8 have been reported in CSF 
in these patients [38,42,43]. Other studies could not confirm this [39,44]. 
Diagnostic value 
Lymphocyte subset examination might provide information on the immune 
(dys)regulation of neuro-immunological diseases and might monitor the effect of 
treatment. 
Group 6: brain metastases and tumour markers 
In 32% of cancer patients, intracranial metastases are detected at autopsy [45]. 
Although CT scanning is an accurate and sensitive diagnostic method, in the case of, 
for example, leptomeningeal metastases, positive findings are only moderate (± 34% 
[46]). MRI is now more sensitive in detecting such metastases. Cytological CSF 
investigation is certainly an important diagnostic tool, but even with this approach, 
malignant cells are only found in 26% of all the cases with proven metastatic tumours 
[1]. Over the past few years, studies have been published on the determination of 
tumour markers in the CSF of patients with brain metastases. Research has 
concentrated particularly on carcino embryonic antigen (CEA) because tumours which 
produce CEA show a strong tendency to metastasize to the brain compartment [47]. 
The normal CEA level in CSF is very low (< 5 ng/1). Reiber et al. [48] reported that 
in analogy with the IgG index, CEA transport from the blood to the CSF/brain 
compartment depends on the function of the BCB and that the CSF CEA 
concentration depends on the blood concentration and the BCB function. An 
increased CSF CEA level as a result of an increased serum level and/or disturbed 
BCB can be distinguished from an increased CSF level due to intrathecal synthesis by 
means of the CEA index. By definition, a CEA index > 1.0 indicates an intrathecal 
synthesis. However, it is not always possible to measure the CEA concentration in 
normal CSF even using a sensitive CEA assay. In cooperation with our laboratory, a 
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CSF "CEA-sensitive" enzyme immunoassay is developed by ELIAS, Medizin Technik 
GmbH, Freiburg, Germany. Besides CEA, ßj-microglobulin and ß-glucoronidase are 
also mentioned in literature as valuable markers for the detection of CNS metastasis 
of leucaemia, lymphoma and solid tumours [49]. 
Diagnostic value 
In 16 out of 18 patients (± 90%) with meningeal metastases and in 14 out of 
30 patients (± 45%) with parenchymal metastases, Jacobi [50] measured intrathecal 
CEA production. The chance of detecting parenchymal metastases by means of CSF 
CEA analysis decreases as the distance between the affected brain area and the 
ventricular system increases. In 55 patients with a primary brain tumour, intrathecal 
CEA production was observed in only 10%. In patients with a CEA producing 
tumour, but without brain metastases, no increase in the CEA index was found. We 
observed an increased CEA index in 6 patients with proven brain metastases (see 
Figure 3). 
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Figure 3. Double logarithmic presentation of the relationship between CSF serum albumin ratio (Q 
alb) and CSF serum CEA ratio (Q CEA) in 17 neurological control patients without metastases (open 
circles) and 6 patients with proven metastases in the CNS (closed circles). The discrimination lines 
have the function Q CEA = 0.7 Q alb (solid line) and Q CEA = 1.0 Q alb (dotted line). (With 
permission from Reiber H. Sensitive quantitation of CEA in CSF and its barrier-dependent 
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In addition to CEA, Ongerboer de Visser et al. [49] investigated the tumour 
markers (^-microglobulin and D glucuronidase in CSF. They encountered an increase 
in ß2-microglobulin level particularly in leptomeningeal metastases from 
haematological tumours. However, raised ß2-microglobulin levels have also been 
found in association with infections within the CNS. An increase in the B-
glucuronidase level forms an indication of leptomeningeal metastases. The analysis of 
tumour markers in CSF can support the diagnosis of brain metastases and can 
monitor the effect of oncological therapy. 
Group 7: neurotransmitters 
A great deal has been published on the relationship between CSF 
neurotransmitters (metabolites) and the metabolism of the CNS. It has been 
established that homovanillic acid (HVA) is a metabolite of the dopaminergic system, 
5-hydroxyindole acetic acid (5-HIAA) of the serotonergic system and 3-methoxy-4-
hydroxyphenylethylene glycol (MOPEG) of the noradrenergic system. Vanilmandelic 
acid (VMA) is not found in brain tissue. Factors such as ventriculospinal gradients, 
24-hour rhythms, physical activity and age influence the basal CSF values. The 
ventriculo/lumbar ratio for the concentration of HVA, 5HIAA and MOPEG is 10, 4.5 
and 1, respectively. Our studies on young children have shown that the 5HIAA and 
HVA levels are much higher than those found in older children and adults, which 
might indicate a higher turnover or alteration in clearance rate. An important study 
was published recently by Wester et al. [51]. They reported that ventricular CSF 
dopamine and HVA originate almost exclusively from the striatum, CSF MOPEG 
correlates with MOPEG in the hypothalamus, temporal cortex and pons, and CSF 
5HIAA correlates with 5HIAA in the thalamus, hypothalamus and cortex. There is no 
relationship between CSF gamma aminobutyric acid (GABA) and specific areas of the 
brain. The spinal cord makes an additional contribution to neurotransmitters 
(metabolites) in the lumbar CSF. According to the above mentioned authors, CSF 
monoamine (metabolites) levels are a good indication of the central monoaminergic 
activity. High pressure liquid chromatography (HPLC) in combination with 
electrochemical detection is a suitable method for analysing monoamine (metabolites). 
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We have shown that GABA can be measured adequately with an amino acid analyzer 
in combination with fluorimetrie detection after postcolumn derivatisation with 
orthophtaaldialdehyde [52]. 
Diagnostic value 
In patients with Parkinson's disease, low HVA, 5HIAA and GABA levels are 
found. Opinions differ with regard to the relationship between CSF HVA and the 
severity of the movement disorder. CSF values may help to distinguish between dopa-
resistant and dopa-sensitive patients [53]. The lowest CSF 5HIAA concentrations are 
found in patients with Parkinson's disease who are suffering from severe depression 
[54]. L-Dopa administration increases CSF HVA, but not 5HIAA and MOPEG. 
Decreased GABA and HVA concentrations are found in patients with Huntington's 
disease. Medication to increase the GABA activity are not very successful. In tardive 
dyskinesia, no monoamine abnormalities are found in the CSF. Low levels of HVA, 
5HIAA and GABA are found in patients with Alzheimer's disease. Decreased 5HIAA 
concentrations are also found in dementia patients and the concentration is lowest in 
multi-infarct dementia [55]. Low levels of 5HIAA may also be found in patients with 
vital depression. As yet, CSF neurotransmitter determination has little significance in 
the diagnosis of a special neurological disease. The investigation may contribute to 
evaluating the severity or prognosis of the disease, or to regulating and monitoring 
medication. 
CSF sampling 
In view of the ventricular/lumbar gradient of these metabolites, we standardize 
the volume of the collected CSF. The first 8 ml of the CSF (tube 1) are used for 
routine tests, the next 3 ml (tube 2) are used for neurotransmitter determination. 
Group & vitamins 
For the correct functioning of the CNS, vitamins B12 and folic acid must be 
imported from the blood. Both these vitamins play a role in the formation of 
methionine which can be further converted into S-adenosylmethionine. The latter 
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compound, as methyl donor, plays an important role in myelin synthesis. It has been 
suggested that a defective metabolism of the methyltransfer pathway with a reduced 
supply of methyl-groups and low S-adenosylmethionine may be a cause of 
demyelination [56,57] It is remarkable that the folate concentration in CSF is 
maintained at a considerably higher level than the concentration in blood through an 
active carrier system in the choroid plexus. No such system is present for vitamin B12. 
Therefore, the vitamin B12 concentration in CSF is more than 10 times lower than 
the concentration in blood, which makes it very difficult to measure in CSF. 
Nevertheless, the concentration can be measured using 5 ml CSF which has been 
concentrated 10 times. Comparisons between the concentrations found in CSF and 
blood show that there is a clear relationship between them for both vitamins [58,59]. 
Diagnostic value 
So far, there are little clinical applications for vitamin assays in CSF in 
individual patients. Both decreased CSF vitamin B12 and CSF/serum vitamin B12 
ratio are demonstrated in a group of 42 patients with dementia, who could not be 
assigned to a definite traditional diagnostic group [60]. For groups of patients with MS 
and patients with Alzheimer's type dementia, we reported significantly decreased CSF 
vitamin B12 values [58]. In a subsequent study we have shown that there is a 
relationship between corticosteroid treatment and decreased vitamin B12 and folic 
acid concentrations in the CSF of MS patients [61]. 
Group 9: metabolic investigation 
Glucose, lactate and pyruvate 
For metabolic investigation of CSF (glucose, lactate and pyruvate), it is 
necessary to fix (a portion of) the CSF immediately to prevent any further metabolism 
of glucose and pyruvate. 
Glucose 
The CSF glucose concentration is strongly dependent on the blood glucose 
concentration. Therefore, simultaneous blood and CSF analyses must be performed. 
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The CSF/blood glucose ratio is about 0.65. In a previous study on children aged 3 to 
16 years, we were not able to establish an age-dependent ratio for glucose [62]. 
Transport of glucose over the BCB is carrier-dependent. 
Diagnostic value 
An increased CSF glucose concentration has no diagnostic value. A decreased 
glucose level (after the exclusion of hypoglycemia) occurs particularly in acute 
purulent meningitis, tuberculous meningitis, meningitis carcinomatosis, fungal 
infections, meningeal sarcoidosis and cysticercosis. It is possible that the glucose level 
remains low 2 weeks after adequate treatment, while pleocytosis and the increased 
albumin ratio content have normalized. A study by Donald [63] on children with 
either aseptic meningitis (n=97) or bacterial meningitis (n=119), showed that a CSF 
blood glucose ratio of < 0.40 and/or a CSF glucose level of < 2.2 mmol/1 are 
suspicious of bacterial meningitis. In the case of viral meningitis, the CSF glucose level 
is normal, with the exception of mumps meningitis and herpes simplex encephalitis (± 
25% abnormal). A low glucose level in meningitis is probably caused by increased 
anaerobic glycolysis (also by bacteria) and by inhibition of the glucose transport over 
the BCB. A low glucose level can also occur in association with cerebral haemorrhage, 
as a result of anaerobic glycolysis by erythrocytes and hypoxia. 
Lactate, pyruvate and L/P ratio 
It is generally accepted that the CSF lactate concentration is a good reflection 
of the brain lactate concentration. The CSF lactate concentration is hardly influenced 
by the (raised) blood lactate concentration, except in the case of obvious BCB 
disturbances [64]. The CSF L/P ratio reflects the redox state of the brain. In case of 
increased cerebral glycolysis (hypoxia, ischemia), the CSF lactate and L/P ratio 
increase. The increase in L/P ratio in association with hypoxia is caused by an increase 
in the conversion of pyruvate into lactate as a result of an increase in the 
NADH/NAD+ ratio. 
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Diagnostic value 
The CSF lactate concentration is an important parameter for the metabolic 
status of the brain and has frequently been the subject of study in various neurological 
diseases. For the differential diagnosis of meningitis, a (strongly) raised lactate level 
occurs particularly in untreated bacterial or fungal infections, contrary to viral 
infections. The level of the increased CSF lactate in infections generally is an 
indication for the severity and the prognosis, and a decrease in the lactate level 
appears a measure for the efficacy of the treatment. In patients with bacterial 
meningitis, Kömel [65] reported a relationship between the number of 
granulocytes/monocytes in the CSF and the increase in lactate concentration. Hypoxia 
in the affected tissue, decreased blood flow and anaerobic glucose consumption by 
leukocytes, are probably responsible for the raised lactate level. In the case of 
cerebrovascular disease, the CSF lactate concentration also is an important measure 
of the severity and prognosis of the disease. Lamers examined the lactate 
concentration in 302 patients with an acute cerebrovascular disease and found a clear 
relationship between the lactate concentration and the severity of the stroke (see 
Figure 4) [66]. 
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Busse [67] found a strong relation between CSF lactate and ischemic cerebral 
oedema using CT scanning in cerebral infarcted patients; none of the patients with a 
lactate value of > 4000 дтоі/і survived. Besides hypoxia, other factors can be 
responsible for an increased CSF lactate, such as vitamin Bl deficiency or heavy metal 
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intoxication in which the enzymatic conversion of pyruvate into the Krebs cycle is 
inhibited. In this case, the L/P ratio is usually normal. In addition, an increase in the 
lactate level can occur in case of haemorrhage as a result of anaerobic glycolysis by 
erythrocytes and in most cerebral tumours. If all the above mentioned causes have 
been excluded, an increased CSF lactate level is very suspicious for a (congenital) 
metabolic defect in the mitochondrial transition of pyruvate in the brain, as is the case 
in the mitochondrial encephalomyopathies (e.g. Melas, Merff). 
Amino acids, purines, pyrimidines and ketones 
Patients with congenital metabolic disturbances commonly suffer from 
neurological symptoms. In these cases it is likely that the metabolism of the brain will 
also be disturbed as a result of a local metabolic defect and/or abnormal substrate 
availability. Supplementary investigation of the CSF (in addition to plasma and/or 
urine) for metabolites can possibly elucidate pathophysiology of the brain metabolism 
in this group of patients. A few publications have appeared in the literature on 
metabolic CSF analysis in the above-mentioned group of patients [68-70]. It can be 
expected that in children with, for example, unexplained mental retardation or 
epilepsy, disturbances in the brain metabolism may be the underlying cause. 
Unfortunately, there are very few reliable age-dependent reference values for these 
metabolites in CSF, particularly in children. Therefore several years ago, we started 
an extensive study to measure metabolic products in the CSF and plasma of more 
than 1000 children who underwent a diagnostic lumbar puncture on the suspicion of 
an infectious disease or an other neurological disorder. The study was aimed at amino 
acids, purines, pyrimidines and fuel-related substrates (glucose, alanine and ketones) 
after prolonged fasting. Age-dependent reference values for these products in CSF 
have now been established and published [52,62,70]. Follow-up studies on selected 
neurological patient groups are in progress. Clear elevations in CSF of 
argininosuccinic acid, pseudouridine and uridine were observed in 3 children with the 
late onset form of argininosuccinic aciduria [72]. In 10 children with chronic renal 
failure a marked increase of pseudouridine and cytidine was demonstrated in CSF 
[73]. Recently in 7 patients with biotinidase deficiency increased values of CSF lactate 
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and 3-hydroxy isovaleric acid were observed. The values in CSF were higher than in 
plasma [74]. Abnormalities of amino acids levels in CSF in association with other 
neurological disorders besides metabolic disturbances are also reported [75]. 
Recommended CSF investigations at a general hospital laboratory 
A general hospital laboratory should be able to perform the following routine 
CSF analyses for neurological diagnosis: 
• Leukocyte and erythrocyte number. 
• Leukocyte differentiation. 
• Total protein content or (better) albumin ratio. 
• Lactate, glucose. 
• Detection of oligoclonal IgG bands. The recommended method is IEF with 
unconcentrated CSF and diluted serum, in combination with immunoblotting or 
immunofixation. 
• IgG index as option: the determination of the IgG index cannot replace IEF, not 
even as prescreening. 
All the other CSF analyses are so specialized and the frequency is so low that 
they can be left to a selected number of specialized laboratories. During evenings, 
nights and weekends, only total protein, cells and glucose should be determined. 
Table 2 shows the CSF and serum reference values at our laboratory and the 
necessary quantities of CSF. 
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Table 2. Reference values (p5-p95) of CSF and serum components in adults determined at our 
laboratory. The necessary quantity of CSF is mentioned per group. 
group 
1 
2 
3 
4 
5 
6 
7 
8 
9 
composent 
leukocytes 
haemoglobin 
bilirubin 
total protein 
albumin (ratio) 
LD 
calcium 
phosphate 
potassium 
sodium 
chloride 
MBP 
S-100 
NSE 
IgG 
IgA 
IgM 
IEF 
C3 complement 
C4 complement 
lymphocyte subsets 
CEA 
02-microglobulin 
B-glucuronidase 
HVA 
5HIAA 
MOPEG 
G ABA 
folic acid 
vitamin B12 
glucose 
lactaat 
pyruvaat 
UP ratio 
amino acids 
purines/pyrimidines 
CSF 
ml 
1.0 
0.8 
0.6 
0.5 
0.5 
0.5 
0.4 
>10 
2.5 
2.0 
5.0 
1.0 
1.0 
unit 
/μΐ 
μπιοΙ/1 
μπιοΙ/Ι 
mg/l 
mg/l 
ил 
mmol/1 
mmol/1 
mmol/1 
mmol/1 
mmol/1 
μ ^ 
μβ/ι 
μ«Λ 
mg/l 
mg/l 
mg/l 
mg/l 
mg/l 
% 
μβ/ι 
mg/l 
U/l 
nmol/I 
nmol/I 
nmol/1 
nmol/1 
nmol/1 
pmol/1 
mmol/l 
μιηοΙ/1 
цтоІЛ 
-
CSF 
reference vaine 
<5 
< 0.025 
<0.08 
180-580 
130-380 
8-30 
1.02-1.18 
0.40-0.55 
2.7-3.1 
144-152 
120-128 
0.2-1.5 
1.4-4.6 
3.7-12.6 
11-38 
0.6-4.0 
0.1-0.4 
0.3-5.8 
0.4-2.8 
<0.010 
0.8-3.0 
10-27 
100-400 
40-170 
25-55 
50-610 
14-42 
2.1-22.9 
2.5-3.7 
1380-1900 
100-145 
11.7-16.5 
C) 
Г) 
(*) 
Г) 
О 
О 
С) 
О 
С) 
(*) 
С) 
С) 
С) 
scrum 
reference vaine 
60-80 g/l 
35-55 g/l 
<330 
2.20-2.60 
0.80-1.30 
3.4^1.6 
137-144 
98-107 
2.0-7.0 
7.4-16.2 g/I 
0.8-3.8 g/l 
0.3-2.0 g/l 
580-1200 
160-460 
<5.0 
1.0-4.0 
75-265 
5.5-19 
142-541 
4.0-5.5 
700-1800 
41-68 
index/ratio 
1.7-9.0 (*) 
(xl0'3=ratio) 
0.5-0.8 
(=ratio) 
0.36-0.60 
0.10-0.41 
0.01-0.07 
0.27-0.75 
0.12-1.56 
<0.7 
1.3-4.3 
1.0-6.6 
(xl0"2=ratio) 
0.5-0.8 (=ratio) 
(*) = age dependent reference values apply to children. 
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SUMMARY 
In order to study the relationship between sex, age and glucose, and the 
concentrations of various fuel related blood substrates in children during prolonged 
fasting, we have selected data of fasting procedures in 13 control children aged 3-5 yr, 
fasted 24 h, and 58 control children aged 6-15 yr, fasted 40 h. 
Compared to the blood results after overnight fast, glucose is decreased, and 
lactate, pyruvate, ketones and non-esterified fatty acids (NEFA's) are all clearly 
increased at the end of fast. The concentrations of alanine and triglycerides remain 
unchanged. The relation with sex, age and glucose has only been analyzed in the older 
children group. A sex-dependency is indicated for the ketones. Ketones are negatively 
related with age. NEFA's, pyruvate and alanine are not age-related, whereas glucose, 
lactate and triglycerides are moderately age-dependent. Ketones are negatively related 
with glucose, whereas pyruvate, NEFA's and triglycerides are not glucose-related. 
Lactate and alanine are weakly related to glucose. 
The data demonstrate diminished glucose homeostasis and increased 
ketogenesis in younger children compared to older ones during prolonged fasting. 
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INTRODUCTION 
Adaptation to fasting is a complex of interrelated mechanisms, involving 
regulation of substrate mobilization, interconversion and utilization. Monitoring this 
transition has been recognized as a particularly useful tool in the differential diagnosis 
of childhood hypoglycemia and other disturbances in energy metabolism [1-10]. There 
are many publications dealing with fasting studies in children [2,6,8,11]. Metabolic and 
hormonal responses have been measured under various fasting conditions. From 
recent studies it became clear that substrate responses in children after fasting are 
age-dependent [2,5,7,9,10.12-14]. The relationship between the blood glucose 
concentration and the concentrations of other energy-yielding blood substrates during 
fasting has also been described [2,5-10,13,14]. However, fuel related components in 
blood during fasting have not been systematically investigated and therefore the 
results from the various studies are only partly comparable. Regularly, the number of 
children in the fasting experiments is low and the age and sex distribution is 
inadequate. Moreover, the period of fasting with older children is often too short and 
the spectrum of the investigated substrates is not complete with respect to fuel 
metabolism. Therefore, we collected data of prolonged fasting procedures in children. 
These data met the following conditions: a sufficient number of children to study age 
and sex effects and the relation with blood glucose; fasting periods adjusted to age; 
biochemical analysis of the relevant circulating blood substrates with respect to fuel 
metabolism. 
In this paper, data are presented on blood glucose, lactata, pyruvate, 
acetoacetate, ß-hydroxybutyrate, plasma non-esterified fatty acids (NEFA's) and 
serum alanine, triglycerides and cholesterol concentrations. 
The purpose of our investigation was, on the one hand, to study fuel related 
substrates in children and the relationship of sex, age and glucose with these 
substrates during prolonged fasting, and on the other hand, to obtain reference values 
related to age after a distinct fasting period (24 h in children aged 3-5 yr, 40 h in 
children aged 6-15 yr). 
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SUBJECTS AND METHODS 
Subjects 
Over a period of 5 yr a total of 71 children, 25 girls and 46 boys, ranging in age 
from 3-15 yr, were included in this study. These children were observed clinically 
because of intermittent behavioral problems and/or unexplained seizures, where the 
possibility of a hypoglycemia disorder was considered or had to be ruled out. They 
were classified retrospectively as suitable reference subjects because of lack of 
evidence for endocrine or metabolic abnormalities . Appropriate studies ruled out 
immunologic and chronic infectious diseases, deficiencies and disorders caused by 
toxic agents. The children were divided into two groups according to age (table 1) and 
fasting period. Informed consent of the parents and of the older children themselves 
was obtained before the investigation. 
Table 1: Age characteristics of the subjects. 
Total group 
Group I 
Group II 
3-15 yr 
3-5 yr 
6-15 yr 
Number 
Boys 
46 
13 
33 
Girls 
25 
25 
Total 
71 
13 
58 
Age (mean±SD) 
Boys Girls 
8.7+3.4 10.5+3.2 
4.8+0.9 
10.2±2.8 10.8+2.8 
Total 
9.3+3.4 
4.8±0.9 
10.5±2.8 
Fasting test procedure 
The subjects were on a normal hospital diet for at least 72 h before the test. 
Fasting was always started after a last meal at 6 p.m. Only drinking of water was 
allowed during the fast. For group I, blood was sampled after 15 h and at the end of 
the 24-h fast, for group II after 14 h and at the end of the 40-h fast. 
Biochemical and statistical procedures 
Biochemical methods have been reported previously [14]. 
Except for the ketone bodies, statistical analysis was performed within the 
previously reported linear model [14], which gives a satisfactory fit to the data both 
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for the blood concentrations at 14-h and at 40-h of fasting. Due to the rather constant 
median level of the ketones in children aged 6-11 yr, it was necessary to modify the 
statistical model for the blood concentrations of the ketones at 40-h fast. Therefore, 
for these ketone values, instead of the standard regression model with age, we fitted a 
two-phase regression model using the technique described by Hinkley [15]. 
RESULTS 
In table II we present the median concentrations of the blood components at 
overnight fast and at the end of the fast for groups I and II. 
Group I (age 3-5 yr): in comparison with the median overnight fasting blood 
concentrations, glucose is decreased, and lactate, pyruvate, ß-hydroxybutyrate, 
acetoacetate (ratio ß-hydroxybutyrate/acetoacetate, total ketone bodies) and NEFA's 
are all clearly increased at the end of fast. The ratio lactate/pyruvate and the 
concentrations of alanine, triglycerides and cholesterol remain unchanged. 
Group II (age 6-15 yr): the same phenomena as in group I are found for the 
various blood components in group II. 
Table II: Median blood values after overnight (14 h) and prolonged fast (respectively 24 h and 40 h). 
Blood parameter Unit Boys aged 3-5 yr (n= 13) Boys and girls aged 6-15 yr (n=58) 
Glucose 
Láclate 
Pyruvate 
Ratio L/P 
Alanine 
fl-OH-butyrate 
Acetoacetate 
Ratio ß-OH-B/AcAc 
Total ketone bodies 
NEFA's 
Triglycerides 
Cholesterol 
mmol/1 
μπιοΐ/ΐ 
μπιοΠ 
μπιοΙ/Ι 
μΠ10ΐ/1 
цтоІЛ 
цтоІЛ 
μιηοΐ/ΐ 
ттоІЛ 
mmol/1 
14 h 
4.3 
860 
97 
9.8 
284 
321 
115 
2.8 
397 
990 
0.89 
4.2 
24 h 
3.5 
1750 
167 
11.1 
292 
2068 
551 
3.7 
2561 
1975 
0.84 
4.6 
Boys ( 
14 h 
4.4 
840 
87 
9.0 
332 
117 
93 
1.5 
242 
700 
0.62 
4.2 
η «=33) 
40h 
3.4 
1640 
177 
9.6 
345 
3687 
723 
4.6 
4444 
1780 
0.69 
4.6 
Girls 
14 h 
4.3 
840 
84 
9.0 
362 
100 
78 
1.7 
170 
675 
0.84 
4.1 
(n=25) 
40h 
3.6 
1720 
200 
9.2 
354 
2836 
600 
4.4 
3450 
1775 
0.83 
4.3 
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Relation between sex and age and blood concentrations at the end of the fasting 
period 
While the number of childen and the age range in group I is small, statistical 
analyses of the relation of sex, age and glucose with blood concentrations of the 
various biochemical parameters were not considered. In the older children group II, 
however, we have evaluated these matters. Within the statistical model referred to 
(see statistical procedures), the effects of sex and age on blood levels after 40-h fast 
were tested for their significance. 
Sex 
A moderate sex-dependency is indicated only for alanine and total ketone 
bodies (p = 0.06 and 0.03, respectively). The median blood ketone level for boys at 
40-h fast is 1.18 times the level for girls, adjusted for age. The ratio B-
hydroxybutyrate/acetoacetate is significantly sex related (p = 0.02). 
Age 
Age effects, while adjusting for possible sex differences, are clearly (p < 0.001) 
demonstrated for B-hydroxybutyrate, acetoacetate, (ratio B-hydroxybutyrate/ 
acetoacetate, total ketone bodies). A moderate (0.05 < ρ < 0.10) age-dependency is 
indicated for glucose, lactate and triglycerides. For other components any age-
dependency is not apparent. The ketones and the ratio ß-hydroxybutyrate/acetoacetate 
are negatively correlated with age. 
In table III, the mean value and the standard deviation are presented for the 
various blood components in group II. Within the statistical model used, estimates ρ 
2.5, ρ 50 and ρ 97.5 are give for respectively the 2.5, 50 and 97.5 percentiles. For the 
variables that show clear age-dependency, estimated percentile values are presented 
for 6-, 9- (12- when ketones are concerned) and 15-yr-old children. For illustrative 
purposes, individual values together with the estimated percentiles are presented for 
ketone bodies in figure 1. 
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Table Ш: Blood values after 40-h fast for 6- to 15-yr-old children. 
Blood parameter 
Glucose 
Lactate 
Pyruvate 
Ratio L/P 
Alanine 
ß-OH-butyrate 
Acetoacctate 
Ratio 3-OH-B/AcAc 
Total ketone bodies 
NEFA's 
Triglycerides 
Cholesterol 
Unit 
minol/1 
μιηοΙ/1 
μΠΙΟΐΛ 
• 
μΓΠΟΐ/Ι 
μαιοΐ/ΐ 
цтоІЛ 
-
цтоІЛ 
μΓποΙ/1 
mmol/I 
mmol/1 
Mean 
3.44 
1795 
190 
9.55 
357 
3151 
661 
4.79 
3812 
1779 
0.78 
4.60 
SD 
0.44 
561 
49 
1.96 
72 
1384 
250 
1.78 
1555 
615 
0.23 
1.04 
Age 
6-15 
6-15 
6-15 
6-15 
6-15 
6-11 
12 
15 
6-11 
12 
15 
6 
12 
15 
6-11 
12 
15 
6-15 
6-15 
6-15 
P2.5· 
2.64 
962 
108 
6.31 
240 
1360 
1010 
490 
333 
278 
181 
3.18 
2.30 
1.96 
1770 
1350 
700 
779 
0.40 
2.94 
Ρ 5 0 · 
3.41 
1720 
183 
9.36 
351 
3480 
2570 
1250 
710 
594 
386 
5.64 
4.08 
3.47 
4200 
3200 
1660 
1670 
0.74 
4.50 
Ρ97.5· 
4.41 
3070 
311 
13.90 
513 
8900 
6580 
3180 
1520 
1270 
814 
10.00 
7.24 
6.16 
9980 
7600 
3950 
3560 
1.36 
6.88 
* Estimates within the lognormal model 
Relation between the concentration of glucose and various blood substrates at the end 
of the fasting period 
For children of the same age, the concentrations of ß-hydroxybutyrate, 
acetoacetate (and total ketone bodies) are negatively correlated with glucose, 
respectively, r = -0.53, r = -0.39, г = 0.53 (all ρ values < 0.05). No significant 
correlation is found for pyruvate, NEFA's, triglycerides and cholesterol. Lactate (ratio 
lactate/pyruvate), alanine and ratio ß-hydroxybutyrate/acetoacetate are all moderately 
correlated with glucose. 
Relation between the concentrations of ketones and serum alanine at the end of the 
tasting period 
In view of the discussion about the supposed non-hormonal regulation of 
muscle alanine release by ketone bodies [16,17], we have tested also the correlation 
between ketones and alanine in blood at the end of fast. The correlation coefficient 
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between alanine and total kenone bodies was -0.28 (p < 0.05). Controls for age as 
well as for glucose give similar results. 
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Figure 1: Total ketone bodies concentrations after 14-h (+) and 40-h (*) fast 
DISCUSSION 
It is known that hormones play an important role in regulating blood glucose 
concentration and other fuel related substrates during fasting. The hypoglycemic 
effects of insulin are counter-regulated by the actions of adrenocorticotropic hormone 
(ACl'H), Cortisol, glucagon, epinephrine and growth hormone. The net effect of these 
hormones during fasting is to stabilize the blood glucose level and to provide free fatty 
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acids and ketones as a source of energy. Hormonal responses during fasting have 
been studied in children and adults [2,10,13,18]. Differences were observed between 
young and old children [10]. The differences in the fasting responses of fuel related 
blood substrates (glucose, alanine, NEFA's and ketones) were even more striking. 
Therefore, we have studied blood substrate responses during fasting periods of 24 h in 
young children (n = 13) and of 40 h in old children (n = 58). 
In our study, the pattern of changes in concentration of glucose, NEFA's and 
ketones during fasting agrees well with other observations of fasting experiments 
[2,3,5-11,13,18]. The concentrations of lactate and pyruvate clearly increase in the 
period from overnight fast to the end of the fast. The same phenomenon was also 
observed by Haymond et al [13] in children as distinct from adults. This increase can 
possibly be explained by an inhibition of the pyruvate dehydrogenase complex by both 
an increased mitochondrial acetyl-CoA level from ketone-utilization and an increased 
mitochondrial NADH concentration [20], indicated by the increased ratio ß-
hydroxybutyrate/acetoacetate at the end of fast in our study; a phenomenon which has 
been described also by Huth et al [21]. The ratio lactate/pyruvate as an index of the 
cytosolic redox state remains stable. The blood alanine concentration does not change 
in our study from overnight fast to the end of fast. Other observations showed that 
blood alanine decreases very strongly during the first 12-16 h postprandial^, while 
after prolonged fasting, the blood alanine level decreases at a much lower rate [10,13] 
or remains relatively stable [8]. In literature, no explanation was given for this alanine 
effect with respect to fasting time. 
The relationship between blood parameters and sex, age and glucose 
concentration in the group of children between 6 and 15 yr of age was also studied. 
Sex effect 
A sex-dependency was found for ketones after 40-h fast, including the ratio ß-
hydroxybutyrate/acetoacetate. There is a tendency that after prolonged fasting, in 
contrast to overnight fasting, girls develop a lower level of ketone bodies than boys. 
Data in the literature about sex-dependency in fasting children are very scarce. Only 
in adults, Haymond et al [13] studied differences in fasting substrate responses 
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between men and women. Glucose, alanine and ketone bodies responses were 
significantly different (higher) in women compared to men [13]. This is not found for 
children in our study. 
Age effect 
The glucose response after 24-h fasting in both children groups is different; 
younger children show lower glucose concentrations than older ones. This is in 
agreement with observations from other studies [5,7,9,10]. However, in group II, at 
the end of fast (40 h) there is no clear age-dependency for glucose. The fat-derived 
ketones and NEFA's increase rapidly in the period between overnight fast and the 
end of fast, and a clear age-dependency is found for ketones (fig 1). This finding 
agrees well with other observations [7,9]. The two-phase regression model fits the 
ketone data much better than the standard one-phase regression model. This might 
indicate that children in the age range 6-11 yr reach a ketone level after 40-h fasting 
where production and utilization of the ketones are in balance (fig 1). Another 
possibility could be that a feedback mechanism stabilizes the ketone production. 
Neither the concentration of NEFA's nor the serum alanine level show any age 
relation at 40-h fast. Chaussain et al [5] found a clear age-dependency for alanine in 
children after 24-h fasting, and we found the same phenomenon after 14-h fasting 
[14]. It might be supposed that the role of alanine in providing gluconeogenic 
substrate is diminished during prolonged fasting. It may also be possible that during 
prolonged fasting an equilibrium is established between muscle release and blood 
extraction for alanine. 
With respect to blood sugar we found a relation between glucose and ketones 
after correction for age. This relation has been previously described in various studies 
of fasting experiments in children [6,9,10]. NEFA's are not related, and alanine 
demonstrates a weak correlation. Other studies showed a clear relationship between 
glucose and alanine [5,6,8,10]. The absence of a stronger relationship between glucose 
and alanine in our study can possibly be explained by a combination of factors, such 
as the relatively long period of fast (40 h), the age range (6-15 yr) and the adjustment 
for age with respect to this dependency. 
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With respect to ketones we found a negative relation between alanine and 
ketones. It has been suggested that ketones may serve as a protein sparing signal, 
diminishing muscle protein catabolism and alanine release. Ketone bodies should 
decrease alanine production by inhibition of proteolysis and branched chain amino 
acid catabolism [16,17]. The effect is a lower alanine level and a reduced 
gluconeogenesis in the presence of ketones. The negative relationship found in our 
study can support the existence of such a regulatory mechanism. 
The observed alterations in blood substrates during fasting in children in our 
study have their significance in a complex of inter-related metabolic processes, like: 
glycogenosis, proteolysis, gluconeogenesis, lipolysis and ketogenesis, to maintain the 
blood glucose level and to generate alternative substrates for an adequate body 
energy supply [10,13,18]. A number of fasting experiments in children have 
demonstrated diminished glucose homeostasis and increased ketogenesis in younger 
children compared to older ones [5,7,26]. Our results generally support this 
phenomenon in children owing to the finding of a clear interrelationship between 
glucose, ketones and age. Sex differences are found for ketones and alanine at 40-h 
fast. Age effects are evidently present for various blood components and the results 
indicate that younger children provide more ketones for energy supply during 
prolonged fasting than older ones. Parallel with this phenomenon, the glucose 
concentration and probably the utilization of this substrate are reduced in younger 
children. 
By means of these reference values from the standardized fasting test we 
intend to screen young neurological patients with possible disturbances in energy 
metabolism. 
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SUMMARY 
In order to obtain information about blood and cerebrospinal fluid (CSF) 
concentrations, and CSF/blood ratio data of fuel related substrates at the end of a 
prolonged fast in children, we have selected biochemical data from fasting test 
procedures in 11 control children aged 3-5 yr, fasted 24 h, and 58 control children 
aged 6-15 yr, fasted 40 h. There was a good correlation between blood and CSF 
concentrations for glucose, acetoacetate and ß-hydroxybutyrate. The relation with age 
and sex has been analyzed only in the older children. CSF and blood values for 
glucose are positively related with age, and both ketones are negatively related with 
age. Lactate, pyruvate and alanine concentrations in blood and CSF are not related 
with age, except for CSF pyruvate. With respect ot the CSF/blood ratio for the above 
mentioned components, only the value for acetoacetate is sex and age related. The 
calculated median caloric values for the sum of glucose, lactate, pyruvate and ketones 
in CSF are independent of age at the end of a 40-h fast. The diminished glucose 
contribution on the CSF caloric homeostasis in younger children is fully compensated 
by the ketone bodies. 
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INTRODUCTION 
It is knwon that the brain can utilize ketones as an alternative energy supply. 
Generally, during (prolonged) fasting the contribution of glucose as the most 
important energy yielding substrate for brain diminishes. Simultaneously, there is an 
increase in acetoacetate and B-hydroxybutyrate utilization in brain. 
Studies on fuel requirements of the central nervous system (CNS) under 
postabsorptive and fasting conditions have been performed by (1) catherization 
techniques, which combine arteriovenous concentration differences with estimated 
brain blood flow [1-3], (2) radioisotopic and radioautographic techniques in brain 
[4,5], and (3) cerebrospinal fluid (CSF) and blood level studies of fuel related 
components [6,7]. As the CSF compartment reflects the (alterated) CNS metabolism, 
data of CSF might give information about the metabolism of energy providing 
substrates in CNS. 
Fasting experiments, especially in younger children, have demonstrated the 
tendency to develop hypoglycemia, and the rapid production and utilization of ketones 
to spare glucose [8-15]. It is known that disturbances in the brain energy provision in 
children can cause alterations in cerebral functions [16]. However, data in the 
literature about the metabolism of energetic substrates in CNS of children are very 
scarce. We have collected data of several fuel related components in blood and CSF 
in children after prolonged fasting. In this paper, data are presented of blood and 
CSF glucose, lactate, pyruvate, alanine, B-hydroxybutyrate and acetoacetate. The aim 
of this study was to obtain information about CSF concentrations of fuel related 
substrates, the CSF/blood ratios for these components, the CSF caloric homeostasis at 
the end of a prolonged fast in children, and the relation with age and sex. 
Furthermore, we intend to develop a model to detect disturbances in the energy 
balance of metabolism of the CNS in children. 
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SUBJECTS AND METHODS 
Subjects 
Over a period of five years a total of 69 children, 25 girls and 44 boys, ranging 
in age from 3-15 yr, were included in this study. These children were observed 
clinically because of intermittent behavioral problems and/or unexplained seizures, 
where the possibility of a hypoglycemia disorder was considered or had to be ruled 
out. They were classified retrospectively as suitable reference subjects because of lack 
of evidence for hypoglycemic and endocrine or metabolic abnormalities. Appropriate 
studies ruled out immunologic and chronic infectious diseases, deficiencies and 
disorders caused by toxic agents. Informed consent of the parents and of the older 
children themselves was obtained before the investigation. 
Fasting test procdures 
The subjects were on a normal hospital diet for at least 72 h before the test. 
Fasting was always started after a last meal at 6 p.m. Only drinking of water was 
allowed during the fast. The length of fasting period was indicated by the child's age 
(table 1). For group I (age 3-5 yr), blood was sampled at the end of a 24-h fast, for 
group II (age 6-15 yr) at the end of a 40-h fast. Analysis of CSF components is a test 
which belongs to the standard laboratory examination of patients with possible 
disorders of CNS in our university department of child neurology. The lumbar 
puncture was always performed at the end of the fast in children. 
Table I: Group characteristics of the subjects. 
Group I 
Group II 
3-5 yr 
6-15 yr 
Number 
Boys 
11 
33 
Girls 
25 
Age (mean ± SD) 
Boys Girls 
4.7±1.0 
10.2±Z8 10.8±18 
Biochemical analysis 
Biochemical analyses of blood components have been reported previously [17]. 
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These methods are also used for the analysis of the CSF components. For the assay of 
glucose, pyruvate and lactate in CSF, 1.0 ml CSF was directly mixed with 50 mg NaF 
and 50 μΐ 1.75 mol/1 citric acid, adjusted to pH 4.0 with NaOH (40%). 
The caloric value of the fuel substrates can be calculated by assessing caloric 
values of 16.4 kJ/g glucose, 19.7 kJ/g ß-hydroxybutyrate, 17.4 kJ/g acetoacetate, 15.2 
kJ/g lactate and 13.0 kJ/g pyruvate [18]. 
Statistical analysis 
Statistical analysis was performed within the previously reported linear model 
[17]. However, due to the rather constant median level of the ketones in the children 
aged 6-10 yr, we fitted a two-phase regression model according to the technique 
described by Hinkley [19]. 
RESULTS 
CSF components and CSF/blood ratios at the end of fast 
In table II, we present the median concentrations of blood and CSF 
components, and the values of the ratio CSF/blood at the end of fast for group I (age 
3-5 yr, 24-h fast) and group II (age 6-15 yr, 40-h fast). There was a good correlation 
between the blood and CSF concentrations for glucose (r = 0.55), acetoacetate (r = 
0.56) and ß-hydroxybutyrate (r = 0.71). CSF lactate, pyruvate and alanine 
concentrations show no correlations with the blood concentrations. For glucose the 
CSF/blood ratio is always about 0.70. The CSF/blood ratios for lactate and pyruvate 
are about 1.0, and for alanine about 0.12. It is remarkable that the median CSF/blood 
ratio for acetoacetate is consistently twice that for ß-hydroxybutyrate. The median 
CSF/blood ratios for acetoacetate and ß-hydroxybutyrate are lower in group I than in 
group II. Because the number of children and the age range in group I are small, 
statistical analyses of the various biochemical parameters with respect to sex and age 
were not considered. In the older children group II, however, we have evaluated these 
matters. 
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Table II: Median blood and CSF values, and median ratios CSF/blood at the end of fast (respectively 
24 and 40 b). 
Boys aged 3-5 yr (n= l l ) ; 24-h fast 
Parameter 
Glucose 
Lanate 
Pyruvate 
Ratio L/P 
Alanine 
8-OH-butyrate 
Acetoacetate 
Ratio ß-OH-B/AcAc 
Total ketone bodies 
Unit 
mmoiyi 
μιηοΐ/ΐ 
μιηοΐ/ΐ 
μπιοΐ/ΐ 
μπιοΙ/1 
цтоІЛ 
цтоІЛ 
Blood 
3.5 
1720 
166 
10.8 
291 
2200 
560 
3.7 
2656 
CSF 
2.5 
1730 
155 
11.9 
47 
250 
130 
1.9 
380 
Ratio 
0.69 
1.12 
0.90 
0.15 
0.10 
0.20 
0.13 
Boys and girls ages 6-15 yr (n=S8); 40-h fast 
Boys (n-33) Girls (n=25) 
Parameter 
Glucose 
Lactate 
Pyruvate 
Ratio L/P 
Alanine 
B-OH-butyrate 
Acetoacetate 
Ratio B-OH-B/AcAc 
Total ketone bodies 
Unit 
mmol/l 
μπκ>1/1 
μιηοΙ/Ι 
цтоІЛ 
μΓηο1/1 
μτηοΙΊ 
цтоІЛ 
Blood 
3.4 
1640 
177 
9.6 
345 
3687 
723 
4.6 
4444 
CSF 
2.4 
1680 
173 
9.8 
40 
595 
266 
2.2 
870 
Ratio 
0.69 
1.12 
0.90 
0.15 
0.10 
0.20 
0.13 
Blood 
3.4 
1640 
177 
9.6 
345 
3687 
723 
4.6 
4444 
CSF 
2.3 
1680 
165 
10.4 
41 
346 
174 
2.1 
522 
Ratio 
0.68 
0.98 
0.87 
0.12 
0.14 
0.27 
0.16 
Influence of sex and age on blood and CSF concentrations and CSF/blood ratios for 
the various components at the end of fast 
Within the statistical model referred to, the effects of sex and age on the blood 
and CSF components, and on the ratio CSF/blood for group II after 40 h fast were 
tested for their significance. The results (p values of these test procedures) are 
presented in table III. 
Sex 
Blood and CSF values for glucose, lactate, pyruvate and alanine are not clearly 
sex related. Especially for children above 10 yr, there is evidence for a difference 
between boys and girls with regard to the blood and CSF concentrations of the ketone 
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bodies. For girls, the median total blood ketone concentrations are 20% lower and the 
median CSF concentrations are 40% lower than in boys (table II). Furthermore, with 
respect to the CSF/blood ratios only the ratio for acetoacetate is highly sex related. 
Age 
Blood and CSF values for lactate, pyruvate and alanine are not clearly age 
related, except for CSF pyruvate. Age effects are indicated for the CSF as well as for 
the blood concentrations of glucose and individual (and total) ketones (table III). 
With respect to the CSF/blood ratios, only the ratio for acetoacetate is age related. In 
table IV, the mean value and the standard deviation are presented for the various 
CSF components in group II. Within the statistical model used, estimates p2.5, p50 
and p97.5 are given for, respectively, the 2.5, 50 and 97.5 percentiles. For the 
variables that show clear age dependency, estimated percentiles are presented for 
different ages. The individual values of CSF/blood ratios, and the CSF and blood 
concentrations of glucose, acetoacetate and ß-hydroxybutyrate together with the 
estimated percentiles (2.5 and 97.5 percentiles) for group II are presented in fig. 1. 
For comparison the values for group I are plotted in. For the interpretation of the 
figure it should be remembered that the age group 3-5 yr has fasted 24 h while older 
children have fasted during 40 h. 
CSF caloric homeostasis 
In order to obtain information about the contribution of glucose, lactate, 
pyruvate and ketones to the CSF caloric value at the end of fast in relation to age and 
fasting time in children, we calculated this value for these components. 
In our study, the median caloric value in CSF for the sum of glucose, lactate, 
pyruvate and ketones is independent of age for group II at the end of fast (10.8 kJ/ml 
CSF). Moreover, there is no difference between the median caloric value for group I 
and II (respectively 10.6 kJ/ml CSF and 10.8 kJ/ml CSF). The age course of the CSF 
caloric values is presented in fig. 2. In order to obtain information about the relative 
contribution of glucose to the total CSF caloric values in relation to age, we have 
given the ratio glucose joules/total joules in CSF in the same figure. The lower glucose 
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contribution in younger children is compensated by a higher ketone contribution. 
Table III: p-values for statistical significance testing of sex and age effects on the blood and CSF 
concentrations and the ratios CSF/blood after 40-h fast for age group II (n»58). 
Parameter 
Glucose 
Lactate 
Pyruvate 
Ratio LTP 
Alanine 
0-OH-butyrate 
Acetoacetate 
Ratio ß-OH-B/AcAc 
Total ketone bodies 
Test of 
Blood 
0.86 
0.64 
0.26 
0.49 
0.06 
0.06 
0.29 
0.02 a 
0.03 a 
sex effect 
CSF 
0.66 
0.58 
0.83 
0.48 
0.83 
0.03 a 
0.005* 
0.44 
0.02 a 
Ratio 
0.37 
0.51 
0.15 
0.09 
0.66 
0.002' 
0.18 
Test of age effect 
Blood 
0.07 
0.09 
0.21 
0.68 
0.13 
0.0001a 
0.001a 
0.0002 a 
0.0001a 
CSF 
0.001a 
0.42 
0.01a 
0.03 a 
0.48 
0.0001a 
0.0001a 
0.28 
0.001a 
Ratio 
0.19 
0.12 
0.83 
0.30 
0.90 
0.006 a 
0.58 
' Statistically significant ρ < 0.05. 
Table IV: CSF values after 40-h fast for 6-to-15-yr-old children. 
CSF parameter 
Glucose 
Lactate 
Pyruvate 
Ratio L/P 
Alanine 
0-OH-butyrate 
Acetoacetate 
Ratio A-OH-B/AcAc 
Total ketone bodies 
Unit 
mmol/I 
μπιοΐ/l 
цтоІЛ 
цтоі/і 
μιηοΙ/1 
μιηοΐ/ΐ 
μ mol/1 
Mean 
2.37 
1694 
171 
10.1 
40 
494 
225 
2.17 
719 
SD 
0.34 
201 
29 
1.51 
И 
257 
104 
0.49 
357 
Age 
6 
12 
15 
6-15 
6 
12 
15 
6 
12 
15 
6-15 
6-10 
12 
15 
6-10 
12 
15 
6-15 
6-10 
12 
15 
Р2-5а 
1.64 
1.90 
2.04 
1334 
136 
118 
110 
7.0 
7.8 
8.3 
23 
186 
123 
71 
96 
66 
39 
1.44 
288 
193 
113 
Р50 а 
г ю 
2.43 
2.61 
1682 
187 
162 
151 
9.2 
10.3 
10.9 
39 
547 
362 
209 
252 
172 
104 
2.12 
803 
537 
314 
Р97.5а 
2.69 
3.11 
3.35 
2121 
257 
223 
207 
12.1 
13.5 
14.3 
66 
1610 
1064 
613 
664 
454 
274 
3.12 
2235 
1494 
874 
1
 Estimates within the lognormal model. 
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Figure 2: The estimated regression lines (2.5th and 97.5th percentiles) for both the total CSF caloric 
values and the caloric ratio glucose joules/total joules versus the age are presented for group II. 
Individual values of group I and group II are spotted In. 
DISCUSSION 
Especially in children during fasting, ketone bodies have an important role in 
supplying fuel for brain energy requirements in order to spare glucose. Changes in 
blood concentration of fuel related substrates in children during fasting have regularly 
been observed ([17,20-23]. A number of fasting experiments in children have 
demonstrated that glucose homeostasis and ketogenesis are related to age [8,10,12-
15,24]. The blood concentrations of fuel related substrates after a prolonged fast in 
children in this study agree well with other observations [8,10,12-14,25]. 
The transport of energy yielding components from blood to brain is regulated by 
the blood/brain barrier. Glucose enters the brain by a carrier mediated transport. A 
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common carrier mechanism is assumed for transport of lactate, pyruvate, acetoacetate 
and ß-hydroxybutyrate [26]. Measurements of fuel related components in CSF might 
give information about the metabolism of energetic substrates in CNS, but we have to 
keep in mind that concentrations in CSF of above mentioned components are 
determined by the passage over the blood/brain barrier, the exchange with the brain 
extracellular fluid, and the bulk flow reabsorption by the arachnoid villi. 
In our study, concentrations of glucose and ketone bodies in CSF show a clear 
correlation with the concomitant blood concentrations. Like the blood values, the CSF 
values for glucose and ketones show an age dependency at the end of fast. For 
ketones, we observed that children in the age range 6-10 yr have a distribution of 
blood and CSF values after a 40-h fast independent of age (fig. 1). This most likely 
represents a direct effect of ketone bodies both on the adipose tissue (antilipolytic 
effect) [27,28] and on the rate of ketogenesis by means of inhibiting free fatty acid 
oxidation [29,30]. This feedback mechanism might play an important role in 
preventing the development of uncontrolled hyperketonemia during starvation. 
Furthermore, an even more pronounced sex dependency is found for ketones in CSF 
than in blood. Maybe, a hormonal regulation is responsible for this phenomenon, as 
the difference is especially present in the oldest children. Also an effect of different 
weight or body mass can be an explanation for this phenomenon. 
With respect to the CSF/blood ratios for the various components, the ratio for 
glucose is relatively stabile, independent of the blood concentration or age. The value 
agrees well with other observations [7]. The ratio for acetoacetate is consistently twice 
that for ß-hydroxybutyrate. In CSF/blood studies in adult persons, Owen et al [7] 
found the same result at the end of a prolonged fast. In arteriovenous extraction 
studies in brain, Persson et al [1] also observed that the uptake of acetoacetate by 
brain of infants and children is twice that for ß-hydroxybutyrate at any given blood 
concentration. Studies in dogs during fasting ketonemia and also after blood infusions 
of ketones demonstrated the same preferential brain uptake of acetoacetate both by 
measurements of CSF/blood ratios as by arteriovenous extraction methods [6]. 
With respect to age effects, a clear negative relation was only observed between 
age and CSF/blood ratio for acetoacetate. Surprisingly, the ratio for ß-hydroxybutyrate 
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did not show any age dependency. In rats, Cremer et al [31] observed a decrease of 
brain uptake capacity for ß-hydroxybutyrate with age. Settergren et al [3] found also 
higher brain uptake rates for ketones in children compared to adults. 
Summarizing for the ketones, the following provisions during fasting in children 
can be concluded from our results: (1) the increase during fast of blood and CSF 
ketones is age related, (2) an age and sex relation for the CSF/blood ratio of 
acetoacetate. 
One might tentatively postulate that CSF/blood ratio data give information about 
transport capacity for ketones from blood to CSF/brain. In a study of ketones 
transport from blood to brain in dogs after prolonged fast, Wiener et al [6] found 
comparable results both with CSF/blood ratio studies as with arteriovenous extraction 
studies. Therefore, the age related changes of CSF/blood ratio for ketones might be 
interpreted as a facilitation of the transport of blood ketones to brain in younger 
children. 
The median CSF caloric values in children at the end of a 40-h fast are 
independent of age. A lower glucose level in CSF in younger children is fully 
compensated by a higher ketone level, suggesting that ketone bodies contribute to 
CSF caloric homeostasis and compensate for diminished glucose provision. 
Furthermore, it is striking that the median values of the CSF caloric values in children 
of group I, fasted 24 h, and of group II, fasted 40 h, are almost equal. The 
concentration of these substances in CSF may in some way reflect the availability of 
these fuel substrates to the CNS for oxidation. 
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SUMMARY 
Alterations in the cerebral energy supply are likely to cause cerebral function 
disturbances. Fasting is a suitable method for studying the energy metabolism. As the 
cerebrospinal fluid (CSF) compartment reflects the brain metabolism, data in CSF 
might give information about the metabolism of fuel substrates in brain. Children 
aged 6-15 yr with encephalopathies of unknown origin were fasted for 40 hours. We 
compared the biochemical data on several fuel-related components in blood and CSF 
at the end of the fast with the values of a reference group of children. In patients with 
mental retardation and behaviour disorders only the blood glucose level was 
significantly higher than that in the reference group. In patients with complex partial 
epilepsy many significant abnormalities were found, especially low CSF ketones. In 
patients with primary generalized epilepsy no abnormalities were found. The possible 
significance of the observed abnormalities in concerned patients are discussed. 
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INTRODUCTION 
The brain (especially the cerebellum) has a very low energy reserve and one of 
the highest metabolic rates in the body. To meet its energy requirements, glucose as 
well as ketones form a major source of fuel for the brain. Ketones are especially 
important in young children during fasting because they not only provide fuel, but also 
help to conserve glucose (Owen et al. 1974, Settergren et al. 1975, Saudubray et al. 
1981, Lamers et al. 1987). Cerebral function is closely linked to energy metabolism: 
cerebral glucose utilization directly reflects the brain's level of functional activity 
(Sokoloff et al. 1977). Fasting is a suitable method for studying (disturbances in) the 
energy metabolism of the brain (Saudubray et al. 1981). Alterations in the cerebral 
energy supply are likely to cause cerebral function disturbances. 
In this study, children with encephalopathies of unknown origin were investigated 
to evaluate whether there was any underlying pathophysiology of the cerebral energy 
metabolism. This group comprised children with mental retardation and behaviour 
disorders and children with cryptogenic or non-lesional epilepsy. Furthermore, also 
children with perinatal problems or with congenital malformations of the central 
nervous system (CNS) and paroxysmal behaviour disturbances not caused by 
pedagogic or psychosocial factors were included in this study. We collected 
biochemical data on several fuel-related components in the children's blood and CSF 
after prolonged fasting procedures and compared the results to those obtained from a 
reference group of children. 
SUBJECTS AND METHODS 
Subjects 
Over a period of five years, we collected data on a total of 176 children. All the 
children had undergone appropriate tests to rule out endocrinological or metabolic 
abnormalities, immunological and chronic infectious diseases, deficiencies and 
disorders caused by toxic agents, chromosomal abnormalities and syndromes. 
Informed consent was obtained from the parents and the older children themselves 
72 
before enrolment in the study. The population also included a group of 58 children 
who served as suitable non-organic reference subjects. These reference children were 
referred to our clinic because of intermittent behaviour problems, headaches and/or 
unexplained seizures, with the aim of detecting or ruling out a biochemical, especially 
hypoglycaemic, disorder. 
The study subjects were divided into 5 groups: group 1 had perinatal problems 
and paroxysmal behaviour disturbances (n=21), group 2 had congenital malformations 
of the CNS and paroxysmal behaviour disturbances (n=30), group 3 had mental 
retardation of unknown etiology without epilepsy (n=46), groups 4 and 5 had 
cryptogenic or non-lesional epilepsy; group 4 comprised patients with primary 
generalized epilepsy (n=10) and group 5 patients with complex partial epilepsy 
(n=ll). Data on the epilepsy patients were collected in a seizure-free period. The 
antiepileptic drugs used by the epilepsy patients are presented in Table 1. The 
administration of these drugs was not changed in any way during the testing period. 
Table 1. Medication regime for epilepsy groups 4 and 5. 
medication 
valproate 
valproate + phénobarbital 
phénobarbital 
phénobarbital + diphentoin 
phénobarbital + carbamazepine 
carbamazepine 
no medication 
Fasting test procedure 
All the subjects had been eating normal hospital meals for at least 72 h before 
testing. In each case, fasting was started after the last meal of the day at 6 p.m. The 
children (age 6-15 yrs) were fasted for 40 hours. At the end of the fasting period, 
blood samples were taken and CSF was obtained via a lumbar puncture (at our 
University Department of Child Neurology, the analysis of CSF components is a 
standard laboratory examination for patients with possible disorders of the CNS). The 
standard fasting procedure has been described previously (Lamers et al. 1987). 
group 4 (n=10) 
1 
1 
1 
0 
0 
4 
3 
groupS (n=ll) 
1 
0 
1 
2 
3 
2 
2 
73 
Biochemical analysis 
In a previous report on the patients who served as the reference group, we 
described the biochemical methods and presented the concentrations of blood and 
CSF components, and the calculated CSF caloric values (Lamers et al. 1987). The 
following parameters were tested in CSF: glucose, alanine, total ketones (= ß-
hydroxybutyrate + acetoacetate), lactate and the CSF caloric value; in blood: glucose, 
alanine, total ketones (= ß-hydroxybutyrate + acetoacetate), lactate and non-
esterified fatty acids (NEFAs). To measure the CSF caloric value, we calculated the 
sum of the caloric values for glucose, lactate, pyruvate and ketones. The ratio 
CSF:blood for glucose, alanine and ketones was also calculated. 
Statistica] analysis 
Statistical analyses were performed within the previously reported linear model 
(Lamers et al. 1985). A one-sample student t test was used to test the significance of 
age-corrected patient residuals. Age-corrected patient residual: 
Rpal = Xpat — ^ref 
(Xpg, = log. concentration in patient; Tt^ = mean of the log. concentration in 
reference children of the same age as the patient; Sref = standard deviation of the log. 
concentration in reference children of the same age as the patient). 
We calculated a 'median percentage' (MP) for each separate parameter in 
each patient group, using the formula: 
observed patient value χ 100% 
median reference value at patient age 
RESULTS 
The MP values and the results of the significance tests are presented in Table 
2. There were no significant differences between the reference group and the patients 
with perinatal problems or the patients with congenital malformations of the CNS, 
with the exception of a lower CSF alanine in the congenital malformation group (p = 
0.04, MP = 86). The blood glucose level in the group of patients with mental 
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retardation was significantly higher than that in the reference group (p = 0.01, MP = 
107) and the CSF glucose level showed the same tendency (p = 0.06, MP = 105). 
There were no significant differences between the primary generalized epilepsy group 
and the reference group, whereas for the complex partial epilepsy group, remarkable 
differences were observed: the blood lactate and alanine levels were significantly 
lower (p < 0.01, MP = 70 and 83, respectively), the CSF lactate concentration (p = 
0.03, MP = 91), the CSF ketone concentration and the CSFrblood ratio for ketones 
were also significantly lower (p < 0.01, MP = 64 and 80, respectively); the blood 
ketone levels (both acetoacetate and ß-hydroxybutyrate) were lowest in this group but 
the differences were not significant (p = 0.07, MP = 81). There was no significant 
difference in the CSF caloric value between the reference group and any of the 5 
groups of study subjects. 
Table 2. Median percentage*** (MP) of blood and CSF parameters in the 5 patient groups 
Group 1 Group 2 Group 3 Group 4 Group 5 
perinatal congenital mental retarda- epilepsy epilepsy 
problems malformations tion without primary complex 
of the CNS epilepsy generalized partial 
n=21 n=30 n=46 n=10 n=l l 
Blood 
glucose 
lactate 
alanine 
ketones 
NEFAs 
101 
106 
101 
94 
100 
105 
97 
94 
90 
108 
CSF 
glucose 
lactate 
alanine 
ketones 
caloric value 
101 
105 
108 
92 
102 
102 
103 
86* 
92 
100 
CSF:blood ratio 
glucose 100 97 
alanine 100 95 
ketones 90 102 
* 0.01 < Ρ < 0.05 
** P s 0.01 
*** MP = observed patient value JE 100% 
median reference value at patient age 
107** 
108 
98 
92 
111 
105 
104 
102 
86 
103 
98 
108 
97 
98 
97 
89 
93 
112 
99 
99 
89 
81 
96 
100 
95 
91 
101 
70** 
83** 
81 
112 
103 
91· 
89 
6 4 · · 
97 
104 
115 
80** 
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DISCUSSION 
No significant abnormalities were found in the children with perinatal problems 
and the children with primary generalized epilepsy. We were unable to find an 
explanation for the isolated observation of a reduced CSF alanine level in the group 
of patients with congenital malformations of the CNS and there were no indications in 
the literature for alanine involvement in such cases. In the patients with mental 
retardation only the blood glucose level was significantly higher. Various factors may 
have been responsible for this: 1) inadequate fasting, 2) higher gluconeogenesis, 3) 
lower blood-brain glucose transport or 4) lower glucose utilization by a retarded brain. 
We can exclude inadequate fasting because the children were under constant 
observation during the fasting period and their blood NEFAs and ketone levels 
indicated normal lipolysis and ketogenesis during fasting. Increased gluconeogenesis is 
conceivable, but the blood levels of the glyconeogenic substrates: alanine (from 
muscle proteolysis) and lactate (from anaerobic glycolysis) were normal, which 
indicates the normal provision of substrates for gluconeogenesis. Lower blood-brain 
glucose transport can also be excluded on the grounds of reports in the literature and 
our results. Lund-Andersen et al. (1977) found that the transport of glucose from the 
blood to the metabolic apparatus of the neuron and glia cells of the brain involves 3 
steps: 1) transport across the blood-brain barrier (BBB), 2) diffusion to the neuron 
and glia cell membranes and 3) transport across the nerve and glia cell membranes. 
Recently, persistently low CSF glucose levels and low CSF:blood glucose ratios (0.19 
to 0.35) were described by De Vivo et al. (1991) in two young children with seizures 
and developmental delay. These authors demonstrated a partial defect in the type I 
glucose transporter in erythrocytes. This erythrocyte transporter protein appears to be 
identical to the glucose transporter type I present in brain capillaries. Such a defect 
can be expected to interfere with cerebral energy metabolism and brain function. In 
our study, the CSF:blood glucose ratio in each individual mentally retarded patient 
was normal, which therefore excludes a glucose transport defect in their BBB. Lower 
cerebral glucose utilization cannot be excluded. Fiorelli et al. (1992) reported lower 
cerebral glucose utilization in patients with myotonic dystrophy (MD). Using PET 
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scanning, these authors demonstrated a reduction in the F-labelled 2-fluoro-2-deoxy-
D-glucose (FDG) rate constant K, of the blood-to-brain glucose transporter in MD 
patients. A possible defect in the function of the insulin receptor on the BBB in MD 
patients has been considered (Moxley et al. 1984). Fiorelli et al. (1992) concluded that 
the lowered glucose utilization in MD brains could not be explained by a glucose 
transporter defect, but it could be attributed instead to a primary reduction in brain 
metabolic needs. Jagust et al. (1991) observed similar glucose transport reduction 
(20%) using PET scanning on adults with Alzheimer's disease. The decline in glucose 
transport in Alzheimer's disease is more likely related to the cortical atrophy and to 
the decline of functional activity of the surviving tissue (Kalaria et al, (1989) and 
Jagust et al, (1991)). It has been established that the glucose transport across the 
neuron membranes far exceeds the rate of glucose metabolism in neurons. Therefore, 
in our patients with mental retardation, a lower glucose metabolism/utilization in the 
brain itself could have been responsible for the higher blood and CSF glucose levels. 
We could not find any data about altered glucose metabolism, including PET scan 
disturbances, in the literature on pure mentally retarded children. However, it is 
known that patients with mental retardation show a slow background activity for their 
age on an EEG, which indicates reduced brain functioning. This phenomenon may 
also indicate that the brain has lower metabolic needs. 
Many abnormalities were observed in the patients with complex partial epilepsy. 
The lower blood alanine level in combination with lower blood lactate may have been 
caused by reduced proteolysis and alanine delivery from muscle tissue during fasting 
or an increased gluconeogenesis. The normal blood glucose level does not indicate an 
alteration in gluconeogenesis. The CSF ketone levels and the CSF:blood ketone ratios 
were also significantly decreased (MP = 64 and 80, respectively). The anticonvulsant 
medication may have been responsible for the above-mentioned abnormalities in these 
patients, because it is known that antiepileptic drugs cause liver enzyme induction 
(Perucca et al. 1984). In 7 epileptic children, Holowach Thurston et al. (1983) 
demonstrated that chronic valproate administration (mean daily dose of 38 mg/kg) 
reduced the level of ketonaemia after an overnight fast, probably by inhibiting fatty 
acid oxidation. Although we could not find any clear differences in the medication 
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type and daily dose between our group 4 with primary generalized epilepsy and group 
5 with complex partial epilepsy, it was striking that the biochemical abnormalities, 
especially the lower CSF ketone levels, were only observed in the complex partial 
epilepsy patients. The low CSF ketone levels in our study can party be explained by 
the concomitant low blood levels. A substantial proportion of the lower CSF ketones 
can be explained by 1) defective ketone transport over the BBB (the MP of 
CSF:blood ketones ratio was 80) and/or 2) by increased brain ketones utilization. 
Gjedde et al. (1975) reported that blood ketone extraction by the brain in contrast to 
blood glucose extraction, increased significantly with an increasing duration of 
starvation, which indicated that the transport mechanism adapted to ketonaemia. 
Moreover, the cerebral extraction of ketones is known to be much higher in young 
infants than in older children and adults (Kraus et al. 1974, Settergren et al. 1976). 
However, in our study all the children were fastened for the same period (40 hours) 
and all the significance tests were performed after correction for age effects, so we 
can exclude alterations caused by differences in the fasting duration or age. In our 
study, we could not distinguish ketone transport (adaptation) disturbances from 
increased brain ketones utilization in our low CSF:blood ketone ratio. The altered 
energy metabolism in our complex partial epileptic patients may have been caused by 
alterations in endocrine function, because the conversion and provision of fuel 
substrates are also regulated by hormones. It is known that the serum prolactin level 
always increases after a seizure involving the temporal lobes in complex partial 
epilepsy (Pritchard et al. 1983). One possible explanation is that the limbic structures 
serve as a trigger for subcortical discharges on the hypothalamus, which regulates 
anterior pituitary secretions (Sperling et al. 1986). However, changes in the serum 
level of other endocrine functions, such as growth hormone, thyroid-stimulating 
hormone and Cortisol, were not observed in complex partial epilepsy patients after a 
seizure or in the seizure-free period (Pritchard et al. 1983). In the light of these 
observations, we can exclude the possibility of neuroendocrine disturbances as a cause 
for the altered fuel metabolism in our patients. It has been suggested that the 
anticonvulsant effect of ketones on patients with epilepsy, which can be generated by 
fasting or a ketogenic diet, is due to metabolic adaptation of the brain metabolism to 
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ketones utilization (Appleton et al. 1972, Uhlemann et al. 1972, De Vivo et al. 1978). 
When Huttenlocker (1976) prescribed two ketogenic diets in an experiment on 
childhood epilepsy, he found support for a direct anticonvulsant action of ketones. 
Similarly, in two young children with a glucose transporter type I defect, who suffered 
from seizures (De Vivo et al. 1991), treatment with a ketogenic diet resulted in nearly 
normal subsequent neurological development as well as cessation of the seizures. 
These observations stress the possible relevance of brain ketones utilization in 
epilepsy and the significance of our finding of a low CSF ketone level during fasting in 
complex partial epilepsy. 
In conclusion, in our patients with mental retardation with an unknown etiology 
and without epilepsy, a lower brain glucose demand (utilization) could have been 
responsible for the higher blood and CSF glucose levels. Further investigations with 
PET scanning might elucidate this phenomenon. In the patients with complex partial 
epilepsy, an alteration in brain ketone transport and/or utilization could have been 
responsible for the lower CSF ketone levels. As ketogenic diets have seldom been 
prescribed for patients with complex partial epilepsy, it would be interesting to study 
the effect of ketogenic diet treatment on these patients. 
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SUMMARY 
Studies on cerebrospinal fluid (CSF) concentrations of neuron-specific enolase 
(NSE), S-100 protein (S-100) and myelin basic protein (MBP) in patients with 
neurological lesions indicate a quantitative relation between the degree of cell damage 
in the central nervous system (CNS) and the concentration of these CNS-specific 
proteins in CSF. Thus NSE, S-100 and MBP could be of use as markers for 
destructive processes in the CNS. We collected 937 specimens of CSF from children 
and adults ranging in age from newborn to 91 years, who were undergoing a diagnos-
tic lumbar puncture for several clinical indications. Of these, 79 samples from subjects 
ranging in age from 0.7 to 66 years could be used retrospectively to construct a 
reference interval according to our criteria. In these 79 reference samples no sex-
dependency existed. The relative increase of NSE, S-100 and MBP with age was 
similar (1 % per year), suggesting a common underlying mechanism. These results 
emphasize the necessity of using age-matched reference values when the CNS-specific 
proteins are to be evaluated in neurological diseases. We also present three case 
histories to discuss the possible clinical relevance of the measurement of NSE, S-100 
and MBP in children and adults. 
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INTRODUCTION 
The clinician dealing with neurological disorders has to answer three questions. 
Is there a disease involving the nervous system? If so, where is the disease located? 
What kind of disease is it, what is its pathological nature? The first question is often 
the most difficult one to answer. To answer it, but also the third question, the 
assessment of damage to the central nervous system (CNS) by determination of 
neuron-specific enolase (NSE), S-100 protein (S-100) and myelin basic protein (MBP) 
in cerebrospinal fluid (CSF), may be helpful. NSE, S-100 and MBP are regarded as 
nervous-system-specific proteins. NSE, the γγ-isoenzyme of enolase, is a soluble 
cytoplasmic protein localized mainly in neurons (1). S-100, named after its solubility in 
100% saturated ammonium sulfate at neutral pH, constitutes a major component of 
the cytosol predominantly of glial cells (2,3). MBP is detectable in developing 
Oligodendroglia and is bound to cellular membranes of central and to a lesser extent 
peripheral myelin (4,5). Thus, increased concentrations of NSE, S-100 and MBP in 
CSF indicate CNS damage and may help to identify the cell type or part (neuron, glia 
or myelin) affected by the pathological process. NSE, S-100 and MBP can now be 
measured with sufficient sensitivity by immunoassays (1-4). However, data on sex- and 
age-related reference values are lacking. 
We measured the concentrations of NSE, S-100 and MBP in CSF from 937 
children and adults, ranging in age from newborn to 91 years, who were undergoing a 
diagnostic lumbar puncture for several clinical indications. To establish possible sex-
and age-related effects in the concentrations of NSE, S-100 and MBP, we retrospecti­
vely selected, according to certain criteria, 79 of the patients as a reference group. 
We also present three case histories to discuss the possible clinical relevance of 
the measurement of NSE, S-100 and MBP in CSF. 
MATERIALS AND METHODS 
Reference group 
From 1985 to 1988, 937 CSF samples were obtained from patients undergoing 
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a diagnostic lumbar puncture for conventional clinical indications such as suspected 
CNS infection or neurological disorder. Of each CSF sample 0.5 mL was used for the 
present investigation. Retrospectively, we were able to use 79 of the samples (from 37 
females and 42 males; age 0.7 - 66 years) for the formation of reference ranges. These 
samples were selected according to the following criteria: no use of medication, no 
evidence of an organic neurological disorder, an inherited metabolic disease, or a 
malignant disease; and normal concentration of total protein in CSF. The diagnoses 
selected in this way, comprise predominantly somatoform disorders [6]. To get normal 
controls subjects in a hospital population remains a problem: although we started with 
nearly 1000 cases, only 79 could be used for the formation of reference ranges. 
Relaxing our entry criteria led to qualitative differences in the reference ranges; e.g., 
when we included patients with migraine, the overall reference ranges significantly 
increased. So we used strict entry criteria. 
Determinations in CSF 
NSE in serum and CSF were determined by radio-immuno assay (RIA) 
according to instructions of assay manufacturer (Pharmacia Diagnostics AB, Uppsala 
Sweden). This double antibody assay contains human NSE as antigen and rabbit anti-
human antiserum. Sepharose-anti-rabbit IgG, raised in sheep is used as precipitating 
reagent. The detection limit for NSE is 2 μg/L. 
S-100 concentrations in CSF were determined by a particle-counting-immuno-
assay (PACIA), essentially as described by Sindic et al. (3). The S-100 immunoassay 
kits were received from C.J.M. Sindic of the department of Experimental Medicine, 
University of Brussels. The detection limit is 0.5 Mg/L. 
MBP was determined by a double-antibody RIA kit according to the 
instructions of the manufacturer (catalog no DSL 1500; Diagnostic Systems Laborato­
ries, Webster TX). Human MBP (whole molecule) is used as the antigen and rabbit 
anti-human MBP as antiserum. Goat anti-rabbit gamma globulin is the MBP 
precipitation reagent. The detection limit is 0.2 Mg/L. 
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Statistics 
After logarithmic transformation, we performed a regression analysis to yield 
age-related reference intervals for NSE, S-100 and MBP. We estimated the median 
value and the reference limits as the S t b and 95* percentiles. P-values for sex- and 
age-dependency were calculated. 
The scatter diagrams of NSE and MBP against age contained no clear outliers. 
The scatter diagram of S-100 against age contained one clear outlier (7 Mg/L at age 7 
years), which we removed before calculating the reference intervals for S-100. 
RESULTS 
Age- and sex-dependency 
NSE, S-100 and MBP in CSF increase with age. Table 1 lists the age-related 
reference intervals (Mg/L). Figure 1 illustrates the NSE, S-100 and MBP concentrati­
ons as functions of age (years). The P-values for age-dependency were 0.03 for NSE, 
< 0.001 for S-100 and 0.001 for MBP. The 95% confidence intervals for the relative 
increase of NSE, S-100 and MBP with age overlapped and were as follows (percenta­
ge increase per year): NSE 0.1-1.4%; S-100 0.4-1.5%; MBP 0.5-1.9%. 
There were no significant differences between males (n = 42) and females (n 
= 37) in age or in NSE, S-100 and MBP concentrations (0.20 < Ρ < 0.80). Therefore 
we combined the data for further analysis. 
Table I. Reference values (μβ/L) for NSE, S-100 and MBP in CSF. 
age in years 
1 
20 
40 
60 
P5a 
2.2 
2.7 
3.1 
3.8 
NSE 
P50 
5.0 
5.8 
6.5 
7.8 
P95 
10.2 
12.0 
13.8 
16.0 
P5 
0.9 
1.1 
U 
1.6 
S-100 
P50 
1.5 
1.8 
2.2 
2.7 
P95 
2.6 
3.3 
4.0 
5.0 
P5 
0.12 
0.17 
0.22 
0.30 
MBP 
P50 
0.30 
0.40 
0.52 
0.70 
P95 
0.72 
0.95 
1.21 
1.57 
•P = percentile 
Figure 1: Scatter diagram of CSF concentrations ^g/L) as a function of age (years) for reference 
sample patients: (top) NSE, (middle) S-100, (bottom) MBP. 
Solid lines indicate 5-95% confidence limits and median values. 
Clinical examples 
Serial analysis of NSE, S-100 and MBP in CSF has been recommended in the 
literature as a very sensitive but unspecific screening variable for pathological organic 
CNS processes (2,4,7-9). In our opinion, these measurements have even greater 
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clinical relevance and potentials. To illustrate this we present three case histories 
(table II). 
Table II: Details of clinical case histories. 
Patient and diagnosis Age 
Acute transverse myelopathy 
1 Borrelia myelopathy 
2 Adenovirus myelopathy 
(untreated) 
Acute panencephalitis 
3 Herpes encephalitis 
: in years 
6 
10 
1.5 
Duration of 
sickness in days 
5 
Treatment started 
13 
27 
11 
23 
10 
Treatment started 
24 
40 
49 
NSE 
(2.2-10 
7.3 
7.2 
9.7 
3.9 
7.3 
44.8 
11.0 
8.1 
5.9 
Concentration in 
•2)" 
S-100 
(0.9-2.6) 
2.8 
3.1 
2.1 
2.2 
2.5 
8.6 
1.9 
1.3 
1.5 
μβ/ι 
MBP 
(0.12-0.72) 
20.0 
10.9 
0.4 
12.9 
1.1 
8.7 
2.9 
4.2 
-
" Reference interval (5-95 percentiles) given in parentheses. 
Transverse myelopathy. 
Patients with an acute transverse myelopathy show distinct nervous-system-
specific protein profiles in CSF, depending on the different underlying causes and 
corresponding with different prognosis. Patient 1, with acute transverse myelopathy 
after infection with Borrelia Burgdorferi treated with penicillin G and patient 2, 
affected after adenovirus infection, show MBP values solely above the reference 
interval. The values of NSE and S-100 in the acute stage of the disease are within the 
respective reference intervals. This combination indicates acute and isolated 
demyelination. If this process terminates spontaneously (patient 2) or after treatment 
(patient 1), remyelination and clinical recovery occur. No neurological deficit remains 
because there was no irreversible damage to the neuron compartment. 
In these cases, the determination of NSE, S-100 and MBP may serve to assess 
which compartment (neuron, glia or myelin) is affected. By elucidating which 
functional structure is involved in an acute neurological disorder, the CNS-specific 
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proteins can serve as a diagnostic but also as a prognostic tool. 
Panencephalitis. 
In the CSF of a child (case 3) with an acute disease with fever, focal epilepsy 
and hemiparesis, we found clearly increased values for NSE ,S-100 and MBP. Such an 
acute and severe panencephalitis has to be treated as a herpes encephalitis. The 
remarkably high values of NSE correspond to a very bad prognosis when therapy is 
delayed. After therapy was started, NSE and S-100 values decreased in our patient 
(table II). Thirty days after the start of the therapy, MBP was still clearly above the 
reference interval, indicating ongoing demyelination. 
In this case the CNS-specific proteins may again serve as a diagnostic and 
prognostic tool. Another possible use is for evaluation and measurement of the effect 
of therapeutic interventions. 
DISCUSSION 
NSE, S-100 and MBP in these CSF samples increased with age from 0.7 until 
66 years. It is remarkable that the relative increases of NSE, S-100 and MBP with age 
are similar. The 95% confidence limits of the relative increases of NSE, S-100 and 
MBP overlap. The median increase of the CNS-specific proteins is 1% per year. 
We found no prior reports on age dependency of CNS-specific proteins in the 
literature. 
A supposed age-dependent increase in blood-brain barrier permeability, 
resulting in an increase in CSF total protein with age, cannot be the explanation for 
the age-dependency of the CSF CNS-specific proteins. Because they originate from 
the nervous system, there is no transudation of these proteins from the serum to the 
CSF across the blood-brain barrier. At least three explanations for increases in NSE, 
S-100 and MBP with age are possible: a) the age-dependency reflects increasing cell 
and myelin loss with age, b) the NSE, S-100 and MBP concentrations in the cells and 
myelin increases with age, whereas the turnover of the cells and myelin remains 
constant or, c) the same relative increase of NSE, S-100 and MBP (1% per year) with 
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age, could be the result of a common underlying mechanism, e.g., an increased half-
life attributable to a reduced CSF bulk flow at older ages. The CSF bulk flow 
reportedly decreases with age (10), resulting in a synchronous increase of the 
concentrations of proteins (10-12). 
Some investigators have reported about NSE, S-100 and MBP in CSF of 
children and adults in relation to various neurological diseases: head injury (2,9); CNS 
tumors (4,7,8,13-15); cerebral ischemia, including stroke (2,7,8,14-16); inflammatory 
diseases of the CNS, such as encephalitis or myelitis (3,7,13,14); multiple sclerosis 
(3,7,8); Guillain-Barre syndrome (3,7); epilepsies (8,14); migraine (8); cervical 
myelopathy (7,8); amyotrophic laterosclerosis (7); Huntington disease (17); 
Creutzfeldt-Jacob disease (18); dementia (8) and subarachnoidal and intracerebral 
bleeding or hematoma (2,7). We shall discuss the clinical potentials and restrictions of 
the CNS-specific proteins in relation to neurological diseases more in general. 
Many modern imaging techniques yield important information concerning the 
status of the brain or spinal cord but cannot distinguish between irreversibly damaged 
brain or spinal cord (infarcts) on the one hand and reversible changes in viable tissue 
(edema) on the other. Although the neurological deficit depends on the size as well as 
on the site of the lesion -a small strategically placed lesion can lead to substantial 
clinical deficit- quantification of CNS-specific proteins may contribute to the more-
detailed estimation of the actual structural and irreversible brain or spinal cord 
damage in various clinical situations (19). Therefore assessment of CNS-specific 
proteins can be of diagnostic and prognostic value (2,7-9). Markers of CNS cell 
damage can also be of clinical value in evaluating the effect of therapeutic measures 
to reduce cerebral cell damage caused by vascular reconstruction, hemodilution, 
hyperventilation, and treatment with barbiturates, calcium blockers, or mannitol (2). 
Although the nervous-system-specific proteins are very sensitive indexes (13), normal 
NSE, S-100 and MBP do not exclude disease. The time of CSF sampling in relation to 
the ictus of the cytolytic process is of crucial importance: in ischemic stroke patients, 
concentrations of NSE and S-100 were increased only between 18 h and 4 days after 
the ictus (2). In demyelinating diseases, MBP is cleared within 5 - 7 days after the 
ictus (5). Therefore, serial measurements can elucidate the dynamics of the patholo-
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gical process in relation to therapy. 
From our own clinical examples and review of the literature, we think the signi-
ficance of the assessment of NSE, S-100 and MBP in clinical (child)neurology could 
be: 
• to help to determine if the disease is involving the nervous system; 
• to differentiate between damage to the glia or neuron compartment (clinical 
symptoms and signs, neuroradiology and neurophysiology also contribute to this diffe-
rentiation, but in a less direct and specific way); 
• to differentiate between irreversible damage or reversible changes in nervous tissue 
(in addition to a diagnostic value, there is a potentially prognostic one) and 
• to help in evaluating the effect of treatment. 
In this study we obtained reference values for NSE, S-100 and MBP in children 
and adults of different ages and both sexes. The availability of these age-matched 
reference values allows interpretation of CNS-specific proteins in CSF of patients with 
different neurological disorders, perhaps leading to a better understanding of their 
basic mechanisms. 
In a second paper we intend to use age (but not sex) matching to investigate 
whether the CNS-specific proteins behave independently and show distinct profiles in 
various neurological disorders. 
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SUMMARY 
In this study levels of neuron-specific enolase (NSE), S-100 protein (S-100) and 
myelin basic protein (MBP) in cerebrospinal fluid (CSF) of children and adults with 
distinct neurological disorders were examined. The median concentration level of the 
3 proteins between 19 different neurological disease groups versus the reference 
group was compared. Significantly higher MBP values were observed in patients with 
multiple sclerosis (MS), cerebrovascular accident (CVA), tumour cerebri (adults), 
metabolic disorder and infection. Furthermore, significantly higher values were 
demonstrated for S-100 in CVA and for NSE in metabolic diseases, whereas 
significantly lower values were observed in communicating hydrocephalus. To 
determine a possible (in)dependent behaviour of these proteins we performed 
correlation analyses for 2 groups of patients with acute neurological disorder (MS and 
CVA). In CVA, the NSE and S-100 values were significantly related with MBP values, 
whereas in MS the NSE and S-100 were not related with MBP values. This might 
suggest that the demyelination process is different in MS compared to CVA. 
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INTRODUCTION 
Neuron-specifïc enolase (NSE), S-100 protein (S-100) and myelin basic protein 
(MBP) are regarded as nervous-system-specific proteins. NSE, the γγ-isoenzyme of 
enolase, is a soluble cytoplasmic protein localized mainly in neurons [1]. S-100 
constitutes a major component of the cytosol, predominantly in glial cells [2,3]. MBP 
is detectable in developing Oligodendroglia and is bound to the cellular membranes of 
central and, to a lesser extent, peripheral myelin [4,5]. Thus, increased concentrations 
of NSE, S-100 and MBP in CSF may indicate CNS damage and may help to identify 
the cell type or part (neuron, glia or myelin) affected by the pathological process. 
Over the past 10 years, a number of reports have appeared on abnormalities of brain-
specific proteins in neurological patients. Recently, we reported that the 
concentrations of NSE, MBP and S-100 in the CSF of a reference group of adults and 
children, were age-dependent [6]. Therefore levels of CSF brain specific-proteins in 
neurological patients should be compared to age-related reference values. Most of the 
studies conducted until now have dealt with adults, so there is a lack of data in the 
literature on the appearance and significance of these markers in children with 
neurological disorders. Finally, most of the studies only measured one brain-specific 
protein and the findings and interpretations remain restricted to one brain 
compartment. This study described possible abnormalities of three brain 
compartments simultaneously; neurons, glial cells and myelin. 
In this study we examined values of NSE, S-100 and MBP in the CSF of young 
and adult patients with distinct neurological disorders and compared the results to 
age-related reference values. We also investigated whether these brain-specific 
proteins behave independently and show distinct profiles in some neurological 
disorders. 
PATIENTS AND METHODS 
Patients 
CSF samples were obtained from patients who underwent a diagnostic lumbar 
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puncture for a clinical indication, such as CNS infection or another neurological 
disorder. Lumbar puncture was generally performed within 4 days after admission to 
hospital. We obtained CSF samples from 596 patients with a definite diagnosis of an 
organic neurological disorder (357 adults and 239 children) referred to our 
Neurological Department between 1986 and 1990. 
Children are different from adults with respect to the appearance and types of 
CNS involvement and were therefore studied separately. The patients (children and 
adults) were divided into several neurological subgroups (Table 1). In order to 
investigate whether brain-specific proteins behave independently, we examined the 
CSF patterns in two neurological disorders in more detail: multiple sclerosis (MS) and 
cerebrovascular accidents (CVA). Our study group comprised 91 MS patients with 
definite clinical MS according to Poser's criteria [7]. All the patients showed 
symptomatic deterioration of the disease (chronic progressive η=42, relapsing 
remittent n=34 and a combination n=15). The CVA patient group consisted of 41 
non-haemorrhagic patients. It was not always possible to obtain an adequate CSF 
volume for all three protein examinations. 
Methods 
CSF samples were centrifugea (1500 χ g for 10 min.) and a 0.5 ml portion of the 
cell-free supernatant was stored at -20°C for the analysis of the brain-specific proteins. 
Any sample which showed definite blood contamination was discarded because human 
red cells contain a significant level of NSE [8]. The assay procedure for NSE, S-100 
and MBP in CSF has already been reported previously [6]. In order to test for 
significant differences between the neurological groups and the reference group, the 
log transformed values were adjusted for the age trend and Dunnett's test for many-
to-one comparisons was applied. 
RESULTS 
After logarithmic transformation, a linear relation became clear in each group, 
with (the logarithm of) the concentrations generally distributed around a mean which 
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was directly proportional to age. In each group (with the possible exception of MBP 
in the MS group and the infantile encephalopathy group) the regression line through 
the means proved to run parallel to that for the reference group. Consequently, the 
mean value for each group and age differed from the mean value in the reference 
group by a constant amount. On the original (untransformed) scale this implies that 
(for each of the groups) the ratio between the median value (for that group) and the 
median value for the reference group was constant (independent of age). Therefore, it 
was possible to estimate the percentage increase or decrease of the (median) value 
for each group compared to the reference group, independent of age. 
Table 1 presents the (age controlled) median value (as a percentage of the 
median in the reference group) of the three brain-specific proteins for the different 
patient groups. The percentage of patients with an abnormal value (> p95 percentile) 
is given for each parameter in the various patient groups. For example, in the MS 
group, 40% of the patients had a MBP value which was higher than the p95 of the 
reference group (age controlled). 
The median NSE value in the hydrocephalus patients was significantly lower than 
that in the reference group, whereas it was significantly higher in the group with 
metabolic diseases (p < 0.0S). 
The median MBP value in the patients with MS, CVA, tumour (adults), metabolic 
disease, infection, including infection in children, was significantly higher (p < 0.05) 
than in the reference group. 
The median S-100 value in the CVA group, was significantly higher (p < 0.05) 
than in the reference group. 
Table 2 presents the individual values of the 3 brain-specific proteins in the CSF 
of 9 patients with a metabolic neurological disorder. In the two Tay-Sachs patients the 
NSE level was strongly elevated. The MBP value was also increased in the infantile 
form, but normal in the juvenile form. 
To determine whether the three protein markers behave (in)dependentry, we 
performed correlation analyses (age-controlled) on the log values of two groups of 
patients with acute neurological disorders (MS and CVA) and the reference values. 
The results are presented in Table 3. In the CVA patients, the MBP values were 
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Table 2. Brain-specific proteins in the CSF of 9 patients with a metabolic neurological disorder. 
Diagnosis 
Mitochondrial encephalomyopaihy 
Mitochondrial encephalomyopathy 
Mitochondrial encephalomyopathy 
Tay-Sachs (juvenile) 
Tay-Sachs (infantile) 
Ceroid lipofuscinosis 
Zellweger's syndrome 
Adrenoleukodystrophy 
Nonketotic hyperglycinemia 
age (ія years) 
0.2 
10 
1 
14 
0.5 
5.2 
0.6 
5.5 
0.1 
NSE 
цел 
9.0 
-
-
39· 
21* 
2.8 
9.2 
-
11* 
S-100 
μβΛ 
1.8 
-
-
3.3* 
1.6 
0.8 
0.7 
-
1.6 
MBP 
μβΛ 
1.0* 
0.9* 
0.4 
0.4 
18* 
0.8* 
0.7 
3.0* 
1.9* 
value > p95 of the age-related reference value 
Table 3. Correlations between MBP and NSE, MBP and S-100, and between NSE and S-100 in 3 
patient groups. 
patient group 
MS 
CVA 
Reference 
η 
86 
36 
47 
MBP/NSE 
R' 
0.01 
0.54" 
0.05 
R = correlation coefficient 
Significant (p < 0.05) 
MBP/S-100 
R 
0.15 
0.45 
0.05 
NSE/5-100 
R 
0.31" 
0.59" 
0.15 
significantly related with the NSE and S-100 values, whereas in the MS patients, the 
MBP values were not related with the NSE and S-100 values. We found only a minor 
relation between NSE and S-100 in the MS group and a clear relation in the CVA 
group. In the reference group, there was no significant relation between the three 
parameters. Figure 1 presents the individual MBP values in the CSF of the reference 
group, the MS group and the CVA group. 
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Figure 1. Scatter diagram of CSF MBP concentrations on a logarithmic scale as a function of age for 
reference patients (bottom), CVA patients (middle), MS patients (top). 
Solid lines indicate 5-95% confidence limits and median values of the reference patients. 
DISCUSSION 
The diagnostic and prognostic value of CSF levels of the brain-specific proteins 
NSE, S-100 and MBP in neurological diseases have formed a frequent study topic. 
Increased CSF values of (some of) these brain-specific protein markers have been 
observed in: inflammatory diseases of the CNS [3,9-11], MS [3,12-15], CVA 
[2,9,11,17], head injuries [2,18], CNS tumours [4,9-11,19,20], Creutzfeld-Jakob's disease 
[21], epilepsy [11,22] and other neurological disorders. 
In our study population, we observed significantly increased MBP values in six 
different patient groups: in MS, CVA, tumour cerebri (adults), infection (adults and 
children) and metabolic disorders. 
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Multiple sclerosL· 
We observed increased MBP levels in the patients with the chronic progressive 
form and in those with the relapsing remittent form. All the patients had an active 
form of the disease. Several authors have reported on the appearance of increased 
CSF MBP levels in patients with active MS [12,15,24,25]. In a previous study 
performed at our department on the same MS group, we stated that there was a 
correlation between the CSF MBP level and the clinical score on the EDSS 
(Kurtzke's expanded disability status scale) of relapsing MS patients [14]. Martin-
Mondiere [26] only observed increased CSF MBP levels in MS patients with an 
exacerbating course with new lesions. He found normal CSF values both in active 
chronic progressive MS and in exacerbating MS with recurrence of old signs or 
symptoms. The levels of NSE and S-100 in our study were no different from the 
control values. 
Cerebro-vascular accident 
We found increased MBP levels in ischemic disorders of the CNS, which is in 
agreement with the results published in other reports [12,19] and indicate that 
demyelination often occurs in association with these disorders. According to Whitaker 
et al [25] the degree of MBP elevation generally correlates with the volume of the 
lesion. In our patients, the S-100 level was also significantly increased and indicated 
concomitant parenchymal damage of the CNS; this is in accordance with other reports 
[3,9,17,27,28]. 
The low incidence of elevated NSE in the CVA patients in our study was not 
surprising, because neuronal damage occurs predominantly in severe stroke patients 
where the infarct involves both the cerebral cortex and the white matter [9]. In a 
recent study performed at our neurological department on 8 patients who had 
suffered severe infarction of the middle artery, we observed a clearly increased CSF 
NSE value in all of them (unpublished data). 
Tumours 
We found increased MBP levels in our patients with primary brain tumours, but 
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not in the patients with brain metastases. Raised MBP levels have also been 
demonstrated by other authors in patients with leptomeningeal metastases [5] and in 
primary intracranial tumours [19]. Increased S-100 levels were found frequently in our 
patients, while the NSE values were unchanged with the exception of a very high CSF 
NSE level in a patient with a cerebellar tumour. Increased NSE values have been 
reported in the literature, especially in primary tumours [11,20]. 
injections 
In young and adult patients with an infection of the CNS we found significantly 
elevated MBP levels. The S-100 levels were also increased (> 40%) but not 
significantly, while the NSE values remained within the normal range in both age 
groups. Several studies have appeared on brain-specific proteins in infections of the 
CNS. Mokuno et al [9] observed significantly elevated S-100 levels in meningitis and 
encephalitis, while the NSE values were only increased in encephalitis. 
Metabolic disorders 
In our patients with a metabolic neurological disorder, an increased MBP level 
occurred very frequently, e.g. in infantile Tay-Sachs, non-ketotic hyperglycinemia, 
adrenoleukodystrophy, ceroid lipofuscinosis and mitochondrial encephalomyopathy 
(Table 2). It is remarkable that the CSF MBP was normal in juvenile Tay-Sachs and 
abnormal in the infantile form. It is known that in severe infantile cases there is 
enormous accumulation of G^gangliosides in neurons which may amount to 12 per 
cent of the dry brain weight. Such an accumulation of storage products may lead to 
other secondary aberrations, e.g. demyelination. In Tay-Sachs with a late onset, the 
Сод accumulation is far less pronounced. 
The NSE values in both Tay-Sachs patients were strongly increased, which 
indicates neuronal damage as a consequence of gangliosides storage. 
Communicating hydrocephalus 
In our communicating hydrocephalus group, the significantly decreased CSF NSE 
level was striking. We could not find any data on these markers in the literature. The 
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normal levels for MBP and S-100 in the presence of a decreased NSE, could indicate 
loss or atrophy of neurons in this disorder. 
Other disorders 
In our patient groups, various disorders were associated with (non-significantly) 
increased CSF brain specific protein values. Increased MBP levels (> p95) in the 
absence of S-100 and NSE elevations were observed in the CSF of adults and children 
with neurological disorders, such as trauma capitis and drain dysfunction. Increased 
MBP and S-100 levels were observed in patients with epilepsy and migraine. Our 
patients with HNP, dementia or an extrapyramidal disorder, did not show abnormal 
levels for the three proteins. In a recent study conducted at our department on 135 
patients with various types of dementia, the CSF brain specific proteins were also 
normal (unpublished data). 
Comparison of two acute neurological disorders 
We observed different patterns of the brain-specific proteins in the CSF of two 
patient groups with acute neurological disorders: one group had deteriorating MS and 
the other group had suffered a CVA. Lumbar puncture was always performed within 
4 days after admission to hospital. 
In our MS patients we found increased MBP values and normal levels for NSE 
and S-100. The absence of NSE elevation may indicate that neurons are not involved 
in the acute stage of the disease. 
Conflicting results have been reported for S-100 in MS patients. Michetti et al. 
[29,30] found increased CSF S-100 levels in patients with active MS and interpreted 
them as an index for active cell injury during exacerbation of the disease. Our results 
support those reported by Noppe et al. [27] who did not find any S-100 abnormalities 
in patients with active MS. Massaro [13,31] demonstrated that MBP and S-100 were 
not released simultaneously following exacerbation. MBP reached its highest level 
during the first week, while S-100 reached its peak during the third week. This 
suggests that the origin of S-100 and its pathobiologjcal significance in MS are 
different from those -of MBP. In addition, S-100 cannot be regarded as a direct 
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marker of myelin destruction in MS, but is more likely to indicate the onset of gliosis 
in the CNS or increased astrocytic secretory activity. 
In our CVA patients, both the S-100 and MBP values were significantly increased 
and a correlation was found between them, in contrast to those in MS. This might 
indicate that (parenchymal) astrocytic involvement is associated with demyelination in 
CVA. It is likely that demyelination in CVA is secondary to other causes while 
demyelination in MS is a primary process. 
General remarks 
• We should be very cautious about drawing conclusions about the levels of CSF 
brain-specific proteins in patient groups and individual patients. The levels of brain-
specific proteins in CSF depend on several factors, such as the distance between the 
affected brain area and the CSF compartment, the severity and extent of brain 
damage, the regional variability of these proteins in the brain, the degradation of 
these proteins by macrophages and/or proteinases either locally or in the CSF. 
Also the time of lumbar puncture in relation to the onset of tissue damage is a very 
important factor. It is known that an increase in the levels of these proteins in the 
CSF is maintained for at least 4 to 8 days post-damage, depending on the type, extent 
and location of the brain lesion. In this study we used existing data without any well-
defined standardization of the CSF sampling time. However, our records showed that 
lumbar puncture was generally performed within 4 days after admission to hospital. 
• Increased levels of these proteins in CSF indicate that the brain compartment is 
affected. However, normal levels of (one of) these proteins does not exclude the 
presence of local brain damage. 
• We observed significantly increased brain-specific protein levels in various patient 
groups and non-significant increases in other groups. It is possible that the numbers of 
patients in some of these groups were too small to reach statistical significance, for 
example the MBP and S-100 values in children with tumour cerebri. 
• Increased values for CSF MBP were observed most frequently, S-100 less frequently 
and NSE least frequently. The frequent occurrence of an increase in MBP can partly 
be explained by the fact that the regions of the brain close to the ventricles consist 
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mainly of myelinated white substances. NSE is released from the grey substance of the 
cortex which is further away from the ventricles and it therefore takes longer for it to 
appear in CSF. It is also possible that a proportion of NSE leakage is transferred 
from the extracellular space directly via capillary wells into the blood stream and does 
not enter the CSF space. This might explain the rapid NSE increase in the serum of 
the patients in coma after head injuries [23]. Finally, neurons might be more resistant 
against damage than myelin. 
CONCLUSION 
Increased CSF levels of brain-specific proteins are found in patients who are 
suffering from brain tissue damage. This damage can be the result of 1) an acute 
neurological disorder with brain damage, such as CVA, exacerbating MS and infection 
or 2) a chronic progressive disorder, such as active chronic progressive MS, metabolic 
disorders (Tay-Sachs) and tumour cerebri. 
Data on brain-specific proteins in CSF provide information on the patho-
physiology of a particular disease process. It is likely that the concentration of these 
proteins in CSF might be of relevance for assessing the severity and the activity of a 
disease process and for monitoring treatment effects. 
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SUMMARY 
Cerebrospinal fluid (CSF) levels of myelin basic protein (MBP) and intrathecally 
produced CSF IgG (de novo IgG) were measured in 11 chronic progressive multiple 
sclerosis patients with a deteriorating course of the disease for at least 6 months 
preceding observation and a reference group of 17 neurological patients suffering 
from disc herniation. In the multiple sclerosis patients, CSF levels were determined 
just before and once in the period 3 to 10 weeks after the start of an immunosuppres­
sive treatment with cyclophosphamide and prednisone. For multiple sclerosis patients 
the CSF MBP levels before treatment were significantly higher than for controls. The 
CSF MBP levels after the treatment were nearly all within the control range. The high 
concentration of intrathecally produced CSF IgG (de novo IgG) in multiple sclerosis 
patients was reduced after treatment. A correlation between CSF MBP and CSF de 
novo IgG in multiple sclerosis patients could not be demonstrated. If CSF MBP is an 
indicator of the myelin breakdown in the brain, it can be concluded that an intensive 
immunosuppressive treatment in combination with prednisone has, at least, a short-
term, beneficial effect on the amount of demyelination and possibly on the disease 
activity. 
I l l 
INTRODUCTION 
Increased levels of myelin basic protein (MBP) or fragments of it in cerebrospinal 
fluid (CSF) have regularly been observed in patients with neurological diseases such 
as head injury and stroke [1-7]. The measurement of MBP in CSF has appeared to be 
a useful indicator of tissue damage. Furthermore, recent studies in multiple sclerosis 
patients have also shown increased MBP levels in CSF, especially after an acute 
exacerbation of the disease [3,4,8-12]. From these studies one may conclude that the 
amount of CSF MBP in exacerbating forms of multiple sclerosis is higher (1) during 
the first week after onset of an attack [2,11], (2) in polysymptomatic attacks compared 
with monosymptomatic attacks [10], (3) in severe attacks with complete paralysis [4] 
and (4) during exacerbations with the presence of new signs and symptoms [12]. In 
chronic progressive forms of multiple sclerosis increased MBP levels in CSF are 
regularly found, but the percentages of abnormalities and the amount of MBP in CSF 
are generally lower than during an acute phase of the disease process in exacerbating 
forms [3,4,10,12]. If the CSF MBP levels can be used as an indicator of demyelination 
and/or disease activity in patients with multiple sclerosis, measurements of CSF MBP 
before and after therapy might give information about the effect of the therapy on the 
myelin degradation in the central nervous system (CNS). 
The purpose of our investigation was to study the possible effect of an immuno-
suppressive treatment on the level of CSF MBP in 11 chronic progressive multiple 
sclerosis patients with a deteriorating form of the disease. The effect of treatment on 
intracerebrally produced IgG and the relation between IgG and MBP were also 
studied. 
SUBJECTS AND METHODS 
Subjects 
The multiple sclerosis patients (n=l l , age 20-36 yr) were definite multiple 
sclerosis patients with a chronic progressive course of the disease. These patients had 
a continuous deterioration of clinical symptoms for at least 6 months before treat-
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ment. They received an intensive immunosuppressive treatment consisting of a daily 
dose of 400 mg cyclophosphamide and 100 mg prednisone, with a total dose of 8 g 
cyclophosphamide [13]. The duration of treatment was between 4 and 5 weeks. Just 
before starting treatment and once 3-10 weeks later blood and CSF samples were 
taken. The multiple sclerosis patients had never received any immunosuppressive 
treatment before. As reference a control group of neurological patients (n=17, age 
24-72 yrs) suffering form disc herniation in whom no clinical signs of demyelinisation 
could be observed was used. 
Methods 
MBP assay 
MBP was determined according to the instructions of the manufacturer, Diagnos­
tic Systems Laboratories, Webster Texas USA cat. nr. 1500, using a double antibody 
RIA kit containing human myelin basic protein (whole molecule) as antigen and 
rabbit antihuman MBP as antiserum. Goat anti-rabbit gamma globulin was used as 
MBP precipitation reagent. Human MBP (J125 2дСі/ іа1) was included in the test kit. 
IgG/albumin assay 
IgG and albumin were measured in unconcentrated CSF and diluted serum 
(1:400). Sheep antihuman IgG (Boehringer, Mannheim) and rabbit antihuman 
albumin (Behringwerke, Marburg) were used in the assay. 
Q alb = CSF alb/serum alb 
Q IgG = CSF IgG/serum IgG 
IgG index = Q IgG/Q alb 
The calculation of CSF IgG, synthesized within the CNS (de novo CSF IgG), was 
performed according to the formula of Reiber [14] with minor modifications. De novo 
CSF IgG is total CSF IgG minus transsudate (serum derived) IgG. 
Statistics 
For each of the biochemical variables we present the median value and the range 
of the observed levels. For the multiple sclerosis patients the statistical comparison of 
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the pre- and posttreatment values was performed by means of the Wilcoxon test for 
the paired case. The statistical comparison between different patient groups was 
performed by the Wilcoxon test for the unpaired case. The results of a comparison 
were considered to be significant if its corresponding ρ value was smaller or equal to 
0.05. The statistical dependence between two variables was evaluated by means of 
Kendall's test for rank correlation. 
RESULTS 
MBP 
The individual results of the CSF MBP determination are shown in figure I. The 
median value and the range of CSF MBP are given in table I. Within the group of 11 
multiple sclerosis nine patients showed an elevated CSF MBP level (higher than the 
estimate of the 95th percentile for the control group = 2.3 ßgfl) before treatment. 
After treatment only three patients had increased levels of CSF MBP. 
For multiple sclerosis patients the CSF MBP levels were significantly (p = 0.01) 
lower after treatment (median 1.7 jtg/1) than before treatment (median 4.2 μg/l). The 
MBP levels for multiple sclerosis patients before treatment were significantly higher 
than for controls (p = 0.001), while the MBP levels of multiple sclerosis patients after 
treatment were not significantly different from that of controls (p = 0.29). From these 
results it can be concluded that the abnormal CSF MBP levels of "active" chronic 
multiple sclerosis patients are decreased to the reference limits 3-10 weeks after the 
start of the treatment. 
De novo CSF IgG 
The median values and ranges for CSF de novo IgG and IgG index in multiple 
sclerosis patients and controls are presented in table I. 
With respect to CSF IgG, before treatment all multiple sclerosis patients had 
increased IgG indices (higher than the upper limit (0.59) of reference values from our 
laboratory) and de novo CSF IgG production (median 43 mg/1). 
After treatment, the de novo CSF IgG value (median 19 mg/1) was significantly (p 
= 0.004) decreased compared to the pretreatment value. 
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Figure I: CSF MBP values in chronic progressive multiple sclerosis patients with a deteriorating course 
before and after treatment and controls. 
Relation between MBP level and de novo IgG level in CSF 
We could not demonstrate any significant correlation between MBP and de novo 
IgG or IgG index in the multiple sclerosis group. 
Table I: Median value and range for CSF MBP, de novo IgG and IgG index in multiple sclerosis 
patients and controls. 
Patients 
Multiple sclerose group 
Controls 
Number 
11 
17 
Before treatment 
Median Range 
MBP in CSF (Mg/1) 
4 2 (1.2-15) 
1.4 (0.7-2.3) 
After treatment 
Median Range 
MBP in CSF (jig/1) 
1.7 (0.6-3.1) 
Comparison 
p-value 
0.01 
Multiple sclerosis group 11 
Multiple sclerosis group 11 
De novo CSF IgG (mg/1) 
43 (16-100) 
De novo CSF IgG (mg/1) 
19 (0-70) 0.004 
IgG index 
1.25 (0.93-3.21) 
IgG index 
1.02 (0.76-1.91) 0.002 
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DISCUSSION 
CSF MBP levels are probably an indication of the degree of demyelination in 
multiple sclerosis patients and its quantitation might be used to monitor disease 
activity and to study the effect of putative therapy. The actual level of CSF MBP 
reflects the amount of tissue undergoing demyelination, the actual rate of myelin 
breakdown and the location of the lesion with respect to the lumbar space [4] 
In exacerbating forms of multiple sclerosis it has been emphasized that CSF MBP 
levels mostly return to normal values 2 to 4 weeks after acute attacks [2-4,9]. This, 
however, is not the case in patients in whom clinical deterioration still remains after 
recovery [4,11]. 
Elevated CSF MBP levels are only found in chronic progressive multiple sclerosis 
patients with a deteriorating course [3,4,12]. The results of our study confirm abnor-
mal CSF MBP values in deteriorating chronic progressive multiple sclerosis patients. 
After intensive immunosuppressive treatment CSF MBP levels normalise in nearly 
all patients. The CSF MBP levels in the multiple sclerosis patients, averaged 6 weeks 
after treatment, can statistically not be distinguished from controls. If CSF MBP is an 
indicator of myelin breakdown in the brain, one can conclude that an intensive 
immunosuppressive treatment in combination with prednisone has, at least a short-
term, beneficial effect on demyelination and possibly on the disease activity. The 
question can be raised whether the effect of treatment on disease activity can be 
measured by its alterations in CSF MBP levels. 
With respect to the IgG, this study shows that all multiple sclerosis patients had 
both an intrathecally produced CSF IgG before treatment and a clear reduction of the 
de novo IgG amount after treatment. Although treatment has a beneficial effect on 
the amount of intrathecal IgG production, the de novo IgG production was not 
stopped. 
Finally, the absence of a correlation between CSF MBP level and de novo IgG 
production might suggest that demyelination and (local) immunological activity of IgG 
are not related. A relationship between disease activity and intrathecally IgG produc-
tion is rarely observed in multiple sclerosis studies. 
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SUMMARY 
In a prospective study, we compared the number of gadolinium-DTPA (Gd-
DTPA) enhancing lesions on MRI with the cerebrospinal fluid (CSF) and clinical 
findings before and after a total of 20 courses of high-dose intravenous 
methylprednisolone (MP) in relapsing multiple sclerosis patients. Before treatment, 
there was a significant correlation of Gd-DTPA enhancement (seen on 16 of 20 scans) 
and CSF myelin basic protein (MBP). If enhancement with Gd-DTPA represents 
inflammation and CSF-MBP indicates myelin breakdown, the amount of inflamed 
tissue should correlate with the amount of myelin being damaged. Clinical 
improvement occured following 15 to 20 courses, and decrease of Gd-DTPA 
enhancement in 12 of 16 scans; the mean CSF-MBP level was the only CSF variable 
to return to reference values. There was a significant correlative triad of decrease in 
CSF-MBP, Gd-DTPA enhancement, and clinical disability. Thus, the clinical effect of 
methylprednisolone might be accompanied by a reduction of inflammation and myelin 
breakdown. 
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INTRODUCTION 
Blood brain barrier (BBB) disruption is an early [Grossman 1988, Miller 1988, 
Bastianello 1990] or even preceding [Kermode 1990] feature in the acute stage of 
lesion development in MS. BBB disruption can be demonstrated by means of Gd 
using MR imaging. A recent study showed that high-dose IV MP improved BBB 
integrity in MS, as judged from changes in Gd-enhancement [Barkhof 1991]. Improved 
BBB integrity was found to correlate with clinical improvement. 
CSF examination yields typical abnormalities in MS patients, which reflect the 
immunological status of the patient. After MP treatment, changes in CSF variables 
occur, which consist of reduction of MBP [Frequin 1990, Warren 1986], anti-MBP 
[Warren 1986, Wajgt 1983], and reduction of intrathecal IgG-synthesis [Frequin 1990, 
Warren 1986, Durelli 1986, Milligan 1987]; a reduction in the number of oligoclonal 
gamma bands (OB's) with iso-electric focusing has been found by Frequin [1991], but 
not by Durelli [1986]. There is no clear correlation between CSF and clinical findings, 
except for CSF-MBP which is raised at times of relapse [Cohen 1980, Martin-
Mondiere 1987] and is undetectable in the remission phase [Warren 1987]. 
We hypothesize that there is a correlation between Gd-enhancement and some 
CSF variables, as they all express activity on an immunological level. The purpose of 
the present study is to investigate a) whether there is a relation between clinical 
findings, Gd-enhanced MR imaging and CSF variables in relapsing MS patients before 
treatment and b) whether MP-induced changes in clinical findings and Gd-enhanced 
MR imaging relate to changes in CSF variables. 
PATIENTS AND METHODS 
Sixteen patients (12 women, 4 men) with definite MS [Poser 1983], were 
prospectively investigated. The mean age of the patients was 34 years (range, 22 to 
45), the mean DD 6.8 years (range, 1 to IS). All the patients were treated because of 
a symptomatic deterioration lasting longer than 24 hours, without subsequent 
spontaneous improvement. Treatment consisted of IV MP administered during 15 
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minutes in a dose of 1 gram daily for 10 consecutive days. Four patients were treated 
twice (interval at least 3 months). A total of 20 consecutive courses was thus given 
and used for analysis. Spinal taps and MR scans were performed before and after MP 
treatment. The mean interval between the first tap and first MR scan was 8.6 days 
(range, 0 to 22); the mean interval between the second tap and second MR scan was 
4.2 days (range, 0 to 14). EDSS-scores [Kurtzke 1983] were assessed before and after 
therapy simultaneously with the CSF examination, by an examiner (ORH) who was 
blinded to the MR and CSF findings. 
MR imaging was performed on at 0.6 Tesla system (Technicare, Solon, Ohio) 
before and after treatment using a standard head coil. Repositioning errors were 
corrected by means of 3 consecutive oblique scout images (transverse, coronal, 
sagittal). Gd-DTPA dimeglumine (Schering AG, Berlin) was administered IV in a 
dose of 0.2 mmol/kg, followed by a post-injection flush with 10 cc saline. Axial (double 
oblique) series were made according to internal landmarks (caudal borders of the 
pituitary gland and the fastigium of the 4th ventricle for angulation; caudal border of 
the splenium of the corpus callosum as Z-centre). Tj-weighted SE sequences were 
obtained (repetition time 400 ms/echo time 28 ms/4 excitations) starting 5-10 minutes 
after Gd-injection, with an in-plane resolution of 1.0 χ 1.3 mm, and a slice thickness of 
5 mm (gap 1.25 mm). MR scans were analyzed by 2 of the authors (FB, PS) in 
conference; they were unaware of the clinical and CSF findings. An area of markedly 
increased SI, not related to a physiologically enhancing structure, and consisting of at 
least 3 pixels, was considered a Gd-enhancing lesion. The number, not the size, of Gd-
enhancing lesions was used as study-parameter. 
CSF examination was performed before and after treatment. CSF analysis 
included mononuclear cell count, albumin-quotient (Q-albumin), intrathecal IgG-
synthesis, the number of OB's on iso-electric focusing and CSF-MBP. IgG and 
albumin were measured in unconcentrated CSF and diluted serum (1:400). Sheep 
antihuman IgG (Boehringer, Mannheim) and rabbit antihuman albumin 
(Behringwerke, Marburg) were used. Q-albumin was defined as albumin-CSF/albumin-
serom. The calculation of intrathecal IgG-synthesis (intrathecally produced IgG) was 
performed according to the hyperbolic Reiber formula [Reiber 1987]. Iso-electric 
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focusing was performed with Ampholine PAG-plates (by LKB; pH 3.5-9.5). MBP was 
determined according to the instructions of the manufacturer (Diagnostic Systems 
Laboratories, Webster, Texas) using a double antibody RIA-kit containing human 
basic protein (whole molecule) as antigen and rabbit anti-human MBP as anti-serum. 
Goat anti-rabbit gamma-globulin was used as MBP precipitation reagent. Human 
MBP (J125 2 ¿iCi/vial) was included in the test-kit. 
Statistical analysis was performed using the SPSS/PC™ statistical package. Data 
before and after treatment were compared by means of a Wilcoxon matched-pairs 
signed-rank test. Relations between clinical, MR and CSF data were investigated by 
means of Pearson's correlation coefficients. Nulhypotheses were tested two-sided and 
p-values smaller than 0.05 were considered statistically significant; p-values between 
0.05 and 0.10 were considered as trends. 
RESULTS 
Before MP-treatment, the median EDSS-score was 3.5 (mean 4.2), 84 Gd-
enhancing lesions were seen in 16 out of 20 scans (4 scans showed no enhancement) 
and all the mean values of the investigated CSF variables, except Q-albumin, were 
abnormal. Following treatment a reduction in EDSS score (median, 1.0) was observed 
(after 15 of 20 courses improvement was seen). Table 1 shows the mean values of 
clinical, CSF, and MR findings before and after treatment. Insignificant reduction in 
mononuclear cells (25%), OB's (6%), and Q-albumin (18%) were found after MP-
treatment. Following treatment there was a significant reduction in the number of Gd-
enhancing lesions (76%; 3 out of 16 scans showed less enhancement and 9 out of 16 
scans showed no enhancement), intrathecal IgG synthesis (66%), and CSF-MBP level 
(74%). After treatment, only the mean CSF-MBP level returned to reference values, 
while the mean values of all the other CSF variables investigated remained elevated. 
Table 2 displays the initial EDSS-scores, and changes after MP-treatment in EDSS, 
Gd-enhancement and CSF-MBP for the individual patients. 
The relation between Gd-enhancement, EDSS-score and CSF variables before 
treatment is shown in table 3. Only the number of Gd- enhancing lesions and the 
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CSF-MBP level correlated significantly. Trends were noted in the relation of Q-
albumin to Gd and in the relation of CSF-MBP to EDSS. There were no correlations 
of age or DD with either the EDSS-score or the number of Gd-enhancing lesions 
before treatment (not shown in table). 
The relation between the change in EDSS score and number of Gd-enhancing 
lesions on the one hand and change in CSF variables on the other hand is shown in 
Table 3. Significant relations were found in the decrease in number of Gd-enhancing 
lesions to the decrease in EDSS-score and in the relation of decrease in CSF-MBP 
level to both decrease in EDSS-score and decrease in the number of Gd-enhancing 
lesions. Λ trend was noted towards a negative correlation of the decrease in number 
of Gd-enhancing lesions and the change in number of OB's. There was a significant 
relation between the difference in EDSS score with the initial EDSS score (r=0.631, 
p=0.003) and with age (r=-0.464, p=0.039), and a trend in the difference in number 
of Gd-enhancing lesions with either initial EDSS-score (r= 0.398, p=0.08) or age (r=-
0.390, 0=0.09). The DD did not correlate with the difference in both EDSS-score or 
the number of Gd-enhancing lesions (not shown in table). 
Table 1: Median EDSS and mean MR and CSF variables before and after high-dose intravenous MP 
treatment. 
variable 
EDSS score 
Gd-lesions 
mono's (mm3) 
IgG synth. (mg/1) 
number of OB's 
CSF-MBP (ug/\) 
Q-alb (xlO*) 
reference 
0 
0 
< 9/3 
0 
0 
s 1.5 
< 670 
before (range) 
3.5 (2-7) 
4.2 (0-33) 
17.4 (0.78) 
23.6 (0-135) 
3.4 (0-12) 
2.3 (0-11.6) 
612 (264-1,217) 
SD 
1.3 
7.9 
16.3 
32.8 
3.2 
3.3 
217 
after (range) 
2.25 (2-6) 
1.0 (0-14) 
13.0 (2^9) 
8.1 (0-34) 
3.2 (0-13) 
0.6 (0.2-2.5) 
578 (296-1,191) 
SD 
1.2 
3.1 
11.9 
9.0 
3.3 
0.5 
227 
p-value 
0.0007 
0.0037 
NS 
0.0053 
NS 
0.0042 
NS 
p-values were calculated using Wilcoxon's matched pairs signed rank test. SD: standard deviation; NS: 
not significant; mono's: number of mononuclear cells; IgG synth.: intrathecal IgG synthesis; Q-alb: 
albumin quotient 
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Table 2: Clinical data and treatment effect on EDSS, Gd, and CSF-MBP for each patient 
patient 
A 
В 
С 
D 
El 
E2 
Fl 
F2 
Gl 
G2 
Hl 
H2 
I 
J 
К 
L 
M 
Ν 
О 
Ρ 
age 
35 
34 
39 
30 
26 
39 
33 
27 
22 
28 
35 
36 
27 
45 
39 
29 
sex 
M 
F 
F 
F 
M 
F 
F 
F 
F 
F 
F 
M 
F 
F 
F 
M 
DD 
15 
1.5 
15 
4 
1.5 
2.5 
2.5 
3 
1.5 
3.5 
5 
6 
4.5 
24 
10 
10 
entry-EDSS 
3.0 
3.0 
4.0 
6.0 
5.0 
7.0 
3.0 
3.0 
4.0 
3.0 
2.0 
3.0 
3.0 
6.0 
3.0 
4.0 
5.0 
7.0 
3.0 
6.0 
Û-EDSS 
1.0 
1.0 
го 0 
2.0 
5.0 
0 
1.0 
1.5 
1.0 
0 
1.0 
1.0 
2.0 
0 
1.0 
ZO 
1.0 
0 
3.0 
Û-Gd 
0 
0 
0 
4 
19 
17 
0 
0 
0 
1 
1 
1 
1 
5 
10 
-1 
0 
1 
1 
3 
Û-CSF-MBP 
0.70 
-0.30 
5.30 
0.30 
4.10 
5.50 
0 
-0.30 
0 
0.80 
-0.10 
0.10 
0.10 
1.30 
7.40 
0.30 
0.20 
0.30 
0 
9.10 
Û-EDSS, Û-Gd, Û-CSF-MBP: change 
following treatment. 
in EDSS score, number of Gd-lesions and CSF-MBP level 
Table 3. Relation between EDSS scores, Gd-enhancement and CSF variables, expressed as Pearson's 
correlation coefficients. 
Gd-lesions 
mono's 
intrathecal IgG 
OB's 
CSF-MBP 
Q albumin 
Number of Gd-lesions 
before treatment 
0.12 
-0.05 
-0.27 
0.46 (p=0.04) 
0.40 (p=0.09) 
treatment effect 
0.13 
-0.16 
-0.44 (p=0.05) 
0.56 (p=0.01) 
0.37 
EDSS-score 
before treatment 
0.13 
-0.06 
0.23 
0.12 
0.39 (p=0.09) 
0.32 
treatment effect 
0.50 (p=0.03) 
0.00 
0.02 
-0.36 
0.52 (p=0.02) 
0.36 
The Pearson's correlation coefficients shown are not statistically significant unless otherwise indicated 
(p values). 
DISCUSSION 
MR imaging is a very sensitive tool in the assessment of MS lesions [Paty 1988, 
Uhlenbrock 1988, Baumhefner 1990]. Lesions on T2-weighted images can not 
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differentiate the separate pathological stages of lesion development and represent 
both active and inactive disease. The lesion load on T2-weighted MR imaging 
represents predominantly disease activity in the past and is subject to small 
fluctuations only; some have found these to correlate with the EDSS-score (Truyen 
1990] and with neuropsychological testing [Baumhefner 1990, Rao 1989]. The number 
of hyperintense foci on T2-weighted images has previously been found to correlate 
with intrathecal IgG-synthesis [Baumhefner 1990, Baum 1990], but not with the 
number of mononuclear cells [Baum 1990] or OB's [Baumhefner 1990]. The relation 
of CSF-MBP to the number of hyperintense foci has never been investigated. MR 
imaging is capable of separating lesions with and without BBB disruption by means of 
Gd. The relation of Gd-enhancement to CSF findings has, to our knowledge, never 
been investigated. 
Gd-enhanced MR imaging and some CSF variables present information about the 
separate (early) stages of lesion development or disease activity at present and are 
subject to major fluctuations [Grossman 1988, Miller 1988, Bastianello 1990, Warren 
1987, Thompson 1983 and Thompson 1987]. We hypothesized that there would be a 
relation between Gd-enhancement and (some) CSF variables. Before treatment a 
significant relation was found between the number of Gd-enhancing lesions and the 
level of CSF-MBP. If Gd-enhancement stands for active inflammation [Katz 1990, 
Hawkins 1991, Kuharik 1988] and CSF-MBP stands for demyelination [Warren 1987], 
the volume of inflamed tissue relates to the amount of myelin being damaged and 
indicates that inflammation is directly accompanied (and not followed) by 
demyelination. Evidence for the occurrence of demyelination early in the development 
of lesions is also found in the demonstration of lipid peaks in the MR spectra of new 
lesions [Wolinsky 1990]. 
The intrathecal IgG synthesis is usually elevated during the remission phase of MS 
[Thompson 1987, Caroscio 1986] and therefore seems not especially linked to current 
disease activity. This might explain the correlation reported between intrathecal IgG-
synthesis and T2-weighted MR imaging [Baumhefner 1990, Baum 1990] and the 
absence in our study of a correlation between intrathecal IgG-synthesis and Gd-
enhancement. The number of OB's, although not constant over time [Thompson 
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1983], is not subject to great variations [Thompson 1983 and Thompson 1987], and 
the absence of a correlation with Gd-enhancement is therefore not surprising. 
The rationale for immunosuppressive treatment, such as MP-treatment, is to 
suppress the inflammatory reaction of the immune system, in order to prevent or stop 
the process of demyelination [Warren 1987, Thompson 1989]. In the present study a 
significant decrease of intrathecal IgG-synthesis [Frequin 1990, Warren 1987, Durelli 
1986, Milligan 1987] and CSF-MBP levels was found [Frequin 1990, Warren 1987] 
after MP-treatment, but not of OB's [Wajgt 1983], mononuclear cells number or Q-
albumin. The CSF-MBP level, however, was the only CSF variable to return to 
reference values. Interestingly, the decrease in CSF-MBP level correlated significantly 
with the decrease in number of Gd-enhancing lesions and EDSS-score. After high-
dose intravenous MP treatment both Gd-enhancement and CSF-MBP levels improved 
in a similar way, which might indicate that its clinical action is accompanied by 
improved BBB integrity and decreased myelin breakdown. The changes in other CSF 
variables did not correlate with the decrease in Gd-enhancement. 
There was a trend towards correlation of the number of Gd-enhancing lesions and 
the Q-albumin before treatment, but the decrease in number of Gd-enhancing lesions 
following MP-treatment showed no significant relation with the changes in albumin-
quotient (not significantly lower), although both represent BBB-integrity. In animal 
studies of experimental allergic encephalitis enhancement of Gd-albumin complex was 
only seen in 4 out of 6 Gd-enhancing lesions, while in 2 of these lesions the extent 
and intensity was less than with Gd [Hawkins 1990]. The molecular weight of Gd (550 
Da) and albumin (60kDa) is considerably different, as might their routes of transport 
across the BBB be, thereby giving a possible explanation for the absence of a good 
correlation. 
The correlative triad of clinical improvement, restoration of BBB-integrity and 
decrease of myelin breakdown following MP-treatment is certainly one of the most 
salient findings of this study. The decrease in recent lesions after MP is accompanied 
by a decrease in myelin breakdown. The changes in EDSS, Gd, and CSF-MBP could 
have been the result of the natural course. We think, however, that the finding of a 
correlative triad pleads against this. Placebo-controlled studies could clarify this issue. 
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If the changes in Gd-enhancement and CSF-MBP are indeed the result of MP 
treatment it is impossible to decide from these data whether they are a primary result, 
i.e. that MP actually interferes with the process responsible for demyelination, or that 
they are a secondary result, i.e., that MP only interferes nonspecificaUy with the 
mediators of the disease process or acts directly on the BBB and in that way prevents 
the transfer of mononuclear cells into the brain [Long 1985]. The fact that the 
number of mononuclear cells and OB's did not drop significantly might indicate that 
the inflammatory process is not completely stopped after MP treatment (or that both 
variables are not correlated with acute inflammatory activity in the brain). 
Both age and initial EDSS score showed a significant correlation with the change 
in EDSS after treatment, but not with the decrease in Gd-enhancement, which might 
indicate that there was some favourable change after treatment (decreased BBB 
disruption), which was not appreciated by the EDSS scoring system in relatively older 
or less disabled patients. Clinical disease activity as assessed by the EDSS mainly 
represents the result of lesions in the brainstem and spinal cord. Serial MR studies 
have shown that MR activity is far more frequent (especially in so-called "silent 
regions") than clinical activity. It is therefore far from surprising that there is no 
perfect correlation between Gd-enhancement and EDSS changes. 
The finding of a correlative triad of (changes in) CSF-MBP, Gd-enhancement and 
EDSS (following MP-treatment), indicates that these variables might become of more 
importance for the evaluation of progression of the disease and for monitoring clinical 
trials in addition to ordinal clinical scoring systems like the EDSS with their fallacious 
pitfalls [Noseworthy 1990, Francis 1991]. When substantiated this could have 
implications for the population size and follow-up time needed to be able to 
demonstrate a certain effect of putative drugs in treatment trials in MS. 
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SUMMARY 
A total of 101 patients (62 females; 39 males) with definite MS were treated 
with 1000 mgr methylprednisolone (MP) intravenously for 10 consecutive days. 
Immediately before and after MP treatment clinical scoring: Kurtzke's Expanded Dis­
ability Status Scale (EDSS) and cerebrospinal fluid (CSF) analysis were performed. 
Before MP treatment CSF myelin basic protein (MBP), IgG and IgM levels 
immunoglobulin levels (CSF Ig, index and intrathecal synthesis) were significantly 
elevated. The mean CSF MBP levels were significantly higher in the relapsing-
remitting (RR) and chronic progressive MS patients with relapses (CP+RR) than in 
the CP group without a RR disease course, respectively 2.1, 2.3 and 1.5 μg/l. A weak 
positive correlation was found between CSF MBP level and EDSS in the RR MS 
group (r=.34). CSF MBP was significantly correlated with IgM index (r=.36), IgM 
synthesis (r=.26), but not with the IgG levels. Therefore demyelination seems to be 
related to intrathecal IgM production. 
After MP treatment mean (median) EDSS decreased from 4.4 (4.0) to 3.3 
(3.0). Except for CSF/serum albumin (Q albumin) and IgM index, all CSF levels 
decreased significantly after MP. The mean CSF MBP returned to reference values. 
In the RR group the decrease in CSF MBP was significantly correlated with the 
change in EDSS (r=.39). CSF MBP seems to be a good parameter for disease activity 
in relapsing MS. Following treatment CSF MBP was found to be related with the 
change in IgM index (r=.30). MP treatment reduces CSF MBP and intrathecal IgM in 
a similar way indicating a relation between these 2 parameters. 
131 
INTRODUCTION 
Nowadays high dose intravenously administered methylprednisolone (MP) has 
an established role in the treatment of multiple sclerosis (MS) (1,2). In relapsing 
multiple sclerosis patients a significant decrease in clinical disability scores compared 
with controls (3), placebo (3,4) or other therapy regimens (5) is reported after MP 
treatment. A reduction is found in contrast enhancement of MS plaques on CT-scan 
(6) and recently also in gadolinium-DTPA enhancement on MRI (7), all suggesting 
that restoration of the Blood Brain Barrier (BBB) integrity is improved or accelerated 
after MP. 
There have been relatively few reports discussing the effects of intravenously 
administered MP on cerebrospinal fluid (CSF) parameters in MS. A reduction in 
intrathecal IgG synthesis, myelin basic protein (MBP), anti-MBP, and anti- MAG 
(myelin associated glycoprotein) is reported (8-14). Qualitative IgG abnormalities, i.e. 
oligoclonal banding (OB) on iso-electric focusing (IEF) seems to be uninfluenced 
(3,8,9,15). How exactly the immune response and myelin breakdown in MS are 
tempered or influenced by MP treatment is unclear. We studied the effect of MP 
treatment on CSF MBP and immunoglobulin levels in 101 MS patients and the 
relation between CSF MBP and immunoglobulin levels. 
MATERIALS AND METHODS 
A total of 101 consecutive MS patients ( 62 females ; 39 males) with clinically 
definite MS (CDMS) or laboratory supported definite MS (LSDMS), according to the 
criteria of Poser (16), who presented to the Department of Neurology of the Uni-
versity Hospital in Nijmegen with a symptomatic deterioration, were studied between 
1988 and 1990. Mean age and disease duration (DD) was 3S.4 (range 22-58) and 8.8 
(range 0.7-24.8) years, respectively for the females; 35.2 (range 21-50) and 7.3 (range 
0.3-23.0) years, respectively for the males. 
All patients had a symptomatic deterioration and were classified to disease 
course: chronic progressive (CP) - 47 patients, relapsing remitting (RR)- 37 patients, 
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and a combination (CP+RR)- 17 patients. A relapse was defined as a symptomatic 
deterioration with the occurrence of one or more new symptoms or worsening of 
existing symptoms of less than 8 weeks but lasting longer than 24 hours without 
evidence of spontaneous improvement. A chronic progressive (CP) disease course was 
determined as a continuous symptomatic deterioration of neurological symptoms for 
at least 6 months. CP+RR was the combination of a chronic progressive disease 
course accompanied by relapses and remissions. All patients in the RR and CP+RR 
group had a relapse at the time at entrance into the study. No patient had used 
immunosuppressant agents 6 months or longer prior to entrance. 
Reference values for CSF parameters were determined in a group of 35 
patients (18 females, mean age 41.2, range 15-66 years; 17 males, mean age 45.0, 
range 17-65 years) with psychoneurosis without evidence of any organic, infectious or 
auto-immune inflammatory neurologic disease. The diagnoses were conversion 
disorders, tension headache and nervositas. 
The patients were treated with 1000 mg MP dairy for 10 consecutive days 
administered intravenously between 09.00 and 10.00 A.M. during approximately 15-20 
minutes. No tapering dose was used. Therapy was tolerated well. Four major side-
effects occured : one epileptic seizure, one exacerbation of chronic bronchitis, one 
herpes zoster infection, and one peptic ulcer. Immediately before and after MP 
treatment blood samples and CSF taps were obtained simultaneously. Clinical scoring 
was performed according Kurtzke's Expanded Disability Status Scale (EDSS) (17) 
before and after MP treatment simultaneous with the blood and CSF examination by 
an examiner (S.T.F.M.F.) who was unaware of the CSF findings. 
Peripheral venous blood and CSF samples were drawn according to standard 
procedures. Samples of blood and CSF were stored within 30 minutes at -70 С until 
assayed. IgG and albumin in unconcentrated CSF were measured by means of an 
automated kinetic turbidometric method described by Jongen et al (18). In brief sheep 
antihuman IgG (Boehringer, Mannheim, FRG) and rabbit antihuman albumin 
(Behringwerke AG, Marburg/Lahn, FRG) were used. Serum was always diluted 
(1:400) with saline, and both specimens (CSF and serum) were run in the same batch. 
IgM in CSF was measured by an ELISA method. Plates were coated with 150 μΐ/well, 
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1/500 diluted rabbit anthuman IgM in PBS-buffer, pH 7.4 (DAKO, Copenhagen). 
CSF, ΙΟΟμΙ and (1:10) diluted CSF and human IgM standards (Behringwerke AG, 
Marburg/Lahn, FRG) in duplicate were used per well. Rabbit peroxidase-conjugated 
antihuman IgM (DAKO, P12S) was used for the enzyme reaction. The sensitivity level 
was 0.05 ng/ml. 
We used the following ratios in analysis : Q Albumin = CSF albumin 
concentration * 10s / Serum albumin concentration. Q IgG = CSF IgG concentration 
* 105 / serum IgG concentration. IgG index = Q IgG / Q Albumin. CSF index for IgM 
was calculated with a similar equation. The calculation of intrathecal (de novo) IgG 
and IgM synthesis was performed according to the hyperbolic Reiber Formula (19). 
For iso-electric focusing (IEF) CSF proteins were concentrated in micro-
collodion Bag type under 1000 kPa nitrogen pressure. A constant amount protein of 
CSF and diluted serum were applied for IEF before and after MP treatment. For IEF 
paired CSF and serum examination was done with ready made LKB Ampholine PAG· 
Plates (product nr. 1804-101, pH range 3.5-9.5) and Coomassie blue staining. CSF 
oligoclonal banding was compared with serum. Myelin basic protein (MBP) was dete­
rmined according to the instructions of the manufacturer (Diagnostic Systems 
Laboratories, Webster Texas USA, cat.nr. 1500), using a double antibody 
radioimmunoassay kit containig human basic protein (whole molecule) as antigen and 
rabbit anti-human MBP as anti-serum. Goat anti-rabbit gamma globulin was used as 
MBP precipitation reagent. Human MBP (J125 2 дСі/ іаІ) was included in the test kit. 
The detection limit was 0.1 μg/l ; the variation coefficient of the assay was 7.5%. 
Statistical analysis 
Data before and after MP treatment were compared by means of Wilcoxon's 
signed rank test. The Kruskall Wallis test was used for differences between the three 
disease course groups. Relations between CSF data were calculated by means of 
Spearman's correlation coefficient. Hypotheses were tested two sided and p-values 
smaller than .05 were considered statistically significant. As data were not complete in 
all patients, the calculations were performed on numbers smaller than 101, but high 
enough to guarantee clear statistical decisions. To avoid crowding the numbers are not 
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mentioned in the tables. 
RESULTS 
Table 1 shows the mean and median values of the clinical scoring (EDSS) and 
different CSF parameters before and after MP treatment for 101 MS patients. Before 
MP treatment, all mean CSF values, except for Q albumin, were significantly elevated 
compared to reference values. Oligoclonal CSF bands were present in 92% of the 
patients. Except for Q albumin, and IgM index, all CSF parameters decreased signi-
ficantly after MP treatment. In 10 patients the oligoclonal banding pattern completely 
disappeared after treatment. The decrease in EDSS (1.0 point or more) was 
significantly (p<.05) associated with young age (< 40 years) and short disease 
duration (< 8 years) and was not dependent of the disease course. 
Table 2 gives the results for the three different disease course groups. Before 
treatment the mean CSF MBP levels were significantly (p=.03) higher in the relapsing 
remitting (RR) and in the combined (CP+RR) group of MS patients compared to the 
CP MS group. CSF IgM (p=.014) and intrathecal IgM synthesis (p=.06) were higher 
in the relapsing remitting (RR) group versus the other 2 groups. After MP treatment 
only the mean CSF MBP levels for the three separate disease course groups of MS 
patients returned to normal values with respect to the reference values, while the 
mean values of all other CSF parameters investigated (except Q albumin) remained 
elevated. 
Table 3 shows the relations between CSF parameters for the whole MS group 
(n=101 patients). Before treatment CSF mononuclear cells were highly correlated 
with CSF MBP, IgG and IgM parameters. Moreover CSF MBP was significantly 
correlated with IgM parameters. IgM parameters were significantly correlated with 
IgG parameters. 
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Table 3: Spearman correlation coefficients of 6 CSF parameters in 101 MS patients before high dose 
intravenous methylprednisolone (MP) treatment. 
CSF Monon. MBP IgG index Intrathecal IgM index Intrathecal 
cells IgG synthesis IgM synthesis 
CSF Monon. 
cells 
MBP 
IgG index 
Intrathecal 
IgG synthesis 
IgM index 
Intrathecal 
IgM synthesis 
X 
.30»* 
.36*·* 
.37 *** 
.28** 
.30** 
X 
.06 
.13 
.36**· 
.26· 
X 
XX 
.25· 
.25 · 
X 
. 2 9 " 
.40 **** 
X 
XX 
Legend: Monon. cells = CSF mononuclear cells; MBP = myelin basic protein; Significance: * 
p<.05; ** = p<.01; *·· = p<.001; • · ·* = p<.0001. Without annotation means not significant. 
Before MP treatment (not in table) EDSS of the total MS group was not 
significantly related with any of the CSF parameters. Only in the relapsing MS group 
there was a trend (p=.06) towards a positive correlation between EDSS with CSF 
MBP (r=.34). In the 2 other groups such a correlation could not be demonstrated. 
Following MP treatment (not in table) the decrease in the total CSF mononuclear 
cells was correlated with the decrease in CSF MBP level (r=.26*1), IgG index (r = 
.27*) and intrathecal IgG synthesis (r = .33**). The decrease in CSF MBP was signifi-
cantly correlated with the decrease in IgM index (r = .30**); a trend (p < .10) was 
found between the decrease in CSF MBP and lowering in EDSS following MP treat-
ment (r = .18). This correlation was statistically significant in the RR group (r = .39*) 
but not in the 2 other groups. 
1
 p<.05 *, p<.01 ** 
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DISCUSSION 
Multiple sclerosis is probably an auto-immune mediated inflammatory de· 
myelinating disease from unknown origin. The pathofysiology of MS lesions may be 
divided in 4 different stages (20). Stage I stands for disruption of the blood-brain 
barrier (BBB) and is possible the first step in the demyelinating proces (21). Stage II 
stands for infiltration of lymphocytes and macrophages into the CNS; stage III for 
demyelination/myelin breakdown and stage IV for gliosis and scar formation ("sclerose 
en plaques"). Different lesions may be active at different stages simultaneously in the 
same patient (21). 
Corticosteroids (high dose intravenously administered methylprednisolone) can 
improve BBB integrity (stage I) as found by CT scan (6) and gadolinium enhanced 
MRI (7) and have an immunosuppressive effect (3) on the inflammatory proces (stage 
II). The rationale for immunosuppressive treatment is that the amount of myelin 
breakdown/demyelination (stage III) can be tempered or possibly stopped in order to 
prevent evolution into stage Г . 
In this study we have performed clinical scoring and CSF analysis in MS 
patients directly before and after MP treatment. This gives the opportunity to 
determine the effects of treatment on the different stages of the pathofysiological 
process of demyelination and to make relations between the clinical and CSF data. 
Q Albumin 
In the present study the elevated Q albumin, which may represent a disturbed 
BBB function, showed no significant decrease after MP treatment. Others too have 
reported no statistical difference (13,22). This is not in accordance with radiological 
studies (contrast-enhanced CT and gadolinium-DTPA enhanced MRI) which 
demonstrated an improved BBB integrity after methylprednisolone (6,7). A possible 
explanation for this is that the molecular weight of albumin (60 kDa) and for example 
gadolinium-DTPA (550 Da) is quite different as might their routes of transport across 
the BBB be. Therefore both methods, which may represent BBB function, probably 
are not measuring the same aspect of the BBB. 
139 
CSF mononuclear cells 
In this study, after treatment, there was a significant drop in CSF mononuclear 
cells for the relapsing remitting (RR) and the combined (CP+RR) disease course 
group but not for the chronic progressive (CP) MS group. No correlation was found 
with the clinical scoring (EDSS). Baumhefner et al (11), Compston et al (10), and 
Trotter et al (IS) did not find such changes, but their doses and total MP amounts 
(1000 mg MP intravenously for 3 days and 500 mg MP for 5 days) were much lower 
than our regimen. It is possible that the dose of 10 days 1000 mg MP may produce a 
stronger and significant reduction in CSF mononuclear cells, indicating a stronger 
effect on inflammatory activity than lower doses. 
IgG parameters (CSF IgG, IgG index, intrathecal IgG synthesL·) 
In the total MS group all three IgG parameters decreased significantly after MP 
treatment. IgG index decreased statistically significant only in the RR group. 
Decrease in intrathecal IgG synthesis after MP treatment is reported by several 
authors and is one of the most consistent findings about effects of MP on CSF 
parameters in both relapsing remitting and chronic progressive MS (3,8,9,11,15). In 
agreement with these studies we observed a significant reduction in intrathecal IgG 
synthesis in all 3 disease course groups of MS. 
IgM parameters (CSF IgM, IgM index, intrathecal IgM synthesL·) 
We found a trend towards a significant higher intrathecal IgM synthesis and 
significant higher CSF IgM in relapsing MS versus chronic progressive or the 
combined (CP+RR) disease course. Probably due to higher pre-treatment levels only 
in the relapsing MS group there was a significant decrease in CSF IgM, IgM index 
and intrathecal IgM synthesis after MP treatment. IgM parameters and EDSS were 
not significantly related to each other. 
Recently several studies about IgM in MS have been published. Sharief and 
Thompson (23) detected intrathecal production of IgM (IgM oligoclonal bands in CSF 
and calculation of IgM index) in 55% of MS patients (n=150) which was found tc 
correlate with disease activity defined as a recent relapse as well as the total numbei 
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of relapses. They concluded that intrathecal IgM synthesis as detected by CSF 
oligoclonal IgM bands is a useful parameter in monitoring disease activity in MS. 
Oligoclonal banding of IgM was found to be more specific for active disease than IgM 
index or the total CSF IgM amount. In an other study Sharief et al (24) established 
that CSF oligoclonal IgM is an indicator of recent immunological stimulation. We 
found a relation between IgM and disease activity, with a trend towards a higher in-
trathecal IgM synthesis and significantly higher CSF IgM in the relapsing MS group. 
Possibly the detection of CSF IgM abnormalities by an oligoclonal IgM method is 
more sensitive than the IgM index or calculated IgM synthesis. 
Iso-electric focusing 
After MP administration we found a significant drop in the number of 
oligoclonal bands (OB) on IEF in the whole MS group depending most on the 
decrease in the CP and RR disease course group. In 10 patients oligoclonal banding 
disappeared completely; 5 patients had a RR disease course, 3 a CP course, and 2 a 
combined (CP+RR) disease course. No correlation was found with the EDSS. This 
disappearance of oligoclonal banding pattern is reported in a small number of MP 
treated MS patients (3,15). Baumhefner et al (11) observed no significant changes. 
For determination of the IEF before and after MP treatment we have applied a 
standardized amount of protein and not a constant IgG amount in concentrated CSF. 
Because we found significantly lower CSF IgG levels after MP treatment the 
possibility occurs that faint bands before treatment are invisible after treatment. 
Anyhow in our opinion the significant difference of the number of oligoclonal bands 
between pre and post treatment can not be completely elucidated by the used 
method. In accordance with Tourtellotte et al (9), Durelli et al (3) sustained the 
hypothesis of a steroid-resistent colony of IgG synthesizing immunocytes within the 
CNS (clones of B-cells) because of the resistance of oligoclonal banding (OB). Our 
data suggest that probably the disease course, the dose and route of MP administ-
ration are important for the effects of MP on the decrease and disappearance of 
oligoclonal banding pattern after MP treatment. 
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CSF myelin basic protein 
CSF MBP levels were significantly different in the 3 disease course groups of 
MS. In the RR and the combined (CP+RR) MS group the levels were higher than in 
the CP group. In the relapsing MS group before treatment we found a positive trend 
between CSF MBP and clinical scoring (EDSS) and a significant correlation between 
their changes following MP treatment. Elevated levels of CSF MBP have been found 
in MS patients with active disease and seem to correspond with disease activity (25-
29). In a study of Martin-Mondière et al (30) MBP was not detected in any MS 
patient with inactive or slowly progressive disease nor in any patient during exacerba-
tions with only recurrence of old signs or symptoms. Thompson et al (31) found a 
significant correlation between CSF MBP and relapse severity in MS patients seen 
within 4 weeks of the onset of symptoms. Recently Barkhof et al (22) found a sig-
nificant correlation between CSF MBP, EDSS, and the number of gadolinium enhanc-
ing lesions by MRI in relapsing MS patients. Using gadolinium-enhanced MRI 
Thompson et al (32) found significantly more enhancing lesions in the group of 
secondary progressive (compare CP+RR) MS than in the primary progressive group 
(CP) which may indicate a difference in inflammatory disease activity. These two 
studies demonstrate that both parameters, CSF MBP and the number of enhancing 
lesions by gadolinium-enhanced MRI, seem to correspond with disease activity in MS. 
In our study a significant drop in CSF MBP levels after MP treatment was 
demonstrated. Warren et al (12,13,27) found in exacerbating MS patients a significant 
drop in CSF MBP after MP treatment (160 mg/day or 2 g/day for 10 days) in contrast 
to ACTH treatment (60 units/day intravenously for 10 days). MS patients with 
progressive disease showed relatively insignificant changes in MBP. Our results 
confirm those findings with significant decreases in the RR and CP+RR MS group 
and not in the CP group. All these results from different studies indicate that CSF 
MBP might be a good indicator of disease activity especially in relapsing MS patients. 
Correlations between CSF parameters before and following MP treatment 
Before and after MP treatment CSF mononuclear cells were significantly 
correlated with MBP, IgG index and intrathecal IgG synthesis. There was nc 
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significant correlation between MBP and IgG parameters. This is in accordance with 
findings of Warren and Catz (27) and Lamers et al (33) who also found no correlation 
between CSF MBP and CSF IgG measurements suggesting that demyelination and 
local IgG activity are not related. The only significant relationship before and after 
MP treatment between MBP and immunoglobulines was MBP and IgM index, 
indicating first that demyelination (stage III) occurs at the time of IgM production 
(stage II) and second that the effect of MP treatment is accompanied by a correlative 
decrease of myelin breakdown (expressed by decrease of MBP) and decrease of IgM 
production. This suggests that MP actually interferes with the inflammatory process of 
demyelination. After MP treatment we found a significant reduction in CSF mononu-
clear cells (stage II). This may implicate a reduction in the number of B-lymphocytes 
producing immunoglobulines in the CNS compartment. 
In summary CSF MBP may be a good parameter for disease activity and also in 
evaluation of therapy, especially in MS patients with relapsing disease course. CSF 
MBP seems to be related with intrathecal IgM production and not with IgG synthesis 
in the CNS. Methylprednisolone treatment reduces both parameters in a correlative 
way. The CSF MBP levels return to reference values, however IgM production does 
not normalize. This means that the immunological process of myelin breakdown is not 
completely eradicated and may continue. 
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SUMMARY 
To determine the effects of high-dose intravenous methylprednisolone (MP) on 
lymphocytes and lymphocyte subpopulations in the cerebrospinal fluid (CSF) and 
peripheral blood (PB) in multiple sclerosis (MS) patients, we studied 67 patients with 
definite MS treated with MP. They were classified according to the disease course: 32 
chronic progressive (CP) patients, 25 relapsing-remitting (RR) patients, and 10 
patients with a chronic progressive disease course accompanied by relapses and 
remissions (CP+RR). MS patients were treated with 1000 mgr intravenous MP daily 
for 10 consecutive days. Before and after MP treatment we simultaneously studied 
CSF and PB CD3+, CD4+, CD8+, CD20+, and Ial+ cell subsets. Kurtzke's 
Expanded Disability Status Scale (EDSS) was used for clinical evaluation. Progression 
rate was defined as the ratio of EDSS to disease duration. Thirteen patients with 
lumbar disk herniation were investigated as controls. Before MP, we found in MS 
patients, especially in the CP group, significantly lower CD4+ T-cell percentages in 
the PB with respect to controls (p < 0.05). The percentage of CD4+ T-cells in the 
CSF of MS patients was significantly higher compared with PB (ρ = 0.0001), and 
tended to be higher than in controls (p = 0.072). The CSF mononuclear cell counts 
were significantly correlated with higher percentages of CSF CD3+ (r = 0.40) and 
CD4+ (r = 0.47) T-cells and lower CSF CD8+ (r = -0.33) T-cell percentages. B-cell 
percentages in the CSF were significantly elevated compared with controls for all MS 
groups. No relation could be obtained between T- or B-cell subsets and EDSS or 
progression rate. After MP, a significant decrease in PB CD8+ T-cell percentage and 
simultaneously an increase of the percentage CD8+ T-cells in CSF was noted in the 
entire MS group and in the CP and RR MS patients. Except for the CP+RR MS 
patients, CD4+ T-cell percentages in the PB or CSF showed insignificant changes. 
Our findings support the view that in MS MP might affect the inflammatory process 
of demyelination by a selective and dissociative effect on T-suppressor/cytotoxic cells 
in the PB and CSF. 
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INTRODUCTION 
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central 
nervous system of unknown origin. Contradicting findings have been reported about 
T-cell subsets in the peripheral blood (PB) and cerebrospinal fluid (CSF) of active 
MS patients. Decreased CD8+ (suppressor/cytotoxic) T-cells in PB and CSF with an 
increase in the ratio CD4+/CD8+ which correlates with an increase in T-cell 
activation are found to be related to increased disease activity [1-6]. However, these 
findings could not be confirmed in other studies [7-9]. 
High dose intravenous methylprednisolone (MP) often results in a rapid clinical 
improvement in patients with exacerbating MS [10,11] and as well as a reduction of 
inflammation and demyelination expressed by a decrease of intrathecal IgG synthesis 
and CSF myelin basic protein [12,13]. After MP, suppression of gadolinium enhance-
ment on magnetic resonance imaging (MRI) of the brain is reported indicating 
restoration of the disturbed blood brain banier (BBB), which correlates well with 
clinical improvement [14,15]. 
Whether MP interferes primarily with the process of demyelination or reacts 
non-specifically with its mediators is not clear. MP might act by interference with 
cellular immune mechanisms. Therefore, we studied the effects of MP on lymphocytes 
and lymphocyte subpopulations in CSF and PB of MS patients. In order to determine 
how the changes (after MP) of T-cell subsets in PB are related to the changes in CSF, 
T-cell subsets were simultaneously studied in both compartments. 
PATIENTS AND METHODS 
Between 1988 and 1990 67 consecutive patients (42 women, 25 men,) with 
clinically definite (CD) or laboratory supported definite (LSD) MS [16] were studied 
at the University Hospital Nijmegen. The mean age was 35.5 years (range 21-54 yrs.), 
and mean disease duration was 8.5 years (range 0.5-24 yrs.). All patients suffered a 
clinical deterioration and were classified according to disease course: chronic progre-
ssive (CP- 32 patients), relapsing-remitting (RR- 25 patients), and chronic progressive 
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with relapses and remissions (CP+RR- 10 patients). A relapse was defined as either 
the onset of new symptoms and signs or a deterioration in existing symptoms and 
signs within the previous 8 weeks and lasting longer than 24 hours, without evidence 
of spontaneous improvement. CP was defined as a continuous clinical deterioration of 
neurological symptoms and signs for at least 6 months. All patients in the RR and 
CP+RR disease course groups had a relapse at the moment of entrance into the 
study. No patient had used immunosuppressant agents 6 months prior to entrance into 
the study. 
Patients were treated with 1000 mg methylprednisolone-acetate (MP) daily for 
10 consecutive days administered intravenously between 9:00 and 10:00 a.m. over 
approximately 15-20 minutes. No tapering dose was used after the 10 day MP course. 
Before and after MP treatment, the clinical status was scored according to 
Kurtzke's Expanded Disability Status Scale (EDSS) [17] by a neurologist (SF) who 
was unaware of the CSF and PB findings. Progression rate was defined as the ratio of 
EDSS to disease duration. Thirteen patients (8 women, 5 men), aged 30-69 years 
(mean 42.1 yrs.), with herniated lumbosacral discs served as controls. 
Immediately before and after MP treatment, PB and CSF samples were 
obtained simultaneously according to standard procedures. White blood cell count and 
leukocyte differentation were performed routinely using a Coulter Counter and May-
Grunwald Giemsa staining. For determination of lymphocyte subpopulations, 
lymphocytes from heparinized PB were isolated by Ficol-isopaque density gradient 
centrifugation (1.085 g/cm3). The remaining erythrocytes were lysed and the cells were 
washed twice and labelled according to the procedure described by Reinherz et al. 
[18]. The following monoclonal antibodies (MAB) were used: anti-CD3 (OKT3, total 
Τ cells), anti-CD4 (OKT4, helper/inducer T-cells), anti-CD8 (OKT8, suppressor/cyto-
toxic T-cells), anti-OKIal (activated cells, Ortho Pharmaceutical, Raritan, N.J.), and 
anti-CD20 (B-cells, Coulter clone, Lutton, Beds; England). 
For CSF cell analysis we used a micromethod. The CSF was centrifuged (10 
minutes, 400 χ g, 20°C) and the supernatant was removed. The remaining cell 
suspension was aliquoted over 6 Eppendorf cups ( ± 50 μΐ each). The cells were 
washed once with 2% bovine serum albumin in Tris buffered minimal essential 
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medium. The supernatant was removed, and to the remaining cell suspension ( ± 5 0 
μΐ) 2 μΐ MAB was added and the suspension was incubated for 30 min at 4°C. After 
two wash steps, the suspensions were incubated with 23 μΐ goat anti-mouse 
fluorescene isothiocyanate conjugate (GAM/FITC). After incubation, the cells were 
washed twice and the cell pellets were fixed overnight in 100 μΐ 1% paraformaldehyd-
e. Then 10 μΐ ethidium bromide (10 g/ml PBS) was added for nuclear staining. 
Subsequently, the cell suspensions were cytocentrifuged and embedded in gl-
ycerol/NaN3 (25mg NaN3 and lOmg paraphenylene diamine in 1 ml aqua bidest and 9 
ml glycerol). For cell counting we employed a Zeiss fluorescence microscope equipped 
wih a HBO 50W mercury lamp and the filter combination BP 485/20, FT 510, LP 520, 
using an oil immersion objective 63 χ 1.30 and a pair of 8X oculars. At least 100 cells 
in duplicate were counted per monoclonal antibody. In both PB and CSF the 
proportion of lymphocytes was expressed as the percentage of the total mononuclear 
cell count. 
Statistics 
Differences between the three disease course groups were tested by means of 
the Kruskall-Wallis test. Data before and after MP treatment were compared by 
means of the Wilcoxon's signed rank test. Relations between PB and CSF data were 
calculated by means of Spearman's correlation coefficient. P-values of 0.05 or less 
(two-sided) were considered as statistically significant; p-values between 0.05 and 0.10 
were considered as trends. 
RESULTS 
T-cell subsets in PB and CSF of 67 MS patients before and after MP treatment (Table 1) 
Before MP treatment, CSF B-cells were significantly higher (p < 0.005), PB 
CD4+ T-cells and PB CD4+/CD8+ ratio levels were significantly lower (p < 0.05) in 
MS patients than in controls. The percentage of CSF CD4+ T-cells in MS patients 
tended to be higher compared with controls (p = 0.072) (Figure 1). In the MS 
patients, the percentage of CD4+ T-cells in the CSF was significantly higher than in 
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the PB (ρ = 0.0001) (not in the table). After MP treatment, a significant increase was 
found in the CSF CD8+ cells (p = 0.0009) resulting in a decrease of the CSF 
CD4+/CD8+ ratio, and a decrease in PB CD8+ T-cells (p = 0.0006) resulting in an 
increase of the PB CD4+/CD8+ ratio (Figure 2). Spearman's correlation coefficients 
between the PB and CSF variables before MP treatment are shown in Table 2. There 
is a clear positive correlation between each corresponding T-cell subset percentage in 
the CSF and PB. Table 3 shows the correlation coefficients between the total number 
of CSF mononuclear cells and T-cell subsets in the PB and CSF. A high cell count of 
CSF mononuclear cells correlates with higher percentages of CSF CD3+ and CD4+ 
T-cells and lower CSF CD8+ T-cell percentages, and subsequently higher CSF 
CD4+/CD8+ ratios. 
Table 1: EDSS, peripheral blood (PB) and cerebrospinal fluid (CSF) Τ subsets in 67 Multiple Sclerosis 
(MS) patients before and after treatment with high-dose intravenous methylprednisolone (MP) and in 
13 controls with lumbosacral disk herniation. 
Controls Unit MS patients p-value 
EDSS 
PB leukocytes 
lymphocytes 
CD3+ 
CD4+ 
CD8+ 
CD4+/CD8+ 
Ial+ 
Bl 
CSF mononuclear cells 
CD3+ 
CD4+ 
CD8+ 
CD4/CD8+ 
Ial+ 
Bl 
. 
7.2 (2.8) 
29.9 (5.0) 
66.6 (7.3) 
46.0 (8.9) 
20.3 (4.5) 
2.4 (0.7) 
8.8 (4.4) 
5.5 (2.9) 
2.8 (2.4) 
76.8 (6.1) 
49.8 (9.7) 
18.8 (5.9) 
2.7 (1.1) 
7.3 (2.2) 
2.4 (3.2) 
. 
xl09/L 
% 
% 
% 
% 
-
% 
% 
/3mm3 
% 
% 
% 
-
% 
% 
before MP 
4.3 
6.3 (2.3) 
27.5 (8.8) 
61.3 (11.8) 
37.3 (12.7)· 
23.8 (9.1) 
1.9 (1.1)* 
9.1 (5.8) 
5.2 (4.1) 
19.6 (33.7)·*· 
79.2 (11.2) 
55.7 (13.7)# 
21.9 (7.6) 
2.9 (1.4) 
9.1 (5.5) 
5.6 (4.3)** 
after MP 
3.4 
10.4 (4.5)·· 
19.1 (10.3)··· 
59.9(11.0)· 
37.1 (13.6)· 
21.0 (7.4) 
2.1 (1.3) 
10.7 (6.2) 
5.9 (3.6) 
11.1 (15.6)··· 
78.7 (10.4) 
51.6(11.7) 
25.3 (9.0)· 
2.3 (1.0) 
12.8 (8.1)· 
7.8(5.8)··· 
0.001 
0.0001 
0.0001 
ns 
ns 
0.0006 
ns 
ns 
ns 
0.0005 
ns 
ns 
0.0009 
0.0001 
0.0075 
ns 
Legend: Mean levels with one standard deviation are reported. Wilcoxon's rank sum test; 
* =p < 0.10; * =p < 0.05; · · =p < 0.01; · ·* =p < 0.001 tested against the controls (second co­
lumn); without annotation corresponds to values which are not significantly different with respect to 
the controls. In the last column the p-values indicate the significance between the levels before and 
after treatment. EDSS= Expanded Disability Status Scale; ns» not significant The percentages of 
Ial+ and Bl cells refer to the percentages of mononuclear cells in the PB and CSF, respectively. 
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Figure 1. Mean percentages (± 1 standard deviation) of CD4+ T-cells in the CSF and PB of 67 MS 
patients before and after high-dose intravenous MP, according to the course of the disease, and in 13 
controls. CP= chronic progressive; RR= relapsing-remitting; CP+RR= combination. 
CD8+ T-cells 
% of T-cells 
20 
CSFVPB CSFVPB 
Before After 
MS 
CSFVPB CSF/PB 
Before After 
CP 
CSF/PB CSFVPB 
Before After 
CSFVPB CSFVPB 
Before After 
CP»RR 
CSFVPB 
Controle 
Figure 2. Mean percentages (± 1 standard deviation) of CD8+ T-cells in the CSF and PB of 67 MS 
patients before and after high-dose intravenous MP, according to the course of the disease, and in 13 
controls. 
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Table 2: Spearman correlation coefficients between the percentages of T-cell subsets in the PB and 
CSF of 67 MS patients before MP treatment. 
PB 
CD3+ 
CD4+ 
CD8+ 
CD4+/CD8+ 
Ial + 
Bl 
CSF 
CD3+ 
034· · 
0.36·« 
ns 
ns 
ns 
ns 
CD4+ 
0.28· 
030* 
ns 
0.24* 
ns 
ns 
CD8+ 
ns 
ns 
034· · 
-0.32· 
ns 
ns 
CD4+/CD8+ 
ns 
ns 
ns 
0L29» 
ns 
ns 
Ial+ 
ns 
ns 
ns 
ns 
036 · · 
0.50··· 
Bl 
ns 
ns 
ns 
ns 
0.28· 
0.45··· 
Legend: ns = not significant; · = ρ < 0.05; · · = ρ < 0.01; »·· = ρ < 0.001; · · ·* = ρ < 0.0001. 
Table 3: Spearman correlation coefficients between the CSF total number of mononuclear cells with 
the percentages of T-cell subsets in the PB and CSF of 67 MS patients before MP treatment. 
CSF Mononuclear cells 
PB 
CSF 
CD3+ 
ns 
0.40*·· 
CD4+ 
0.25' 
0.47"·· 
CD8+ 
ns 
-0.33 
CD4+/CD8+ 
0.25* 
0.46 
Ial + 
ns 
ns 
Bl 
ns 
ns 
Legend: See Table 2. 
Relation between clinical variables and T-cell subsets in PB and CSF before and after 
MP treatment 
The EDSS-score decreased significantly after MP for the entire MS group and 
in all subgroups (Tables 1 and 4). The CSF mononuclear cell counts were significantly 
higher in the patients with a RR or CP+RR disease course than in the patients with a 
CP course (p < 0.05). The CSF mononuclear cell counts were negatively correlated 
with age (r = -0.44; ρ < 0.001) and disease duration (r = -0.32; ρ < 0.01). None of 
the other cellular variables were significantly correlated with the course or duration of 
the disease, age, EDSS, or rate of progression of the disease. The values of the 
different PB and CSF variables for the various courses of disease are shown in Table 
4. The changes of the T-cell subset percentages after MP were independent of the 
changes in the EDSS and not significantly correlated with the various courses and rate 
of progression of the disease (not in the table). 
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DISCUSSION 
The most striking finding in this study is the different effect of MP on CD8+ T-
cells in PB and CSF. The percentage of CD8+ T-cells (with corresponding changes in 
the CD4+/CD8+ ratios) decreases in the PB and increases in the CSF concomitantly, 
independent of the course of disease. The decrease of CD8+ T-cells in the PB and 
increase in the CSF may represent migration of these CD8+ T-cells into the central 
nervous system [19]. Although most cells in the CSF are of hematogenous origin [20], 
both selective migration of cells through the blood brain barrier and intrathecal 
expansion could contribute to different Τ subsets in PB and in CSF [21,22]. Weiner et 
al. [23] proposed that (chronic) active lesions in the CNS of MS patients could be the 
sequestration site of the CD8+ T-cells. Hayashi et al. [24] and McCallum et al. [25] 
found also a predominance of CD8+ lymphocytes in the perivascular and 
parenchymal compartments of MS lesions. Raine [26] stated that the strongest 
evidence for cessation or reversal of the immunological events in the resolving MS 
lesion lies in finding fewer CD4+ T-cells in the parenchyma and an increased 
presence of CD8+ T-lymphocytes, particularly around blood vessels. Estes et al. [27] 
indicated that both CD4+ and CD8+ lymphocytes are present in active MS lesions. 
Data on the effects of corticosteroids on T-cell subpopulation in MS patients 
are often conflicting. Compston et al. [28] reported no statistically significant effects 
on OKT4 and OKT8 cells in the PB of MS patients after MP treatment. Salinaggi et 
al. [29] found increased numbers of CD3+ and CD4+ T-cells, with an increased 
CD4+/CD8+ ratio, in the PB of MS patients during dexamethasone treatment 
followed by a decrease 1 and 2 weeks after the end of the treatment. Kirk and 
Compston [30] reported no alterations in CD4+ and CD8+ T-cells, or activated 
lymphocytes in the PB in 25 MS patients who were treated with 0.5 g 
methylprednisolone intravenously daily for 5 days. CSF analysis was not performed in 
these three studies. 
In the present study we found a significantly lower percentage of CD4+ T-cells 
in the PB of MS patients, especially in the CP group. In MS patients, the percentage 
of CD4+ T-cells in the CSF was significantly higher than in the PB and the CSF 
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CD4+ T-cell percentage tended to be higher than that of controls. These findings are 
in accordance with the study of Scolozzi et al. [31]. In our study, normal percentages 
for CD8+ T-cells in the PB and CSF of the MS patients, independent of the course 
of the disease, were obtained. Other studies have revealed a loss of circulating CD8+ 
(suppressor/cytotoxic) T-cells in PB or CSF in active or chronic progressive MS with 
subsequently higher CD4+/CD8+ ratios [6,18,32-36]. However, unchanged levels of 
CD8+ T-cells have been reported by others, both in PB or CSF [8,9]. One reason for 
the conflicting results may be that different methods (staining by fluorescent or 
enzyme-linked antibodies, type of antibody used, enumeration of the cells by 
microscopical evaluation or by flow cytometry) are used for determine the PB and 
CSF cells, usually requiring high CSF cell counts. We used a micro fluorescence 
method with the advantage of performing lymphocyte-subset analysis in the CSF in 
the abscence of pleocytosis. 
Comparing the different disease courses in MS, we found a significant relations-
hip between disease course and CSF pleocytosis: MS patients in acute relapse (RR or 
CP+RR) had higher CSF cell counts than patients with chronic progressive (CP) 
disease. This is consistent with previous reports [31,37,38]. No relationship could be 
found between the percentages of T-cell subsets in CSF or PB with the different 
courses of disease or other clinical variables (EDSS, disease duration, progression 
rate). 
The CSF pleocytosis in the MS patients in our study consisted predominantly of 
CD3+ T-cells, whose percentage is significantly higher in CSF than in PB. This is in 
agreement with previous studies [39,40]. Furthermore, the CSF pleocytosis is positively 
correlated with the percentage CSF CD4+ T-cells and negatively correlated with the 
percentage CSF CD8+ T-cells. A correlation of higher CSF mononuclear cell counts 
with a decreased percentage of suppressor/cytotoxic T-cells in the CSF has been 
found also by others [2,41]. Vanderbark et al. [22] stated that a selective increase of 
CD4+ T-lymphocytes account for increased cellularity in the CSF. 
The percentage of B-lymphocytes in the CSF of MS patients was significantly 
higher than in controls; this was not found in PB. Prior studies, using different 
methodologies, have found either higher or lower percentages of B-cells [42,43]. The 
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lal antigen, usually present on monocytes, B-lymphocytes, and some activated CD4+ 
T-cells [18], was found to be normal in PB and CSF. Similarly, Hauser et al. [2] have 
not found an increased percentages of lai + cells in the PB and CSF of MS patients. 
After treatment with intravenous 1000 mg MP daily for consecutive 10 days, we found 
a leukocytosis in the PB, a decrease in the lymphocyte percentage, and unchanged PB 
CD3+ and CD4+ T-cell percentages. The reduction of the percentage of lymphocytes 
in the PB after MP is probably due to a redistribution of lymphocytes from intravas­
cular into peripheral compartments rather than due to killing of cells [44,45,46]. 
In conclusion, our findings suggest that in MS patients MP increases the Τ suppres-
sor/cytotoxic subset in the CSF, possibly through migration of CD8+ T-cells from the 
PB compartment into the CNS. So, MP might have a selective and dissociative effect 
on CD8+ T-cells in the PB and CSF in MS and MP might affect the inflammatory 
process of demyelination by interference with T-suppressor/cytotoxic cells. 
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SUMMARY 
In extracerebral systemic lupus erythematosus (SLE), the complement system 
plays a prominent pathogenic role and decreased serum concentration of the fourth 
component (C4) is a reliable indicator of systemic disease activity. In diffuse CNS-
SLE, however, the pathogenic role of complement is less clear. In 12 patients with 
active diffuse CNS-SLE, presenting with delirium (4), organic personality syndrome 
(3), or generalized seizures (5), we determined the cerebrospinal fluid indices (CSF 
indices) of the complement components C3, C4, and factor B, and of the 
immunoglobulins IgG, IgA, and IgM. There was a significant increase of the C4 index 
in these patients compared to controls, and a significantly higher CSF C4 index in 
patients with an increased IgM index. We conclude that intrathecal C4 is being 
produced in diffuse CNS-SLE. 
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INTRODUCTION 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease 
characterized by the production of autoantibodies against a large number of antigens, 
as well as the deposition of immune complexes of antigen and antibody (1С), and 
complement components in various organs \ Central nervous system involvement in 
SLE (CNS-SLE) is a common and serious manifestation, occurring in approximately 
half of all patients at some time during the course of their illness *· 3. The most 
common neuropsychiatrie manifestations of SLE - delirium, organic personality 
syndrome, cognitive impairment, and generalized seizures - reflect diffuse brain 
dysfunction 3. Presumably, they result from the combined effect of antineurona] 
antibody binding to brain tissue and immune complex-mediated vasculopathy 3' 4, 
although the exact pathogenic mechanisms have not yet been elucidated. 
In patients with active CNS-SLE there are increased CSF indices of IgG, IgA, 
and especially IgM, indicating intrathecal immunoglobulin synthesis 5' 6 . There are 
also 1С in the CSF of CNS-SLE patients 7. Since IC-induced activation of the classical 
complement system plays a prominent role in SLE pathogenesis 8, intrathecal 
complement activation and consumption might occur in CNS-SLE 9. If so, increased 
complement synthesis is to be expected, analogous to complement production after 
hypocomplementemia in extracerebral SLE 10, n . In fact, in CNS-SLE patients, CSF 
concentrations of the fourth component of complement (C4) are abnormally low 9 or 
normal 1 2 · 1 3 . However, for several reasons, measurement of only CSF concentrations 
is not an appropriate method to detect complement involvement in CNS-SLE. Firstly, 
in view of the wide normal ranges of CSF complement concentrations, minor changes 
do not necessarily lead to abnormal levels. Secondly, CSF complement concentrations 
are derived from, and related to, serum concentrations; therefore abnormally low 
CSF concentrations do not necessarily reflect complement consumption within the 
CNS. Thirdly, impairment of the blood-brain barrier (BBB) results in transudation of 
complement components and an increase of CSF concentrations. Calculation of the 
CSF complement indices, analogous to CSF immunoglobulin indices 14, meets these 
objections and might demonstrate intrathecal synthesis or consumption of 
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complement. 
We determined the values of the 3rd and the 4th complement components 
(C3, C4) and factor B, as well as IgG, IgA, IgM, and albumin, in paired serum and 
CSF samples from 12 patients with diffuse CNS-SLE and examined the respective 
CSF indices. 
PATIENTS 
We studied 12 patients with diffuse CNS-SLE, who had previously or 
concurrently satisfied the 1982 American Rheumatism Association (ARA) diagnostic 
criteria for definite SLE 15. Nine were woman, 3 men. Ages ranged between 17 and 
61 years (Table 1). They were seen in the period 1983 to 1988 when hospitalized at 
the University Hospital Nijmegen. Clinical assessment included internal, neurologic, 
and psychiatric examination. All patients showed unequivocal psychiatric or 
neurologic signs and symptoms of progressive diffuse CNS dysfunction, suggesting 
active CNS-SLE. Psychiatric diagnoses according to the Revised 3rd edition of the 
Diagnostic and Statistical Manual of Psychiatric Disorders (DSM-III-R) 16 were 
delirium with cognitive impairment (2), delirium without cognitive impairment (2), 
organic personality syndrome (OPS) with cognitive impairment (1), and OPS without 
cognitive impairment (2). Generalized seizures (5), in one patient associated with 
cognitive impairment, accounted for the neurologic diagnoses (Table 1). All patients 
showed abnormalities on routine CSF studies (total protein concentration, total 
leucocyte count), electro-encephalogram (generalized slowing of background activity 6, 
generalized spikes 4), or cerebral computerized tomography (slight cortical marking 2; 
slight cortical and central marking 5, moderate cortical and central marking 1, and 
severe cortical and central marking 1). At the time of diagnosis, CNS dysfunction 
could not be attributed to infectious disease, metabolic disturbances, or psychogenic 
reactions. Steroid-induced delirium was unlikely, since all delirium patients improved 
after increases of steroid dosage. In patients 2 and 7 (Table 1) a concomitant SLE 
nephritis existed, but serum urea concentrations did not suggest uremic 
encephalopathy. In no patient did the diagnosis have to be changed during the course 
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of the disease. 
The control group consisted of 25 patients without evidence of systemic 
connective tissue disease, and infectious or autoimmune inflammatory neurologic 
disease. Diagnoses included radiating low back pain, without abnormalities on 
subsequent myelography (21), and psychogenic conversion (4). CSF total protein 
concentration and cell count were within normal limits, and erythrocyte concentration 
was less than 50/mm3, excluding a traumatic puncture. 
After informed consent blood and CSF were obtained for diagnostic purposes. 
METHODS 
In CNS-SLE patients and in controls, peripheral venous blood and CSF were 
drawn simultaneously according to standard procedures. Samples of serum and CSF 
were stored within 30 minutes at -70° С until assayed. In 1:100 diluted serum and 
unconcentrated CSF specimens the concentrations of C3, C4, and factor В were 
measured nephelometrically, using antisera purchased from Kallestad Laboratories 
Inc. (Austin, Texas, USA). In each patient CSF and serum samples were measured in 
the same batch. 
IgG, IgA, and albumin in unconcentrated CSF of the CNS-SLE patients were 
measured by means of an automated kinetic turbidimetric method. The reaction time 
was approximately two minutes. Sheep antihuman IgG and IgA (Boehringer, 
Mannheim, FRG) and rabbit antihuman albumin (Behringwerke AG, Marburg/Lahn, 
FRG) were used. Serum was always diluted (1:400) with saline and both specimens 
(CSF and serum) were run in the same batch. IgM in CSF of CNS-SLE patients was 
measured by an ELISA method I7, with slight modifications. In brief, plates were 
coated with 150 μΐ/well, 1/500 diluted rabbit antihuman IgM in PBS-buffer, pH 7.4; 
DAKO Copenhagen. 100 μΐ of CSF and (1:10) diluted CSF and human IgM 
standards (Behringwerke AG, Marburg/Lahn, FRG) in duplicate were used per well. 
Rabbit, peroxidase-conjugated, antihuman IgM (DAKO, Ρ125) was used for the 
enzyme reaction. The sensitivity level was 0.05 ßg/\. 
Q albumin is CSF albumin concentration χ lO^serum albumin concentration. 
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Q albumin was used as an indicator of blood CSF barrier (BCB) function. The CSF 
index was used as an indicator of intrathecal synthesis of immunoglobulins and 
complement components. CSF IgG index = (CSF IgG concentration χ serum albumin 
concentration)/(serum IgG concentration χ CSF albumin concentration). CSF indices 
for IgA, IgM, C3, C4, and factor В were calculated by the same equation. The 
following reference values have been established in our laboratory. Q albumin < 7.0. 
For normal CSF total protein concentration, reference values for IgG index are 0.36 -
0.56, for IgA index 0.13 - 0.37, and IgM index <0.06. For a CSF total protein 
concentration ranging between 450 - 700 mg/1 these values are 0.36 - 0.62 for IgG 
index, 0.16 - 0.40 for IgA index, and <0.10 for IgM index. 
The Mann-Whitney U-test was used to compare patients and controls. In 
addition, reference values for C3, C4, and factor В concentrations in serum and CSF, 
and for the respective indices were computed using the normal order statistics. It was 
not possible to construct 90%-confidence intervals because of the small number of 
controls. Only the inner limits of these intervals could be estimated. Values between 
the inner limits may be considered normal. 
RESULTS 
In the 12 patients with diffuse CNS-SLE, C4 indices were significantly elevated 
when compared with those of controls (median, 2.3 versus 1.1, ρ = 0.01) (Figure 1). 
C3 and factor В indices were not significantly different (median, 0.6 versus 0.5, ρ = 
0.1; and 0.8 versus 0.7, ρ = 0.2) (Figure 1). Reference values were 0.4 -0.7 for C3 
index, 0.6 -1.6 for C4 index, and 0.6 -0.8 for factor В index. Six patients had normal 
CSF C3 indices, 4 had normal CSF C4 indices, and 6 had normal CSF factor В 
indices. 
In patients and controls the CSF concentrations of C3 (median, 2.8 versus 3.2 
mg/1, ρ = 0.8), C4 (median, 1.8 versus 1.4 mg/l, ρ = 0.1), and factor В (median, 1.0 
versus 0.9 mg/1, ρ = 0.5) did not differ significantly. Reference values were 2.0 -4.5 
mg/1 for CSF C3, 1.0 -1.8 mg/1 for CSF C4, and 0.5 -1.5 mg/1 for CSF factor В 
concentration. Six patients had normal CSF C3 concentrations, 4 had normal CSF C4 
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concentrations, and 8 had normal CSF factor В concentrations. 
The serum concentrations of C3 (median, 960 versus 1214 mg/1, ρ = 0.08) and 
of factor В (median, 248 versus 252, ρ = 0.9), were not significantly different between 
patients and controls. Serum C4 concentrations in the patient group (median 158 
mg/1) were significantly lower than in controls (median 245 mg/1, ρ = 0.02). Serum 
reference values as obtained in controls were 978 -1606 mg/1 for C3, 158 -284 mg/1 for 
C4, and 207 -364 mg/1 for factor B. Six patients had normal serum C3 concentrations, 
4 had normal serum C4 concentrations, and 9 had normal serum factor В 
concentrations. 
In patients 4 and 8 (Table 1) an increased Q albumin (14.2 and 8.7) existed, 
indicating impairment of the BCB. In two patients (9 and 12) the IgG index was 
increased, and in one patient (9) the IgA index. Eight patients had an increased IgM 
index (Table 1). 
Table 1: Neuropsychiatrie diagnosis, CSF and serum C4 concentrations, C4 index, and IgM index of 12 
patients with active diffuse CNS-SLE. 
№/age in years/sex neuropsychiatrie diagnosis C4 CA CA IgM 
CSF (mg/1) serum (mg/1) index index 
Ш7/М 
2/30/F 
3/29/F 
4/49/M 
5/42/F 
6/26/F 
7/55/F 
8/61/M 
9/44/F 
10/45/F 
11/24/F 
12/17/F 
OPS, CI 
D, CI 
GS 
GS 
OPS 
CI, GS 
D, CI 
GS 
D 
D 
OPS 
GS 
2.5·· 
2.0·· 
1.2 
1.6 
0.6* 
0.9· 
1.7 
4.7·* 
3.2·· 
1.2 
zi·· 
1.9·· 
120· 
125· 
40· 
239 
160 
156· 
500·* 
476·· 
190 
148* 
170 
95· 
3.50·· 
3.30·· 
5.37·· 
0.48 
0.87 
1.88·· 
0.86 
1.15 
2.43·· 
2.52·* 
4.11·· 
6.31·· 
0.09·· 
0.08" 
0.18·· 
0.05 
0.05 
0.05 
0.15·· 
0.05 
0.19" 
0.15·* 
0.44·· 
0.07·· 
Legend: OPS = organic personality syndrome; CI » cognitive impairment; D » delirium; GS = 
generalized seizures; * = value below lower limit; · · = value above upper limit 
For reference values see section Methods and Results. 
No relation was seen between type of neuropsychiatrie diagnosis and increase 
of indices, especially the C4 index. 
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Figure 1: CSF indices for complement components СЗ, С4, and factor В in patients with active diffuse 
CNS-SLE (n = 12) and in controls (n = 25). Bars denote median values. 
Comparing C3, C4, and factor В indices with immunoglobulin indices, the C4 
indices in patients with an increased IgM index (n=8) were significantly higher than in 
patients with a normal IgM index (n=4) (median, 3.4 versus 1.0, ρ = 0.03). 
Moreover, the C4 index was normal in 3 of the 4 patients with a normal IgM index, 
and in only 1 of the 8 patients with an increased IgM index (Table 1, Figure 1). 
DISCUSSION 
In this prospective study, we demonstrated increased C4 indices in patients 
with active diffuse CNS-SLE, as compared to controls, and found significantly higher 
C4 indices in patients with an increased IgM index. There was no relation between 
the specific neuropsychiatrie diagnoses and C4 index. C3 and factor В indices were 
normal. 
Calculation of indices is a valid method for the detection of intrathecal 
immunoglobulin synthesis in autoimmune diseases of the CNS 1в' 19, м , and 
complement indices are used to demonstrate intrathecal complement synthesis 1 4 · 2 1 , Ώ . 
The ranges of complement index reference values we found are quite comparable to 
those found by others 1 4 ' 2 1 ' Ώ . However, the blood - CSF exchange rates of individual 
proteins are different °. Following intravenous injection, it takes 20 hrs for albumin, 
and 3 to 6 days for IgG, to reach an equilibrium in the CSF u· и . So, a fast decrease 
of the serum C4 concentration, e.g. due to massive consumption, may increase the C4 
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index value during the equilibrium period. In fact, we found significantly lower serum 
C4 concentrations in our patients, thereby confirming previous reports '• 12, 13. 
However, in SLE the greatest decrease in serum C4 occurs early in exacerbation **, 
and in our patients CSF specimens were obtained when neuropsychiatrie 
manifestations had stabilized for at least 10 to 14 days. Therefore, we think that in 
our patients the increased C4 indices actually do reflect intrathecal C4 synthesis. 
Monocytes/macrophages are the major extrahepatic source of complement 
components H . Recently, Passwell et al. reported an increased renal expression of the 
complement genes C2, C3, C4, and factor B, and an increased renal C3 and factor В 
synthesis in murine lupus nephritis эт; brain tissue was not examined. Mallat and 
Lévi-Strauss demonstrated C3 production in primary culture of rodent brain 
astrocytes, and synthesis of C3 and factor В was demonstrated using clonal cell lines 
belonging to the astrocyte lineage Ά·Ώ. In the light of these experimental data, the 
intrathecal C4 synthesis in our patients suggests activation of astrocytes or 
intracerebral monocytes/macrophages in active diffuse CNS-SLE. 
C3 and factor В indices did not differ significantly from those in controls. This 
finding could be related to the stage of the disease process at the time of examination. 
On the other hand, C3 and factor В might be less involved in CNS-SLE than C4, 
since in active SLE there are usually marked depressions of serum C4 concentrations, 
whereas serum C3 and factor В concentrations are less substantially decreased, or 
even normal * 10. As far as factor В is concerned, it should be stressed that the 
classical complement pathway, and not the alternative one, is predominantly involved 
in SLE \ 
C4 indices were significantly higher in patients with an increased IgM index. 
As mentioned, 1С occur in CSF of CNS-SLE patients 7. Given an activation of the 
classical complement pathway in our patients, as the increased C4 indices suggest, 1С 
containg C3 split products could have stimulated В cells x , leading to intrathecal IgM 
synthesis. 
As far as we know, we are the first to demonstrate intrathecal C4 synthesis, 
related to intrathecal IgM production, in patients with diffuse CNS-SLE, suggesting 
that IgM antibodies and C4 might cooperate in diffuse CNS-SLE pathogenesis. 
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However, our data do not justify the use of the C4 index as an indicator of diffuse 
CNS-SLE disease activity in individual patients, nor do they inform about the 
potential value of the C4 index in distinguishing diffuse CNS-SLE from steroid-
induced delirium or CNS infection. Given the advantages of Ig CSF indices over CSF 
concentrations in CNS-SLE patients 6, serial studies are needed to examine the 
usefulness of the C4 index in diagnosing diffuse CNS-SLE and in monitoring diffuse 
CNS-SLE disease activity. 
171 
REFERENCES 
1. Berden JHM, Theofilopoulos AN. Cur­
rent views on the pathogenesis of sys­
temic lupus erythematosus. Neth J Med 
1982;25:110-117. 
2. Bernstein RM. Cerebral lupus: a peep 
into Pandora's box. J Rheumatol 1982; 
9:817-818. 
3. Bleustein HG. Neuropsychiatrie mani­
festations of systemic lupus erythemato­
sus. N Engl J Med 1987;317:309-311. 
4. Harris EN, Hughes GRV. New reflec­
tions on cerebral lupus. In: Aarli JA, 
Behan WMH, Behan PO, eds. Clinical 
neuroimmunology. Oxford, UK: Black-
well Scientific Publications, 1987:340-
353. 
5. Winfield JB, Shaw M, Silverman R, 
Eisenberg R, Wilson III HA, Koffler D. 
Intrathecal IgG synthesis and blood-
brain barrier impairment in patients 
with lupus erythematosus and central 
nervous system dysfunction. Am J Med 
1983;74:837-844. 
6. Hirohata S, Hirose S, Miyamoto T. 
Cerebrospinal fluid IgM, IgA and IgG 
indexes in systemic lupus erythematosus: 
their use as estimates of central nervous 
system disease activity. Arch Intern Med 
1985;145:1843-1846. 
7. Seibold JR, Buckingham RB, Medsger 
Jr TA, Kelly RH. Cerebrospinal fluid 
immune complexes in systemic lupus 
erythematosus involving the central 
nervous system. Semin Arthritis Rheum 
1982;12:68-76. 
8. Schur PH. Complement and lupus ery­
thematosus. Arthritis Rheum 1982;25: 
793-798. 
9. Petz LD, Sharp GC, Cooper NR, Irvin 
WS. Serum and cerebral spinal fluid 
complement and serum autoantibodies 
in systemic lupus erythematosus. Medi­
cine 1971;50:259-275. 
10. Schur PH. Complement components in 
rheumatic diseases. In: Gupta S, Talal 
N, eds. New York: Plenum Medical 
Book Company, 1985:563-580. 
11. Ruddy S, Carpenter CB, Chin KW, et 
al. Human complement metabolism: an 
analysis of 144 studies. Medicine 1975; 
54:165-178. 
12. Hadler NM, Gerwin RD, Frank NM, 
Whitaker JN, Baker M, Decker JL. The 
fourth componenet of complement in 
the cerebrospinal fluid in systemic lupus 
erythematosus. Arthritis Rheum 1973; 16: 
507-521. 
13. Small P, Mass MF, Kohler PF, Harbeck 
RJ. Central nervous system involvement 
in SLE: diagnostic profile and clinical 
features. Arthritis Rheum 1977;20:869-
878. 
14. Fryden A, Forsberg Ρ, Link Η. Synthesis 
of the complement factors C3 and C4 
within the central nervous system over 
the course of aseptic meningitis. Acta 
Neurol Scand 1983;68:157-163. 
15. Tan EM, Cohen AS, Fries JF, et al. The 
1982 revised criteria for the classification 
of systemic lupus erythematosus. Arthri­
tis Rheum 1982;25:1271-1277. 
16. American Psychiatric Association 
(APA). Diagnostic and statistical manual 
of mental disorders, 3rd ed.-revised 
(DSM-III-R). Washington, DC: Ameri­
can Psychiatric Assn, 1987. 
17. Forsberg P. Hendrikson A, Link H, 
Öhman S. Reference values for CSF-
IgM/S-IgM ratio and IgM index, and its 
application to patients with multiple 
sclerosis and aseptic mengingoencepha-
litis. Scand J Clin Lab Invest 1984;44:7-
12. 
18. Tibbling G, Link H, Öhman S. Princi-
ples of albumin and IgG analyses in 
neurological disorders. I. Establishment 
of reference values. Scand J Clin Lab 
Invest 1977;37:385-390. 
19. Lefvert AK, Link H, IgG production 
within the central nervous system: a 
critical review of proposed formulae. 
Ann Neurol 1985;17:13-20. 
20. Hommes OR, Lamers KJB, van Geel W. 
Intrathecal IgG synthesis and IgG index 
after intensive and chronic immunosup-
pressive treatment of multiple sclerosis. 
Ann Ν Y Acad Sci 1985;436:41fM17. 
21. Annunziata Ρ, Volpi N. High levels of 
СЗс in the cerebrospinal fluid from a-
myotrophic lateral sclerosis patients. 
Acta Neurol Scand 1985;72:61-64. 
22. Dujardin BCG, Driedijk PC, Roijers 
172 
AFM, Out TA. The determination of 
the complement components Clq, C4 
and C3 in serum and cerebrospinal fluid 
by radioimmunoassay. J Immunol 
Methods 1985;80:227-237. 
23. Reiber H, Felgenhauer К. Protein 
transfer at the blood cerebrospinal fluid 
barrier and the quantitation of the hu­
moral immune response within the 
central nervous system. Clin Chim Acta 
1987;163:319-328. 
24. Fishman RA. Exchange of albumin 
between plasma and cerebrospinal fluid. 
Am J Physiol 1953;175:96-98. 
25. Culler RWP, Watters GV, Hammersud 
JP. The origin and turnover of cerebro­
spinal fluid albumin and gamma globu­
lin in man. J Neurol Sci 1970; 10:259-
268. 
26. Lloyd W, Schur PH. Immune complex­
es, complement and anti-DNA in exa­
cerbations of systemic lupus erythe­
matosus (SLE). Medicine 1981;60:208-
217. 
27. Passwell J, Schreiner GF, Nonaka M, 
Beuscher H, Gölten H. Local extrahe-
patic expression of complement genes 
C3, factor B, C2, and C4 is increased in 
murine lupus nephritis. J Clin Invest 
1988;82:1676-1684. 
28. Mallat M, Lévi-Strauss M. Astrocytic 
production of complement components: 
C3 and factor В [Abstract]. J Neuro-
immunol 1987;16:114-115. 
29. Mallat M, Lévi-Strauss M. In vitro pro-
duction of C3 and factor В by brain 
cells [Abstract]. Acta Neurol Scand 
1989;79:262. 
30. Soderberg LSF, Coons AH. Comple­
ment-dependent stimulation of normal 
lymphocytes by immune complexes. J 
Immunol 1978;120:806-811. 
CHAPTER 6 
SUMMARY, DISCUSSION AND DEVELOPMENTS 
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SUMMARY 
Cerebrospinal fluid (CSF) analysis has received increasing interest for studying 
(abnormal) brain metabolism and for diagnosing diseases of the central nervous 
system (CNS). In the present study we investigated the relevance of CSF analysis for 
the diagnosis of neurological diseases. 
Chapter 2 gives an overview of various components in CSF and outlines the 
significance of these components for the differential diagnosis of neurological diseases. 
Investigation of cells, albumin ratio, glucose, lactate, Ig indices and isoelectric focusing 
(IEF) are especially indicated for the (differential) diagnosis of (sub)acute infections 
of the CNS and for chronic inflammatory neurological diseases, such as multiple 
sclerosis (MS) and autoimmune diseases with cerebral involvement. CSF cell and 
blood pigment analyses are important for diagnosing and distinguishing between 
haemorrhagic and non-haemorrhagic CNS infarcts. The microscopic observation of 
malignant cells in CSF and the determination of tumour markers are indicated for the 
diagnosis of brain metastases and for monitoring the effect of oncological therapy. 
A strategy for CSF investigation is proposed. The relevant CSF components 
are subdivided into diagnostic groups and each group comprises a number of coherent 
CSF components. In our opinion, this design will help the clinician to select the 
appropriate CSF tests for making a diagnosis. 
Chapter 3 reports on metabolic investigations in CSF and blood. During 
prolonged fasting in reference children, we observed a complex of interrelated 
metabolic processes to regulate the blood glucose level and to generate alternative 
energy substrates. Our finding of a clear interrelationship in blood between glucose, 
ketones and the age of the subject during prolonged fasting, supports the concept of 
diminished glucose homeostasis and increased ketogenesis in younger children 
compared to older ones (Chapter 3 section 1). The levels of glucose and ketones in 
CSF after prolonged fasting showed a clear correlation with the age-related concomi-
tant blood concentrations. It may be postulated that CSFrblood ratios give information 
about the transport process of substrates from blood to CSF/brain. The ratio for 
glucose and B-hydroxybutyrate was independent of the blood level or age. However, 
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the ratio for acetoacetate was significantly higher in the younger children than in the 
older ones, which indicates age-dependent acetoacetate transport. The CSF caloric 
values after prolonged fasting were independent of age. A lower glucose level in the 
CSF of the younger children was fully compensated for by a higher ketone level. This 
suggests that ketone bodies contribute to CSF caloric homeostasis and compensate for 
decreased glucose provision, especially in younger children (Chapter 3 section 2). 
In section 3, we studied the levels of fuel-related components after prolonged 
fasting in the blood and CSF of children with encephalopathy of unknown origin and 
compared the results to those of the reference children. It was our aim to investigate 
whether there were any disturbances in the energy metabolism of these children, as it 
is known that the functional activity of the brain is related to the brain energy supply. 
After prolonged fasting, in the patients with mental retardation of unknown etiology, a 
significantly higher blood glucose level, compared to the reference patients, was 
found. Several factors could have been responsible for this phenomenon. It is possible 
that a reduction in the glucose metabolism/utilization of brain cells in these patients 
might be a major factor. In patients with complex partial epilepsy, the alterations were 
more pronounced. The lower CSF ketone values and CSF:blood ketone ratios in these 
patients suggest ketone transport disturbances from blood to brain or increased brain 
ketone consumption. The CSF abnormalities were not observed in a group of children 
with primary generalized epilepsy. We could not demonstrate any link between the 
alterations in ketone metabolism and the clinical conditions in patients with complex 
partial epilepsy. 
Chapter 4 elaborates on the relevance of brain-specific proteins in CSF. The 
CSF levels of neuron-specific enolase (NSE), S-100 protein (S-100) and myelin basic 
protein (MBP) were found to be age-dependent. It was remarkable that the relative 
increases in NSE, S-100 and MBP with age were similar. Explanations for this 
phenomenon could be 1) an increase in neuron, glia and myelin loss with age, or 2) 
an unknown common underlying mechanism (Chapter 4 section 1). The behaviour of 
these proteins in the CSF of various young and adult neurological patients was also 
investigated. We did not observe any distinct pattern of brain-specific proteins in the 
different neurological disorders. The three CSF proteins seemed to behave depen-
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dently in some of the disorders, especially in the acute cerebrovascular accident 
(CVA) patients, which would indicate more generalized brain involvement. No 
dependent behaviour was seen in the acute MS patients. 
In CSF, signs of demyelination (MBP increase) were found much more 
frequently than neuronal damage (NSE increase), which may indicate that neurons 
are better protected against damage than myelin (Chapter 4 section 2). 
Active MS patients had increased CSF MBP levels but these returned to 
normal after immunosuppressive treatment either with cyclophosphamide or with 
intravenous methylprednisolone, which indicates a reduction or stop in the demyelina-
tion process (Chapter 4 sections 3 and 4). The mean CSF MBP level was significantly 
higher in the relapsing-remitting (RR) MS patients and in the chronic progressive MS 
patients with relapses than in the chronic progressive MS patients without a RR 
disease course. A relationship was demonstrated between the clinical scoring (Kurtz-
ke's Expanded Disability Status Scale (EDSS)) and the CSF MBP levels in RR MS 
patients. The number of gadolinium-enhancing lesions detected with MRI in active 
MS patients was significantly correlated with the CSF MBP level and a correlative 
triad was found between the decrease in gadolinium-enhancement, a decrease in CSF 
MBP and the clinical improvement after methylprednisolone treatment (Chapter 4 
section 4). These observations stress the importance of CSF MBP in MS as a valid 
parameter for disease activity and may indicate that reduction of inflammation is 
accompanied by decrease in myelin breakdown and clinical recovery. 
For the diagnosis of a particular neurological disease, brain-specific proteins 
are less relevant. However, they do show great promise for assessing the involved 
brain compartment, the extent of the lesion or the activity of the (neurological) 
disease process. An increased CSF level of (one of) these brain-specific proteins 
indicates brain damage, but a normal level does not exclude (minor) brain damage. 
Increased CSF levels of these proteins were found in patients who were suffering 
from an acute neurological disorder with brain damage, or from a chronic progressive 
neurological disorder. CSF determination of brain-specific proteins is not indicated in 
patients with chronic neurological diseases. 
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Chapter 5 describes the value of assessing the humoral and cellular immune 
response in CSF in some neurological diseases. One of the most important CSF tests 
is isoelectric focusing for the detection of oligoclonal gamma bands. These bands were 
observed almost exclusively in infectious, inflammatory and demyelinating diseases of 
the CNS. The CSF aberrations were caused by immunological reactions which caused 
the intrathecal production of microheterogeneous IgG compounds. In infectious 
neurological diseases, these abnormalities were observed much more frequently in the 
subacute and chronic forms than in the acute forms. In the CSF of MS patients, we 
frequently observed (92%) an oligoclonal gamma banding pattern, which indicated the 
presence of oligoclonal IgG-producing B-cells in the brain. The identity of these IgGs 
is unknown. Methylprednisolone treatment reduced the number of oligoclonal bands 
only slightly, indicating that eradication of IgG producing B-cells in brain has not 
really occurred (Chapter 5 section 1). 
Increased IgG indices were frequently observed in MS patients and also in 
patients with systemic lupus erythematosus with diffuse CNS involvement (neuro-SLE) 
(Chapter 5 sections 1 and 3). Both of these diseases are probably autoimmune 
mediated and the increased IgG indices indicate persistent humoral immune activity in 
the brain of patients with these diseases. We did not find any correlation between 
CSF intrathecal IgG and the clinical scoring (EDSS) or demyelination (CSF MBP) in 
MS patients (Chapter 5 section 1). This absence might contradict the existence of a 
direct link between IgG-producing B-cell activity in the brain and the clinical activity. 
IgM was considered to be a more serious candidate for monitoring disease activity in 
MS. In RR MS patients, we observed a correlation between CSF intrathecal IgM and 
demyelination (CSF MBP) (Chapter 5 section 1). The finding of a correlation between 
the CSF IgM index and the complement component C4 index in our study on neuro-
SLE patients might also support the assumption that IgM-producing B-cells in the 
brain are more directly involved in the (auto)immune-mediated inflammatory process 
than IgG-producing B-cells (Chapter 5 section 3). Methylprednisolone treatment 
significantly reduced intrathecal IgG and IgM in MS patients. 
Isoelectric focusing of CSF proteins is strongly indicated in MS, (chronic) 
infections of the CNS and in autoimmune diseases of the CNS. IgG index gives 
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additional support for the monitoring/diagnosis of the above-mentioned diseases. IgM 
index is of more importance to determine the acuity and activity of the disease 
process. 
Section 2 presents our observations on lymphocyte subsets in the CSF and 
blood of MS patients. In the active MS patients, the blood CD4+ (helper/inducer) T-
cell percentage was significantly decreased, while the CSF CD4+ percentage tended 
to be higher in comparison with the controls. Furthermore, the number of mononucle-
ar CSF cells and the percentage of CD20+ (B-cells) in CSF were significantly 
increased compared with the controls. The positive correlation between CSF mononu-
clear cell number and the CSF CD4+ T-cell percentage and the negative correlation 
between cell number and CSF CD8+ (suppressor / cytotoxic) T-cell percentage 
suggest that a selective increase of CD4+ T-lymphocytes accounts for the increased 
cellularity in the CSF and brain of active MS patients. No relationship was found 
between the various percentages of T-cell subsets in the CSF or blood of patients with 
different courses of the disease or with other clinical variables (EDSS, disease 
duration, progression rate). After treatment with intravenous methylprednisolone, the 
percentage of CD8+ T-cells was significantly decreased in blood and increased in CSF 
compared with the values before treatment. This phenomenon might suggest a 
selective traffic of CD8+ cells from the blood to the CSF and to the brain compart-
ment, and this migration might affect the inflammatory process. It still has to be 
established whether determining lymphocyte subsets in patients with MS has any value 
for assessing an abnormal immune regulation within the CNS and monitoring 
treatment effects. 
DISCUSSION 
Many neurological disorders are associated with changes in the composition of 
the CSF. It is beyond the scope of this thesis to give guidelines regarding indications 
for lumbar puncture (LP). CSF analysis at most hospital laboratories is restricted to a 
number of standard laboratory investigations (cells, protein content, glucose, electro-
phoresis, IgG index). Some university hospitals have specialized CSF laboratories 
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where additional "more specific" CSF investigations can be performed. These investi-
gations become integrated into advanced CSF diagnostic tests once their clinical 
relevance has been proved. 
Clinical relevance of CSF investigation 
1. Indicated for clinical diagnosis 
• Acute infections of the CNS 
CSF investigation must be performed without delay in the case of a suspected 
meningitis syndrome. In many patients with fever of unknown origin, even in the 
absence of meningeal signs, CSF investigation can be of great value as a guide to both 
diagnosis and treatment. Furthermore, in the early stages of CNS infection (bacterial, 
viral, fungal or protozoal) it is not possible to make a differential diagnosis without 
CSF analysis. Such an analysis should include CSF leukocyte number, cell differentia-
tion, glucose, lactate, total protein and brain specific protein measurements. For the 
detection of antigens, special tests are available (Elisa, Latex agglutination and 
recently the use of the polymerase chain reaction (PCR)). CSF investigation is also 
indicated in the case of suspected encephalitis. If the patient is found to have Herpes 
Simplex encephalitis, treatment must be started as soon as possible. 
• Chronic inflammatory diseases 
For the differential diagnosis of chronic inflammatory diseases, the following 
questions must be answered: Is the process restricted to the nervous system or does it 
form part of a systemic disease? Is it caused by an exogen agent or does autoimmuni-
ty play a prominent role? Investigation of oligoclonal bands, Ig indices and specific 
antibodies (index) is indicated besides the standard tests. In chronic infections such as 
neuroborreliosis, neurosyphilis, parasitic infections, etc., oligoclonal bands and specific 
antibodies are often observed, including antibodies to opportunistic infections in 
immune compromised patients. In autoimmune-mediated disorders, (non)specific 
immunological abnormalities are observed in CSF in diseases such as cerebral 
vasculitis, neuro-SLE, neuro-sarcoidosis and neuro-Behçet. 
CSF investigation is very important for the diagnosis of MS. Isoelectric focusing 
is the most sensitive test in CSF. The detection of oligoclonal bands supports the 
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diagnosis of MS and the absence of these bands in MS is rare. An European 
consensus article will be published about recommended CSF investigations in MS (see 
Addendum). 
• Brain metastases 
CSF investigation is indicated for the diagnosis of metastases into the CNS. 
Besides the observation of malignant cells in CSF, the determination of tumour 
markers is a particularly sensitive test. 
• Inflammatory polyneuropathies 
CSF investigation is indicated if Quillain-Barré's syndrome or chronic inflam-
matory demyelinating disease are suspected. 
• Neurometabolic diseases 
CSF investigation is indicated in some neurometabolic diseases, such as 
mitochondrial encephalomyopathies, non-ketotic hyperglycinemia, hepatic encephalo-
pathy and encephalopathy e cause ignota. 
2. Important help for diagnosis 
In cases of suspected subarachnoid haemorrhage, CSF investigation is indicated 
if the CT scan is negative or if there is some delay before the patient is admitted to 
hospital (> 12 hours) after the ictus. CSF analysis can also be helpful in some 
patients with a CVA to exclude inflammation, in benign intracranial hypertension and 
normal pressure hydrocephalus and in patients with a radicular syndrome to exclude 
underlying infection. 
3. To assess the activity of the disease process, the prognosL· and treatment effects 
CSF investigation of brain-specific proteins can give important information 
about the severity of the brain damage, the prognosis and treatment effects in 
diseases such as infections, MS and CVA. Neurotransmitter metabolites can be 
analysed to evaluate the involvement of the brain compartment, the prognosis and to 
regulate and monitor medication in diseases such as extrapyramidal disorders. 
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4. Tool f or research 
In various neurological disorders, CSF investigation can serve as a tool for 
research. CSF investigation can be expected to yield important information in neuro-
immunological, neurometabolic and demyelinating disorders and in dementia. Several 
new CSF investigations have already reached an advanced research stage. Various 
developments show great promise for assessing the immune-mediated origin of a 
disease, the activity of a disease process and the possible underlying pathophysiology 
and for making a diagnosis. 
• Cytokines 
Cytokines are produced by a variety of cells, such as monocytes/ macrophages, 
lymphocytes, vascular endothelial cells and also astrocytes and microglia cells of the 
brain. These products stimulate cell replication, cell differentiation and immunoglobu-
lin production of B-cells. Determination in CSF can offer information about ongoing 
intrathecal immunological activity. In active MS patients, increased levels of TNF-a, 
IL-2 and soluble CD8 (suppressor T-cell activator) were observed in contrast to stable 
MS patients [1-4]. In human immunodeficiency virus type 1 (HIV-1) infected patients, 
TNF-a levels were found to be increased [5]. Intrathecal production of cytokine IL-6 
has also been established in infectious neurological diseases, such as viral and 
bacterial infection and cytokine TNF-a in cerebral malignancies, such as CNS 
leukaemia [6-8]. Cytokine determination does not make any significant contribution to 
diagnosis, but it does look promising as a possible marker for the immune-mediated 
status and it may be useful to evaluate the activity of a disease and for therapeutic 
approaches. 
• Anti-brain protein antibodies 
Anti-MBP antibody levels in CSF have already proved to be useful as marker 
for demyelination. It appears that T-lymphocytes respond to MBP and are involved in 
the pathogenesis of inflammatory demyelination [9]. Anti-MBP antibodies have been 
detected in active MS patients [10,11] and in patients with AIDS dementia complex 
[12]. Antibodies against myelin-associated glycoprotein (anti-MAG) have been 
observed in some patients with polyneuropathy associated with IgM paraproteinemia 
[13]. Further investigations on the specificity of this immune reaction and its correla-
182 
tion with disease progression in demyelinating diseases will be worthwhile. 
• Lymphocytes coexpressing more surface antigens 
There is increasing evidence that chronic inflammatory processes, including 
autoimmune diseases, are mediated by imbalance of immunoregulatory cells. Several 
studies have indicated that T-cells in the CSF immune compartment represent 
populations of sequestered, activated cells with different immunological characteristics 
than T-cells in the peripheral blood. 
Dual colour flow cytometry can define lymphocytes which coexpress several 
surface antigens. In the CSF of MS patients, increased levels of fetal-type CDS+ B-
cells and CD4-8-T-cells and decreased levels of CD4+ 2H4+ (suppressor inducer) T-
cells have been demonstrated [14,15]. These findings in CSF indicate the existence of 
an active immune system with low numbers of suppressor inducer T-cells in active MS 
which is accompanied by B-cell hyperactivity. In a patient with AIDS dementia 
complex, the level of CD8+ HLA-DR+ T-cells in CSF was increased suggesting an 
ongoing T-cell respons to НГ in CNS [16]. 
• Neurotransmitters (metabolites) 
Abnormalities in CSF monamine metabolites concentration are often demon­
strated in extrapyramidal disorders, Alzheimer's disease and other diseases with 
dementia. 
Recently, reduced CSF levels of 3-methoxy-4-hydroxyphenylethyIeneglycol, 5-
hydroxyindoleacetic acid (5HIAA) and homovanillic acid (HVA) have been demon­
strated in the primary fibromyalgia fibrositis syndrome (PFS), which supports the 
proposed hypothesis of a metabolic defect in PFS [17]. Furthermore, a new inborn 
error of metabolism due to aromatic L-amino acid decarboxylase deficiency has been 
reported with decreased levels of CSF HVA and 5HIAA in association with increased 
levels of 3-methoxytyrosine [18]. Assessment of cholinergic markers (acetylcholineste­
rase and butyryicholinesterase) in CSF has revealed significantly reduced values in 
patients with various forms of dementia. An anomalous molecular form of acetylcho­
linesterase in CSF was reported in 11 out of 13 patients with Alzheimer's disease, but 
not in any of 10 non-demented individuals of a comparable age [19]. Amino acids 
such as glutamate, aspartate, gamma-amino butyric acid (GABA) and glycine, also 
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serve as neurotransmitters. Reduced CSF glycine levels have been reported in 
Alzheimer's disease [20]. Low CSF GABA levels were found in startle disease 
(hyperekplexia) which may suggest a genetic defect [21]. Inherited disorders of CNS 
GABA metabolism have been reported with both increased and decreased CSF 
GABA concentration [22]. 
• CNS methylation capacities 
The reduced availability of methyl groups within the CNS can cause dys-
myelination of the brain [23]. S-adenosylmethionine (SAM) is the sole methyl donor in 
many important methylation reactions in the CNS and involves neurotransmitters, 
(poly)amines, membrane phospholipids and proteins. Folate and vitamin B12 are 
involved in the formation of SAM. Long-term deficiencies of these vitamins can cause 
reduced SAM levels in the brain and dysmyelination [24]. L-Methylmalonyl-CoA 
mutase and methionine synthetase require vitamin B12 as cofactor for enzyme activity. 
Studies have shown that the CSF levels of methylmalonic acid and homocysteine are 
markedly elevated in patients with vitamin B12 deficiency [25-27]. The normal levels 
for vitamin В12 in CSF are very low. Therefore, measurement of CSF homocysteine 
and/or methylmalonic acid may be a better marker for vitamin B12 deficiency. 
Recently a study has appeared from our department about a neurological patient with 
a severe folate deficiency in CSF and a normal serum folate [28]. Besides vitamin 
deficiencies, inborn errors of the methyl transfer pathway can also cause low brain 
SAM levels [23]. Measurement of SAM in CSF might provide information on the 
methylation capacity of the brain. Decreased SAM levels in CSF were observed in 
several depressed patients and in patients with Alzheimer's disease [29]. The antide­
pressant effect of SAM administration has now been confirmed in several studies 
[29,30]. Children with an inborn error of the methyl transfer pathway also show low 
CSF SAM levels. Treatment with SAM has led to substantial clinical improvement, 
apparent remyelination and an increase in the CSF SAM level. Furthermore, it was 
recently reported that patients with ataxia of various etiologies had significantly 
decreased levels of CSF thiamine and thiamine monophosphate [31]. Other studies 
have also suggested thiamine involvement in several diseases characterized by 
cerebellar damage [32]. 
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Measurement of vitamins or related products, such as homocysteine, methyl-
malonic acid and SAM, in CSF may provide information about the methylation 
capacity of the brain and possibly about the underlying pathophysiology. 
• Glycosphingolipids 
Glycosphingolipids are important constituents of all mammalian cell mem-
branes, but are particularly abundant in brain tissue. The composition of the glyco-
sphingolipids is cell type-specific. Increased release of plasma membrane glyco-
sphingolipids to the intercellular space and the CSF might occur during degenerative 
processes and cell death in the brain. The CSF ganglioside pattern reflects some brain 
diseases [33]. The assay of sulphatide in CSF may provide important information 
about the extent and progress of demyelinating processes, such as those encountered 
in vascular and senile dementia and in MS [34]. 
DEVELOPMENTS 
Harmonisation of protocols for CSF analyste and interpretation 
In 1991, the Commission of the European Community on Multiple Sclerosis 
invited leading scientists working at relevant CSF laboratories in Europe to make 
recommendations regarding CSF tests to assist in the diagnosis of MS, and to publish 
a consensus article on this topic. More than 20 European scientists worked out a 
proposal for relevant CSF tests and in 1993 they will publish a consensus protocol 
based on certain agreed common methodologies for the analysis of CSF components, 
as well as recommendations regarding the interpretation of the analysis results (see 
Addendum) 
The same group of researchers is now engaged in extending this CSF approach 
to the harmonisation of protocols for the diagnosis of inflammatory and infectious 
brain diseases with the aid of advanced immunospecific techniques. 
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SUMMARY 
The authors from twelve European countries discussed a consensus about CSF 
analysis, specifically focused on the relevance of various techniques for the diagnosis 
of multiple sclerosis. As a Committee of the European Concerted Action for MS 
(Charcot Foundation), we organised five workshops on CSF Standards in MS. We 
report here a sequence of recommended CSF investigations most relevant for patients 
who could have multiple sclerosis: 
1. The most sensitive method for the detection of oligoclonal bands is isoelectric 
focusing (IEF). The best procedure is to use the same amounts of IgG in parallel 
CSF/serum samples and to reveal oligoclonal bands by IgG-specific antibody staining. 
2. Any IEF test used for the diagnosis of multiple sclerosis must be checked at least 
once per year using "blind" standards for the five different CSF/serum patterns. 
3. Quantitative measures of IgG for "increased CNS production" are less sensitive 
than isoelectric focusing. 
4. The preferred method for detection of blood-CSF barrier dysfunction is the 
albumin quotient while CSF albumin or total protein is of secondary preference. 
These values must be interpreted with reference to the age of the patient. 
5. Cells should be counted. The normal value is no more than 4 per microlitre. 
6. The combined local synthesis of antibodies against measles, rubella and/or 
varicella zoster could represent a significant advance if this offers higher specificity 
(not sensitivity) for chronic rather than acute inflammation. Other tests which may 
prove to have useful correlations with clinical parameters include: IgM, IgA, free light 
chains or myelin basic protein. 
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INTRODUCTION 
The diagnosis of multiple sclerosis (MS) can be extended by use of modern 
techniques for the analysis of cerebrospinal fluid (CSF). This important fact has been 
previously acknowledged by another group of experts (1'. We have refined their 
notions of "oligoclonal bands or increased CNS production of IgG" and offer 
considered opinions on the relative importance of various analytical techniques. 
Specifically, we have contrasted qualitative (oligoclonal bands) with quantitative 
(various IgG/Alb ratios) methods for their relative sensitivity and/or specificity in the 
diagnosis of MS. 
There are, unfortunately, several papers on MS which do not give sufficient 
technical details of the methods used for determination of oligoclonal bands and/or 
increased CNS production of IgG. These techniques must clearly be calibrated by 
each individual laboratory. To allow proper international comparisons, authors should 
specify what percentage of patients with clinically definite MS are positive using their 
techniques, i.e. sensitivity. They should also state what percentage of normal and/or 
other inflammatory diseases (acute vs. chronic) are positive, i.e. specificity. 
The Diagnosis of Multiple Sclerosis 
This is ultimately a clinical process, but as noted above, CSF examination, among 
other paraclinical tests, is also important. Perhaps the greatest attraction of CSF 
examination (when compared with other paraclinical tests) is that it is the only test to 
primarily demonstrate the inflammatory origin of the abnormalities which may be 
localised by clinical, neurophysiology or MRI tests. 
Amongst the various methods of CSF analysis, those which detect a humoral 
immune response within the central nervous system are the most important in MS. 
This is because local synthesis of IgG is reported in the vast majority (up to 95%) of 
MS patients. 
Detection of CSF oligoclonal bands by isoelectric focusing is the most sensitive 
method to assess local synthesis when compared to all the quantitative analytical 
methods as well as other qualitative methods. It is not specific, however, as there may 
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be oligoclonal bands of IgG in any inflammatory neurological disease. 
Integrated Report 
The results of several tests which give independent or complementary 
information, should be presented as patterns which specifically relate to various 
groups of neurological disorders in a clinically-orientated report. The clinician may 
benefit from graphical representation of such an integrated laboratory CSF protein 
report. It has to be emphasised that the time of lumbar puncture with respect to the 
course of the disease is important for the interpretation of CSF data. 
SINGLE TOPICS OF CONSENSUS 
Sample Handling and Cell Examination 
A defined amount (about 10 mL in adults, less in children) of CSF should be 
collected in polypropylene, siliconised glass or glass tubes. Cell numbers should be 
counted as soon as possible (preferably within 30-60 minutes) after lumbar puncture 
(LP). If the LP is not performed at the same hospital as the CSF laboratory, the CSF 
should be transported to the CSF laboratory as soon as possible (preferably within 6 
hours) for routine cytological examination. Differential cell loss occurs during CSF 
storage. The number of white cells in normal CSF should be no more than 4//iL (see 
Reviews: Tourtellotte). 
Cytological examination is considered complementary in the diagnosis of MS. 
About 50% of patients show a normal cell count and only 1% of MS patients have 
cell counts larger than 35/μ1~ Such elevated cell counts make MS rather unlikely, and 
thus other diagnoses should be considered. 
Different methods such as cytocentrifuge or sedimentation chamber can be used 
for cytological preparation '2 |. The answer to the clinician should be descriptive 
including, if possible, considerations of any alternative diagnosis. 
Evaluation of the Blood-CSF Barrier 
The blood-brain barrier and the blood-CSF barrier are different barriers. By 
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analysing the protein content of the lumbar CSF, it is possible to assess the integrity 
of the (functionally-defined) blood-CSF barrier (BCB), but not just the isolated blood-
brain barrier (BBB). In healthy people and/or in patients without objective signs of 
neurological disorders, the passage of the plasma protein across the BCB depends 
upon their hydrodynamic radii under steady-state conditions '3'. In such reference 
populations the absolute CSF levels of plasma proteins depend on many factors like 
serum concentration, blood-CSF barrier function, CSF flow, molecular size, age of the 
patient and volume of CSF extracted. 
Albumin, the major CSF protein, is synthesised only by hepatocytes and is not 
catabolised within the CNS. Dynamic studies using intravenously injected radio-
labelled albumin '4' have demonstrated that serum albumin is the source of CSF 
albumin and strongly support the use of CSF/serum albumin quotients (QAlb = CSF 
albumin/serum albumin) to assess the BCB function. Another approach [5,6' is related 
to CSF albumin only: any increase of CSF albumin (above the mean) is indicative of a 
transudate. 
Determination of total protein is less reliable than CSF albumin. The technique 
should in any case yield the same extinction coefficient for albumin as for IgG, due to 
the wide variability of IgG relative to albumin (e.g. between 3% and 30% total 
protein). 
The QAlb is age-dependent '7·81. The upper reference limit for the first 10 mL of 
lumbar fluid is 5.0 χ IO"3 for patients under 15 years; 6.5 χ IO'3 for patients under 40 
years; 8 χ IO'3 for patients under 60 years and 8-9 χ IO"3 for older patients. Most 
patients with MS have QAlb values below the upper reference limit. Higher values 
suggest a different neurological disorder. 
Transudated CSF immunoglobulins, as calculated by a CSF/serum quotient, are 
not linearly related to the QAlb in cases with BCB dysfunction. The use of non-linear 
formulae or graphs for the interpretation of IgG values is therefore recommended. 
The albumin concentration in a standardised volume of CSF and in the serum 
collected simultaneously must be analysed with the same immunoassay within the 
same analytical series. 
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Quantification of the Humoral Immune Response in Brain 
The extraordinarily high sensitivity of isoelectric focusing for the detection of 
oligoclonal IgG fractions in the CSF is an important complementary qualitative 
method and is treated separately below. 
It is a necessary requirement for any quantitative assay that each laboratory must 
establish their own reference range for particular tests. 
The detection of a humoral immune response in the CNS requires an expression 
of results which will discriminate between blood-derived and brain-derived 
immunoglobulin fractions in CSF. Such quantitative expressions are based upon 
calculations of the CSF/serum quotients ИА»-"!
 a n c
j these expressions are also used for 
comparisons of intrathecal synthesis of the various immunoglobulin classes (IgG, IgA, 
IgM) as well as for calculation of specific antibody index values to try to characterise 
acute and chronic inflammatory diseases. 
The quotient evaluation reduces the analytical variations for the concentrations of 
plasma proteins in CSF. The CSF/serum ratio of IgG also reduces the individual 
variation of serum IgG. By referring this CSF/serum IgG quotient to the CSF/serum 
albumin quotient it is possible to further reduce the variation of the IgG quotient 
related to individual differences in BCB function. There are many approaches by 
which both of these quotients are combined to obtain an expression which will 
discriminate between the locally-synthesised IgG fraction in brain and the fraction of 
CSF IgG which is derived from the blood by filtration. 
The use of a non-linear relation between the IgG quotient and the albumin 
quotient is recommended, since a linear approach can lead to a loss of sensitivity 
when there is BCB dysfunction, especially for larger molecules such as IgA or IgM ( n" 
14] 
The graphic representation of the immunoglobulin quotients as a function of the 
albumin quotient is suggested as part of a report for the clinician, as this gives 
simultaneous information about any local humoral immune response and/or any BCB 
dysfunctions. 
The quantitation of local IgG synthesis in CSF has gained further importance for 
differential diagnosis by its relation to the intrathecal synthesis of other 
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immunoglobulin classes, namely IgA and IgM. This is the consequence of the special 
neuroimmunological regulation which seems to have some independence from blood 
immunological responses. More or less typical patterns of immunological classes of 
reaction have been observed in various neurological diseases '6'15'. 
The detection of synthesis of specific antibodies in CSF (e.g. against measles 
virus) has gained some clinical relevance through improvement of the sensitivity of the 
evaluation methods, mainly by the introduction of extrapolation methods, which refer 
to interpolated values for the IgG (or IgM) quotient, including corrections for any 
BCB dysfunction I6·16-18!. Of special interest for the diagnosis of multiple sclerosis is 
the notion that poryspecific antibody synthesis can occur in the brain. Thus local 
synthesis (derived from interpolation) of measles, rubella and zoster antibody 
formation is found in the CSF of 80% of patients, in one series i l 8 l The relevance of 
these methods has been confirmed by the identification of oligoclonal patterns in 
isoelectric focusing for the single species (measles, rubella, zoster) by the affinity-
mediated capillary blot technique '19'. In addition, the report that the antibody affinity 
is different in acute compared with chronic diseases, further supports the idea that the 
polyspecific immune response (polyclonal but unspecifically stimulated) may also 
become an important tool for diagnosis in multiple sclerosis (20'. 
For the correct interpretation of the humoral immune response in CSF, it is 
important to keep in mind that the local IgG, IgA or IgM synthesis including any 
specific antibody synthesis in the brain might have several origins. It could be due to a 
persistent antibody response of an old clinically irrelevant immunological process in 
contrast to an acute inflammatory process. Local IgG synthesis, detected either by 
increased IgG quotients or by isoelectric focusing, can still be seen many years 
following sufficiently treated cases of neurosyphilis or neuroborreliosis amongst other 
examples of an intrathecal immune response. 
Table 1 Frequencies of abnormal CSF parameten in clinically-definite MS 
- Oligoclonal IgG in CSF (isoelectric focusing) >95% 
- Abnormal blood CSF barrier function (QAlb >7xl0"3) 12% 
- Increased IgG quotient (IgG index, IgG (local)) 70-80% 
- Increased cell count >4/¿iL 50% 
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Isoelectric Focusing of Oligoclonal IgG 
Our strongest consensus is that isoelectric focusing (IEF) is the most sensitive test 
for multiple sclerosis using the same amounts of IgG in parallel CSF and serum 
specimens I5-13·19·21-31). Bands are preferably visualised by IgG-specific antibody staining. 
In addition, useful information can be obtained on other proteins by using a general 
protein stain. 
It should be emphasised that IEF is not a specific "marker" test for MS, but 
reaches its maximal value in differential diagnosis only when all other known causes of 
CNS inflammation have been excluded by performing other tests for known CNS 
antigenic stimuli. 
The significance of individual bands in CSF can only be properly understood in 
the context of both a parallel serum specimen and with attention to the overall band 
pattern of all sample tracks on the IEF plate. A good practical indicator is to 
compare the serum patterns from different specimens - do they all have the "same" 
banding pattern? Common "same" bands are found uniformly at the same pi in all 
specimens of a given run and are due to artefacts produced by the ampholytes. The 
higher the number of these artefactual bands, the more difficult it is to recognise not 
only legitimate abnormal serum bands, but even CSF bands, which can be obscured 
by interference from the common bands. 
Reports of CSF protein analysis to the clinicians must always clearly distinguish 
the facts from the interpretation and qualitative from quantitative results. Under 
"facts" it should be clear whether the band pattern in CSF is polyclonal (no bands) or 
monoclonal (paraprotein bands) or oligoclonal. There must be parallel investigation of 
serum with a clear comment on the relative band patterns in CSF and serum. 
Examples of the five types of patterns are shown in Figure 1 and Figure 2. 
Banding patterns on isoelectric focusing 
These patterns in Figure 1 are simplified for purposes of demonstration only. 
Densitometrie scanning is not required for interpretation, but can be used to enhance 
the band patterns. 
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FIVE PATTERNS OF ISOELECTRIC FOCUSING 
Different CSF/SER piltems denote loot IgG synthesi· 
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Figure 1. Idealised patterns for heuristic purposes are given. 
Actual patterns are given in Figure 2 as examples of the 5 types. Original 
patterns are always more clearly visualised than any photographic reproductions. 
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Figure 2. Topical patters from individual cases are given. 
Evaluation - Remarks on the 5 types of band patterns 
Note that only patterns 2 and 3 represent local synthesis of IgG within the central 
nervous system. 
1. Normal CSF. 
2. CSF-restricted oligoclonal bands: local synthesis. 
3. CSF-restricted oligoclonal bands with additional, identical bands in CSF and 
serum: local synthesis. 
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4. Identical bands in CSF and serum: not local synthesis. 
5. Monoclonal bands in CSF and serum: not local synthesis. 
IgA 
IgA analysis, either by quantitative or qualitative techniques, is of little value for 
the laboratory-supported diagnosis of MS. 
Strong intrathecal IgA production may imply a different diagnosis. Most methods 
for quantitative analysis of IgA production have so far failed to take into account the 
relative proportion of monomelic and dimeric IgA in both CSF and serum, although 
dimeric IgA was shown to be preferentially produced in cases of intrathecal synthesis 
(32
'. As a consequence, amounts of local IgA synthesis could be underestimated 
depending on the method used. The occurrence of oligoclonal IgA bands on 
isoelectric focusing in MS and/or other neurological diseases is not common I31·33!. 
IgM 
Determination of CSF IgM by quantitative and qualitative methods to 
demonstrate intrathecal production of IgM are optional tests for the diagnosis of MS. 
The recommended method for qualitative detection of oligoclonal IgM bands is 
electrophoresis or isoelectric focusing (agarose) of unconcentrated CSF and 
subsequent immunodetection I34]. Intrathecal production has been found, by 
quantitative and/or qualitative assays, in only 30-60% of MS patients and thus appears 
to be of less value than detection of oligoclonal IgG bands to assist the detection of a 
humoral immune response within the CNS. A degree of clinical relevance of IgM has 
been reported due to its decrease with duration of the disease process ,34' and 
conversely, being more common with early exacerbations of the disease I21·36·37!. 
Further collaborative work is required to ascertain correlations between clinical 
variables and other CSF parameters including myelin basic protein I21·38'. 
Free light chains 
The detection of oligoclonal bands of free light chains in unconcentrated CSF can 
be performed by the same procedures as those used for demonstration of oligoclonal 
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IgG bands. In MS, presence of such oligoclonal free light chain bands is observed with 
about the same frequency as that for oligoclonal IgG bands, and this detection is a 
complementary, although optional, test to establish a laboratory-supported diagnosis 
I19'. Electrophoresis on Polyacrylamide gel ,Э9' or agarose (4°' are alternative techniques 
to immunostain free light chains anodic to the gamma region. 
The quantitative determination of free light chains is critically dependent on the 
specificity of the immunassays used, as no reaction with bound light chain has to be 
observed with a 3 log IgG excess of bound versus free '41'. Absolute levels of free 
kappa and lambda chains are increased in about 80% and 60% of MS samples 
respectively 13*'. The influence of both the serum levels and of BCB on the CSF levels 
are taken into account by the calculation of index values [41l 
Quality assurance 
Most of the standards for anafytes in CSF diagnosis are defined as method-
related values. It is necessary to use for internal quality assurance a reference material 
such as diluted serum or, much better, an accepted CSF control sample. For detection 
of imprecision a local CSF pool can be used as a daily control. External quality 
assessment (CSF survey) by an external agency ,421 is also necessary. The 
International Standardising Organisations have co-operated to develop a harmonised 
proficiency testing protocol for CSF. 
The special situation for CSF analysis is given by the advantage of calculating the 
CSF/serum quotient. If CSF and serum protein values are measured in the same run, 
the quotient formation eliminates many of the discrepancies due to method-related 
calibrations. The CSF/serum quotient thus approximates to a method-independent 
value. 
The problem of a complicated quality control in cytology could be solved by 
sending sets of cytological slide preparations between different laboratories. 
Proficiency testing in CSF analysis should also consider the control of the quality 
of data interpretation by including the five different focusing patterns·421 which have 
been widely recognised in our collaborative studies of "blind" CSF samples (data not 
shown). 
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SAMENVATTING 
De belangstelling voor het onderzoek van de cerebrospinale vloeistof (CSF) ter 
bestudering van de (abnormale) stofwisseling van de hersenen en voor de diagnostiek 
van ziekten van het centrale zenuwstelsel (CZS) is de laatste jaren duidelijk toegeno-
men. In deze studie hebben wij onderzoek gedaan naar het belang van CSF analyse 
voor de diagnostiek en prognostiek van neurologische ziekten. 
Hoofdstuk 2 biedt een overzicht van de verschillende componenten in CSF en 
bediscussieert de betekenis van deze bestanddelen voor de differentiële diagnostiek 
van neurologische ziekten. Onderzoek van cellen, albumine quotiënt, glucose, lactaat, 
Ig indices en isoelectrische focusering (IEF) is vooral geïndiceerd bij de (differentiële) 
diagnostiek van (sub)acute infecties van het CZS en bij chronische neurologische 
ontstekingsziekten, zoals multiple sclerose (MS) en autoimmuun ziekten waarbij ook 
het brein betrokken is. Onderzoek van cellen en bloedpigmenten in CSF is belangrijk 
om onderscheid te maken tussen een herseninfarct met of zonder bloeding. Het 
aantreffen van kwaadaardige cellen in CSF en de aanwezigheid van verhoogde tumor 
merkstoffen in CSF wijzen naar een hersenmetastase en deze componenten kunnen 
belangrijk zijn voor het vervolgen van een medicamenteuze behandeling. 
Een strategie voor CSF onderzoek wordt tevens voorgesteld. De verschillende 
CSF componenten zijn onderverdeeld in een aantal diagnostische groepen en iedere 
groep bestaat uit een aantal samenhangende CSF componenten. Naar onze mening 
zal deze strategie en het CSF aanvraagformulier de klinicus behulpzaam zijn bij het 
selecteren van de meest geschikte CSF onderzoeken. 
Hoofdstuk 3 bediscussieert het onderzoek naar stofwisselingsproducten in CSF 
en bloed. Bij een groep referentie kinderen, die langdurig (40 uur) gehongerd hadden, 
konden wij een samenhangend complex van stofwisselingsprocessen vaststellen om de 
bloedglucosespiegel te reguleren en alternatieve energierijke substraten te genereren. 
Een relatie werd aangetoond in bloed tussen de concentraties van glucose en ketonen 
met de leeftijd na langdurig hongeren. Deze samenhang wijst erop dat jonge kinderen 
in tegenstelling tot oudere kinderen de bloedglucose concentratie slechter kunnen 
handhaven en sneller overschakelen op ketonen productie tijdens hongeren (hoofd-
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stuk 3, sectie 1). De concentraties van glucose en ketonen in CSF na langdurig 
hongeren zijn duidelijk gecorreleerd met de leeftijdsafhankelijke bloedwaarden. De 
verhouding tussen de concentratie in CSF en bloed (CSF:bloed ratio) voor een 
bepaalde component kan informatie verschaffen over het transportproces van deze 
stof vanuit bloed naar CSF/hersenen. De CSF:bloed ratio voor glucose en ß-hydroxy-
boterzuur was onafhankelijk van de bloedspiegel en van de leeftijd. De ratio voor 
acetylazijnzuur was significant hoger bij jonge kinderen vergeleken met oudere 
kinderen. Dit wijst naar een leeftijdsafhankelijkheid van acetylazijnzuur transport bij 
kinderen. De calorische waarde van de CSF na langdurig hongeren was gelijk voor 
alle leeftijden. De lage glucose concentratie in CSF bij jonge kinderen werd gecom-
penseerd door een hoge ketonen concentratie. Deze bevinding suggereert dat ketonen 
bijdragen aan de calorische homeostase van de CSF en voor de energievoorziening 
van de hersenen compensatie bieden voor het lage glucose niveau bij jonge kinderen 
tijdens hongeren (hoofdstuk 3, sectie 2). 
In hoofdstuk 3, sectie 3 bestudeerden wij de concentraties van energierijke 
substraten in bloed en CSF na langdurig hongeren bij kinderen met encephalopathie-
en van onbekende origine en wij vergeleken de resultaten met die bij de referentie 
kinderen. Wij onderzochten of bij deze kinderen stoornissen in de energiestofwisseling 
voorkomen, aangezien bekend is dat de functionele activiteit van het brein mede 
afhankelijk is van de energievoorziening van de hersenen. Bij patiënten met mentale 
retardatie van onbekende oorsprong vonden wij na langdurig hongeren een significant 
hogere bloedglucose waarde in vergelijking met referentie kinderen. Verschillende 
factoren kunnen hiervoor verantwoordelijk zijn. Een verlaging in de stofwisseling/ver-
bruik van glucose door hersencellen bij deze patiënten zou een belangrijke oorzaak 
kunnen zijn. Bij patiënten met complex partiële epilepsie waren de afwijkingen in 
bepaalde substraten nog meer uitgesproken. De lagere CSF ketonen waarden en de 
lage CSF/bloed ketonen ratio's suggereren stoornissen in het ketonen transport vanuit 
bloed naar de hersenen danwei toegenomen verbruik van ketonen in hersenen bij 
deze kinderen. Deze afwijkingen werden niet gevonden in een groep kinderen met 
primair gegeneraliseerde epilepsie. Wij konden geen verband ontdekken tussen de 
biochemische afwijkingen en de klinische afwijkingen in patientjes met complex 
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partiële epilepsie. 
In hoofdstuk 4 wordt het belang van hersenspecifieke eiwitten in CSF nader 
uitgewerkt. De concentraties in CSF van neuron-specifieke enolase (NSE), S-100 eiwit 
(S-100) en myéline basisch eiwit (MBP) bleken leeftijdsafhankelijk te zijn. Het was 
opvallend dat de relatieve toename per jaar voor deze 3 eiwitten gelijk is. Verklarin-
gen voor dit phenoneem zouden kunnen zijn 1) een met de leeftijd toenemend verlies 
van neuronen, gliacellen en myéline, 2) een nog onbekende gemeenschappelijke factor 
(hoofdstuk 4, sectie 1). Wij bestudeerden ook het voorkomen van deze eiwitten in de 
CSF bij jeugdige en volwassen neurologische patiënten. Wij konden geen bepaald 
patroon voor deze hersenspecifieke eiwitten vaststellen bij verschillende neurologische 
ziektebeelden. De drie betrokken eiwitten vertoonden wel een onderlinge afhankelijk-
heid bij bepaalde neurologische ziekten, met name bij patiënten met een cerebrovas-
cular accident (CVA), hetgeen wijst op een meer gegeneraliseerde aandoening van 
de hersenen. Deze afhankelijkheid werd niet geconstateerd in MS-patiënten met een 
actief ziektebeeld. 
Een aanwijzing voor demyelinisatie (toename in MBP) werd in CSF veel 
frequenter gevonden bij neurologische patiënten dan een aanwijzing voor neuronen 
beschadiging (toename in NSE). Dit zou kunnen betekenen dat bij hersenschade de 
neuronen beter beschermd zijn dan myelinen (hoofdstuk 4, sectie 2). 
MS-patiënten vertoonden in een actief stadium van de ziekte dikwijls een 
verhoogde MBP concentratie in CSF. Na een immuunsuppressieve behandeling met 
cyclophosphamide danwei intraveneus methylprednisolon (Г МР) normaliseerden de 
MBP waarden in CSF. Dit wijst op een reductie of beëindiging van het demyelinisatie 
proces (hoofdstuk 4, secties 3 en 4). De gemiddelde MBP concentratie in CSF was 
significant hoger in MS-patiënten met een exacerberende-remitterende (RR) vorm en 
in MS-patiënten met een chronisch progressief ziekteverloop gepaard gaande met 
exacerba ties en remissies (CP+RR) dan in chronisch progressieve MS-patiënten 
zonder een RR ziekteverloop. Wij konden een correlatie aantonen tussen de klinische 
score (volgens de Kurtzke's Disability Status Scale (EDSS)) en de MBP waarde in 
CSF in RR MS-patiënten. Magnetische resonantie afbeeldingen (MRI) met contrast 
(gadolinium-DTPA) van de hersenen van MS-patiënten tonen dikwijls nieuwe laesies. 
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Het aantal gadolinium-aankkuringen (laesies) in actieve MS-patiënten was significant 
gecorreleerd met het MBP gehalte in CSF en een gecorreleerd trías werd gevonden 
tussen afname in gadolinium-aankleuring, door middel van MRI, reductie in CSF 
MBP en klinische verbetering van de patiënt na Г МР behandeling (Hoofdstuk 4, 
sectie 4). Deze waarnemingen onderstrepen het belang van MBP in CSF als een 
valide parameter voor de activiteit van het ziekteproces en suggereren dat een 
vermindering van de ontsteking gepaard gaat met afname van myéline afbraak en 
klinische verbetering. 
Hersenspecifieke eiwitten zijn minder relevant voor het stellen van de diagnose 
van een bepaalde neurologische ziekte. Echter, deze eiwitten kunnen belangrijke 
informatie verschaffen over het betrokken hersencompartiment, de uitgebreidheid van 
de laesie en/of de activiteit van het ziekteproces. Een verhoogde CSF spiegel van (één 
van) deze hersenspecifieke eiwitten wijst op hersenweefsel beschadiging. Een normaal 
gehalte sluit een (lichte) beschadiging niet uit. Verhoogde CSF spiegels van deze 
eiwitten worden aangetroffen bij patiënten, die een acute neurologische ziekte 
doormaken dan wel bij patiënten met een chronisch progressieve verloop van de 
ziekte. Hersenspecifieke eiwitten zijn niet geïndiceerd bij patiënten met een chroni-
sche neurologische ziekte. 
Hoofdstuk 5 beschrijft de waarde van het vaststellen van een humorale of 
cellulaire immuunreactie in CSF bij bepaalde neurologische ziekten. Een van de 
belangrijkste testen is de isoelectrische focusering voor het aantonen van oligoclonale 
gamma banden. Deze gamma banden worden bijna uitsluitend aangetroffen bij 
infectieuze-, ontstekings- en demyeliniserende ziekten van het CZS. Deze afwijkingen 
worden veroorzaakt door immunologische reacties binnen het CZS die tot gevolg 
hebben een intrathecale productie van heterogene IgG componenten. Oligoclonale 
banden worden bij infectieziekten veel frequenter aangetroffen tijdens de subacute- of 
chronische fase van het ziekteproces vergeleken met de acute fase. Wij toonden bij 
MS-patiënten in de CSF heel frequent (92%) oligoclonale gamma banden aan, die 
derhalve wijzen op de aanwezigheid van oligoclonale IgG-producerende B-cellen in de 
hersenen. Het is niet bekend waartegen deze IgG's gericht zijn. IVMP behandeling 
reduceerde het aantal gamma banden slechts gering hetgeen betekent dat volledige 
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uitschakeling van deze B-cel activiteit niet optreedt (hoofdstuk 5, sectie 1). 
Verhoogde IgG indices werden frequent aangetoond in CSF van MS-patiënten 
en patiënten met systemische lupus erythematosus (SLE) met neurologische complica-
ties (neuro-SLE) (hoofdstuk 5, secties 1 en 3). Waarschijnlijk zijn beide ziekten 
autoimmuun gemedieerd waarbij de verhoogde IgG indices wijzen op een persisteren-
de humorale immuunactiviteit in de hersenen. Wij konden geen correlatie vaststellen 
tussen CSF intrathecaal IgG en de klinische score (EDSS) of de mate van demyelini-
satie (CSF MBP) in MS-patiënten (hoofdstuk 5, sectie 1). Dit pleit tegen een direct 
verband tussen IgG producerende B-cel activiteit in de hersenen en de klinische 
activiteit. IgM lijkt een betere parameter voor de ziekteactiviteit bij MS. In RR MS-
patiënten werd een correlatie aangetoond tussen CSF intrathecaal IgM en de mate 
van demyelinisatie (CSF MBP) (hoofdstuk 5, sectie 1). Ook werd een correlatie 
aangetoond tussen CSF IgM index en CSF complement component C4 index in 
neuro-SLE patiënten (hoofdstuk 5, sectie 3). Deze waarnemingen doen vermoeden 
dat IgM producerende B-cellen in de hersenen meer direct betrokken zijn bij het 
(auto)immuun-gemedieerde ontstekingsproces dan IgG-producerende B-cellen. IVMP 
behandeling reduceerde de intrathecale IgG en IgM productie significant. 
Isoelectrische focusering van CSF eiwitten is sterk geïndiceerd bij een verden-
king op MS, (chronische) infecties, ontstekingen en autoimmuunziekten van het CZS. 
De IgG index geeft een verdere ondersteuning voor bovenvermelde aandoeningen. De 
IgM index geeft meer informatie over de activiteit van het ziekteproces. 
In hoofdstuk 5, sectie 2 worden de resultaten vermeld van een studie naar 
lymphocyten subpopulaties in CSF en bloed van MS-patiënten. In actieve MS-
patiënten was het bloed CD4+ (helper/inducer) T-cel percentage significant verlaagd, 
terwijl het CSF CD4+ T-cel percentage hoger was in vergelijking met controle 
patiënten. Het aantal mononucléaire cellen in CSF en het percentage CD20+ (B-
cellen) in CSF waren significant verhoogd in vergelijking met controle patiënten. Een 
positieve correlatie tussen het aantal CSF mononucléaire cellen en het percentage 
CSF CD4+ T-cellen en een negatieve correlatie tussen het aantal CSF mononucléaire 
cellen en het percentage CSF CD8+ (suppressor/cytotoxische) T-cellen werden 
aangetoond. Deze waarnemingen suggereren dat de verhoogde celreactie in CSF en in 
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hersenen in MS-patiënten veroorzaakt wordt door een selectieve toename van CD4+ 
k/mphocyten. Er kon geen correlatie worden gevonden tussen T- of B-cel populaties 
in CSF en bloed en de EDSS of de mate van ziekteprogressie van MS-patiënten. Na 
de IVMP behandeling was er een significante daling van CD8+ T-cel percentages in 
bloed en een toename in CSF vergeleken met de waarden vóór de behandeling. Deze 
waarnemingen zouden kunnen wijzen naar een selectieve migratie van CD8+ cellen 
vanuit bloed naar CSF en hersenen, waardoor het ontstekingsproces beïnvloed wordt. 
Verder onderzoek zal noodzakelijk zijn om de waarde van lymphocyten populatie 
studies in MS te bepalen met betrekking tot een abnormale immuunregulatie binnen 
het CZS en voor het vervolgen van een therapeutische behandeling. 
DISCUSSIE 
Veel neurologische aandoeningen gaan gepaard met veranderingen in de 
samenstelling van de CSF. Het valt niet binnen de doelstelling van dit proefschrift 
richtlijnen te geven omtrent de indicaties voor een lumbaal punctie. Onderzoek van 
de CSF blijft in de meeste ziekenhuislaboratoria beperkt tot het uitvoeren van een 
aantal standaard laboratorium bepalingen (cellen, eiwit gehalte, glucose, eiwitelectro-
forese, serologie en bacteriologie). Sommige universitaire ziekenhuizen beschikken 
over een gespecialiseerd CSF laboratorium, waar additionele "meer specifieke" CSF 
onderzoeken uitgevoerd kunnen worden. Deze analyses worden geïntegreerd in 
geavanceerde diagnostische CSF testen in het geval de klinische relevantie bewezen is. 
Klinische relevantie voor CSF onderzoek 
1. Geïndiceerd voor de klinische diagnose 
• Acute infecties van het CZS 
CSF onderzoek moet direct worden uitgevoerd in geval van verdenking op een 
meningitis syndroom. Bij veel patiënten met koorts van onbekende oorsprong kan, 
zelfs in afwezigheid van meningeale tekens, CSF onderzoek van grote waarde zijn 
voor diagnose en behandeling. Bovendien is het niet mogelijk om in de vroege fase 
van een infectie van het CZS (bacterie, virus, schimmel of protozoa) een differentiële 
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diagnose te stellen zonder CSF onderzoek. Dit CSF onderzoek zou de volgende 
analyses moeten bevatten: aantal leukocyten, celdifferentiatie, glucose, lactaat, totaal 
eiwit en hersenspeciñeke eiwitten. Voor het aantonen van het verantwoordelijke 
antigeen zijn speciale testen beschikbaar o.a. Elisa, Latex agglutinatie en, zeer recent, 
de polymerase keten reactie (PCR). CSF onderzoek is ook geïndiceerd bij verdenking 
op een encephalitis. In geval van Herpes Simplex encephalitis moet behandeling zo 
snel mogelijk gestart worden. 
• Chronische ontstekingsziekten 
Bij de differentiële diagnostiek van chronische ontstekingsziekten moeten de 
volgende vragen beantwoord worden: Is het proces beperkt tot het CZS of maakt het 
deel uit van een systemische aandoening? Is een exogene substantie de oorzaak of 
speelt autoimmuniteit een overwegende rol? Onderzoek in CSF naar oligoclonale 
gamma banden, Ig indices en specifieke antilichamen (index) is geïndiceerd naast de 
standaard CSF testen. In chronische infectieziekten zoals: neuroborreliose, 
neurosyphilis en parasitaire infecties e.a. worden regelmatig in CSF oligoclonale 
gamma banden en specifieke antilichamen aangetroffen, inclusief antilichamen tegen 
opportunistische infecties in immuun-gecompromitteerde patiënten. In autoimmuun-
gemedieerde aandoeningen kunnen in de CSF (niet)specifieke immunologische 
afwijkingen worden aangetroffen o.a. in cerebrale vasculitis, neuro-SLE, 
neurosarcoidose en neuro-behçet. 
CSF onderzoek is heel belangrijk voor de diagnose van MS. Isoelectrische 
focusering is de meest gevoelige test in CSF. Het aantonen van oligoclonale gamma 
banden ondersteunt de diagnose MS. Afwezigheid van deze banden wordt zelden 
gezien bij MS. Een Europees consensus artikel zal gepubliceerd worden over 
aanbevolen analyses in CSF bij MS (lees Addendum). 
• Hersen metastasen 
CSF onderzoek is geïndiceerd bij een verdenking op metastasen naar het CZS. 
Naast het onderzoek naar maligne cellen in CSF is vooral de bepaling van 
tumormerkstoffen een gevoelige test. 
• Inflammatoire polyneuropathieën 
CSF onderzoek is geïndiceerd bij verdenking op Quillain-Barré's syndroom of 
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chronische inflammatoire demyeliniserende ziekte. 
• Neurometabole ziekten 
CSF onderzoek is geïndiceerd bij bepaalde neurometabole ziekten zoals 
mitochondrieële encephalomyopathieën, niet-ketotische hyperglycinemie, hepatische 
encephalopathie en encephalopathie e causa ignota. 
2. Belangrijke hulp bij de diagnose 
Bij verdenking op een subarachnoidal bloeding is CSF onderzoek geïndiceerd 
als de CT-scan negatief is of als vertraging ontstaat bij de ziekenhuisopname (> 12 
uur) na het incident. Bij sommige patiënten met een CVA kan CSF onderzoek 
informatief zijn met name ter uitsluiting van een ontsteking. Ook bij benige intracra-
nieële hypertensie en bij normale druk hydrocephalus en bij patiënten met een 
radiculair syndroom (ter uitsluiting van een onderliggende infectie) kan CSF onder-
zoek nuttig zijn. 
3. Ter beoordeling van de activiteit van het ziekteproces, de prognose en de behande-
lingseffecten 
CSF onderzoek van hersenspecifieke eiwitten kan belangrijke informatie 
leveren over de ernst van de hersenaandoening, de prognose en de effecten van 
medicatie bij ziekten zoals infecties, MS en CVA. Neurotransmittor metabolieten in 
CSF kunnen bovenvermelde informatie verschaffen bij extrapyramidale stoornissen. 
4. Middel voor research 
CSF onderzoek kan bij verschillende neurologische aandoeningen dienen als 
middel voor research. Met name bij neuroimmunologische-, neurometabole- en 
demyeliniserende ziekten en bij dementie mag verwacht worden dat CSF onderzoek 
belangrijke informatie oplevert. Verschillende nieuwe ontwikkelingen in het CSF 
onderzoek zijn reeds veelbelovend v.w.b. het vaststellen van een immuun-gemedieerde 
oorsprong van een ziekte, de activiteit van het ziekteproces, de onderliggende 
pathofysiologie en voor het stellen van een diagnose. 
• Cytokinen 
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Cytokinen worden geproduceerd door verschillende soorten cellen zoals 
monocyten/macrofagen, lymfocyten, vasculaire endotheelcellen en ook astrocyten en 
microgliacellen in de hersenen. (Zytokinen stimuleren celdeling, celdifferentiatie en 
immuunglobulinen productie door B-cellen. Deze producten in CSF kunnen informa-
tie bieden over voortgaande intrathecale immunologische activiteit. In actieve MS-
patiënten werden verhoogde spiegels in CSF van TNF-a, Π^2 en oplosbaar CD8+ 
aangetoond in tegenstelling tot stabiele MS-patiënten [1-4]. Bij door humaan immuun 
deficiëntie virus type I (НГ -І) geïnfecteerde patiënten werden verhoogde TNF-a 
spiegels gemeten [5]. Intrathecale productie van cytokine IL-6 werd vastgesteld bij 
neurologische infectieziekten van virale en bacteriële oorsprong en TNF-a bij cerebra-
le maligniteiten zoals CZS leukemie [6-8]. (Zytokinen metingen leveren geen bijdrage 
aan de diagnostiek maar zij zijn van belang als parameter voor de immuun-geme-
dieerde status van een ziekte, voor evaluatie van ziekteactiviteit en voor medicatie-
effecten. 
• Anti-herseneiwit antilichamen 
Anti-MBP antilïchaam spiegels in CSF hebben reeds hun nut bewezen als 
parameter voor demyelinisatie. T-lymphocyten bleken te reageren op MBP 
presentatie en waren betrokken bij de Pathogenese van inflammatoire demyelinisatie 
[9]. Anti-MBP antilichamen werden aangetoond in CSF bij actieve MS-patiënten 
[10,11] en bij patiënten met AIDS dementie complex [12]. Antilichamen tegen 
myeline-geassocieerd glycoprotein (anti-MAG) werden aangetroffen in sommige 
patiënten met por/neuropathie in associatie met IgM paraproteinemic [13]. Nader 
onderzoek naar de specificiteit van deze immuunreactie en de relatie met de ziekte 
progressie kan waardevol zijn bij demyeliniserende ziekten. 
• Lymphocyten met co-expressie van meerdere oppervlakte antigenen 
Het wordt steeds meer duidelijk dat chronische inflammatoire ziekten inclusief 
autoimmuun ziekten gemedieerd worden door een verstoring in de regulatie van 
immuuncompetente cellen. Verscheidene studies hebben aangetoond dat T-cellen in 
het CSF compartiment een populatie van afgezonderde, geactiveerde cellen 
vertegenwoordigen met andere immunologische eigenschappen dan T-cellen in het 
perifere bloed. 
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Een dubbele kleur "flowcytometrie" techniek kan lymphocyten definiëren met 
co-expressie van meerdere oppervlakte antigenen. Verhoogde spiegels van foetaal-
type CD5+ B-cellen en CD4-8-T-ceIlen en verlaagde spiegels van CD4+2H4+(sup-
pressie inductie) T-cellen zijn aangetoond in de CSF van MS-patiënten [14,15]. Deze 
resultaten wijzen op het bestaan in actieve MS-patiënten van een actief immuun 
systeem met een laag aantal suppressie inductie T-cellen gepaard gaande met B-cel 
hyperactiviteit. Bij een patiënt met AIDS dementie complex was het percentage van 
CD8+ HLA-DR+ T-cellen in CSF verhoogd hetgeen suggestief is voor een voort-
gaande T-cel respons tegen HIV antigeen in het CZS [16]. 
• Neurotransmitters (metabolieten) 
Abnormale concentraties van monamine metabolieten in CSF zijn dikwijls 
aangetoond bij patiënten met extrapyramidale aandoeningen, patiënten met de ziekte 
van Alzheimer en andere vormen van dementie. 
Onlangs werden verlaagde spiegels van 3-methoxy-4-hydroxyphenylethyleengly-
col, 5-hydroxyindolazijnzuur (5HIAA) en homovanilline zuur (HVA) aangetoond in 
CSF in het primaire fibromyalgie fibrositis syndroom (PFS), hetgeen steun verleent 
aan de hypothese van een metabool defect bij PFS [17]. Ook werd gerapporteerd 
over een nieuwe aangeboren stofwisselingsziekte ten gevolge van een aromatische L· 
aminozuur decarboxylase deficiëntie met verlaagde CSF-spiegels voor HVA en 
5HIAA in associatie met een verhoogde 3-methoxytyrosine spiegel [18]. Bij patiënten 
met verschillende vormen van dementie werden significant verlaagde CSF waarden 
van cholinerge merkstoffen (acetylcholinesterase en butyrylcholinesterase) gevonden. 
Bij 11 van de 13 patiënten met de ziekte van Alzheimer werd een abnormale 
moleculaire structuur van het Cholinesterase aangetoond terwijl bij 10 niet-demente 
personen van een vergelijkbare leeftijd dit fenoneem ontbrak [19]. Aminozuren zoals 
glutamaat, aspartaat, gamma-amino boterzuur (GABA) en glycine kunnen ook 
werkzaam zijn als neurotransmittor. Bij de ziekte van Alzheimer werden verlaagde 
glycine spiegels in CSF gevonden. Lage CSF GABA-spiegels werden aangetoond in 
patiënten met hyperekplexia, hetgeen zou wijzen op een genetisch defect [21]. 
Aangeboren stoornissen in de GABA stofwisseling van de hersenen zijn gerapporteerd 
met zowel verhoogde als verlaagde GABA concentraties in CSF [22]. 
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• Methyleringscapaciteit van de hersenen 
Een verlaagde beschikbaarheid van methylgroepen in het CZS kan de oorzaak 
zijn van dysmyelinisatie van de hersenen [23]. S-adenosylmethionine (SAM) is de 
exclusieve methyldonor bij veel belangrijke methyleringsreacties in het CZS en is als 
zodanig betrokken bij de synthese van neurotransmitters, (poly)aminen, membraan 
fosfolipiden en proteïnen. Foliumzuur en vitamine В12 zijn nodig voor de synthese 
van SAM. Langdurige deficiëntie van deze vitaminen kan een verlaagde SAM-spiegel 
in de hersenen veroorzaken en dysmyelinisatie [24]. L-Methyl-malonyl-CoA mutase en 
methionine synthetase hebben vitamine B12 nodig als co-factor voor enzymactiviteit. 
Studies hebben aangetoond dat de CSF-spiegels van methylmalonzuur en 
homocysteine duidelijk verhoogd zijn bij patiënten met een vitamine В12 deficiëntie 
[25-27]. De concentratie van vitamine В12 in CSF is zeer laag. De bepaling van 
homocysteine en/of methylmalonzuur in CSF is hoogstwaarschijnlijk een betere 
methode voor het vaststellen van een vitamine B12 deficiëntie in CSF. Onlangs is een 
publicatie uitgewerkt van onze afdeling over een neurologische patiënt met een 
ernstige foliumzuur deficiëntie in CSF en een normaal serum foliumzuur [28]. Behalve 
vitamine deficiënties kunnen ook aangeboren defecten in de methyl overdracht 
stappen een lage SAM-spiegel in de hersenen veroorzaken [23]. Meting van SAM in 
CSF kan dus informatie verschaffen over de methyleringscapaciteit van de hersenen. 
Bij patiënten met depressies en bij patiënten met de ziekte van Alzheimer werden 
verlaagde spiegels van SAM in CSF aangetoond [29]. Het antidepressieve effect na 
toediening van SAM is nu in meerdere studies bevestigd [29,30]. Lage SAM-spiegels 
zijn ook aangetoond in CSF bij kinderen met een aangeboren defect in methyl 
overdracht reacties. SAM-toediening had een substantieële klinische verbetering, 
duidelijke remyelinisatie en een toename in de CSF SAM concentratie tot gevolg. Een 
recente studie toonde aan dat patiënten met ataxie van verschillende aetiologje signifi-
cant verlaagde spiegels van thiamine en thiamine monofosfaat hadden in de CSF [31]. 
Ook een andere studie toonde aan dat thiamine betrokken is bij ziekten met 
cerebellaire stoornissen [32]. 
Onderzoek in CSF naar vitaminen of aanverwante producten zoals 
homocysteine, methylmalonzuur en SAM kunnen informatie verschaffen over de 
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methyleríngscapaciteit van de hersenen en over de mogelijke pathofysiologie van het 
ziekteproces. 
• Glycosfingolipiden 
Glycosfingolipiden zijn belangrijke bestanddelen van celmembranen. Deze 
lipiden zijn vooral aanwezig in hersenweefsel. De samenstelling van de 
glycosfingolipiden is specifiek voor een bepaald celtype. Bij degeneratie en afsterven 
van cellen in de hersenen kunnen verhoogde concentraties van membraan 
glycosfingolipiden aangetroffen worden in de intercellulaire ruimte en in de CSF. 
Sommige hersenziekten gaan gepaard met een bepaald gangliosiden patroon in de 
CSF [33]. Onderzoek naar sulfatiden in de CSF kan belangrijke informatie verschaffen 
over de uitgebreidheid en de voorgang van demyeliniserende processen o.a. in 
vasculaire dementie en in MS [34]. 
ONTWIKKELINGEN 
Harmonisatie van protocollen voor CSF analyse en 'interpretatie 
De Commissie voor MS-onderzoek van de Europese Gemeenschap heeft in 
1991 een aantal Europese deskundigen, werkzaam in gespecialiseerde 
liquorlaboratoria, uitgenodigd om aanbevelingen op te stellen over relevant 
liquoronderzoek ter ondersteuning van de klinische diagnose MS en om een consensus 
artikel over dit onderwerp te publiceren. Meer dan 20 Europese wetenschappers 
hebben een voorstel uitgewerkt voor relevante CSF testen en in 1993 zal een 
consensus protocol gepubliceerd worden over een aantal overeengekomen 
methodieken voor de analyse van CSF componenten en over aanbevelingen 
betreffende de interpretatie van de analyse resultaten (lees Addendum). 
Dezelfde groep wetenschappers zal haar werkzaamheden voor het CSF 
onderzoek uitbreiden met de harmonisatie van protocollen voor de diagnostiek van 
ontstekings- en infectieziekten van de hersenen met behulp van geavanceerde 
immunospecifieke technieken. 
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I 
Bij de interpretatie van analyses van hersenspecifieke eiwitten in liquor dient rekening 
gehouden te worden met de leeftijdsafhankelijkheid van de referentiewaarden van 
deze eiwitten. (Dit proefschrift). 
II 
Ketolichamen leveren bij kinderen tijdens hongeren een belangrijke bijdrage aan de 
calorische homeostase van de liquor en aan de energievoorziening van de hersenen. 
(Dit proefschrift). 
III 
In het algemeen is voor een correcte interpretatie van een liquoruitslag simultaan 
bloedonderzoek noodzakelijk. (Dit proefschrift). 
IV 
Isoelectrische focusering is de meest gevoelige methode voor het aantonen van 
oligoclonale gammabanden in de liquor. Deze methode dient dan ook toegepast te 
worden door de betrokken laboratoria. (Dit proefschrift). 
V 
Geavanceerd liquoronderzoek dient in verband met de relatief hoge kosten en de 
vereiste kwaliteit uitgevoerd te worden door een beperkt aantal gespecialiseerde 
liquorlaboratoria. (Dit proefschrift). 
VI 
Voor de biochemische diagnostiek van mitochrondriële (encephalo-)myopathieën is de 
lactaatbepaling in liquor relevanter dan in bloed of urine. (In JMF Trijbels, Review, 
Eur J Pediatr 1993;152:178-184). 
VII 
Milde hyperhomocysteïnemie wordt in het algemeen niet veroorzaakt door heterozy-
gotie van cystathionine synthase deficiëntie. (Boers et al, N Engl J Med 1993; 85, 
313:709-715). 
VIII 
Analyse van lipiden in urine sedimenten kan bij verdenking op een lysosomale 
stapelingsziekte een belangrijke aanvulling vormen op de enzymdiagnostiek en kan, in 
bepaalde gevallen, een alternatief zijn voor het nemen van een biopt. (J. de Jong et 
al, Abstracts of the 31sl SSIEM, 1992 nr: P107). 
IX 
Afdelingsgebonden laboratoria waarborgen specifieke deskundigheid op diagnostisch-
en onderzoeksgebied van het betreffende moederspecialisme. Deze laboratoria dienen 
derhalve in academische ziekenhuizen gehandhaafd te blijven. 



